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Abstract 
 The studies described here involve molecular aspects of T cell recognition and the 
reactivity of T cell receptors with novel peptide antigens. The first study (Chapter 2) described a 
collection of novel peptide antigens for a single T cell receptor and their diverse requirements 
for the co-receptor CD8. One of the peptides showed no activity despite binding the TCR, and 
examination of the crystal structure of the complex suggested that an unusual TCR docking 
geometry could influence the T cell signaling complex. The second study (Chapter 3) described 
the peptide-binding effects of two polymorphic residues (Trp and Arg) at position 97 in mouse 
and human MHC proteins.  These polymorphisms in the human gene HLA-B have recently been 
associated with HIV control (tryptophan), or progression (arginine) to AIDS. My findings showed 
that the same polymorphism in position 97 in the mouse protein Ld resulted in a very significant 
affect on the repertoire of self-peptides that bound to the alleles.  Binding of fewer peptides 
(Trp97) would result in broader diversity of the T cell repertoire, which would include T cells that 
enable immunity to HIV. Conversely, binding a broader array of self-peptides (Arg97) would 
result in thymic deletion of a larger number of T cells, including those that would have been 
capable of controlling an HIV infection. Structures of various peptide-MHC complexes allowed 
me to interpret the possible basis of the peptide-binding results. In the third study (Chapter 4), 
novel self-peptide antigens for a single, alloreactive T cell, were isolated in an attempt to 
examine the peptide antigen(s) that selected the mouse clone called 2C. My results showed that 
contrary to earlier studies, there were dozens of naturally expressed and Ld-presented peptides 
that could mediate reactivity with 2C T cells. However, the self-peptide called p2Ca 
(LSPFPFDL) that was identified over 20 years ago as a putative ligand, was not one of them. 
The first project, described in Chapter 2, was performed in collaboration with Drs. Jarrett 
Adams and K. Christopher Garcia (Stanford University). Yeast display libraries that expressed 
diverse nonamer peptides, covalently linked to Ld, were used to identify novel peptide antigens 
that bound to the TCR called 42F3. To screen these peptides for biological activity, I generated 
42F3 T cell hybridoma cell lines, with or without the CD8αβ co-receptor.  Results of T cell 
activation assays revealed that the novel antigenic peptides were either CD8-dependent or 
CD8-independent, but this dependency was not completely associated with the affinity of the 
pep-Ld complex for the TCR, as had been expected. Furthermore, one of the peptides was 
completely inactive, even though it bound well as a complex to the TCR.  This result, in the 
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context of the crystal structure of the complex, suggested that the geometry of TCR docking 
may influence the association of the TCR with signaling components and thus the clustering of 
TCR-peptide/MHC complexes in the immune synapse. 
 The third chapter in this thesis details a project examining the contributions of position 
97 of the murine MHC allele Ld in affecting peptide binding. A 2010 study published by the 
International HIV Controllers Study group described a relationship between HIV disease control 
or progression and HLA-B alleles, and focused on specific amino acids at key positions of HLA-
B, including position 97. The study found that HLA-B alleles that contained a tryptophan at 
position 97 were associated more with HIV control, whereas alleles containing an arginine at 
position 97 were associated more with HIV progression. I focused on the Trp97 and Arg97 alleles 
because our lab, and others, had found independently in the mouse Ld system that an arginine 
at position 97 affected the stability of the Ld molecule. Structurally, the Ld allele shares homology 
with HLA-B alleles; position 97 in Ld and HLA-B lies near the center of the peptide binding 
groove, with the side chain of the position 97 residue directed out into the peptide-binding 
groove, a prime location for affecting peptide binding. For the analysis detailed in Chapter 3, I 
generated immortalized cell lines expressing full length LdW97 and LdR97 and used competitive 
peptide binding assays together with a soluble in vitro reconstitution system to determine the 
relative stability and binding of a panel of peptides to these two variants. The results showed 
that LdR97 bound a broader repertoire of self-peptides than LdW97. An examination of available 
peptide/Ld structures suggested that this was not due to additional flexibility of the arginine, as 
previously suggested in the HLA-B system. Rather, proximal residues at positions 114, 116, and 
156 formed different interactions with either W97 or R97, and these proximal residues showed 
greater flexibility in LdR97 structures compared to LdW97 structures. This suggests that the 
enhanced flexibility of these residues in LdR97 provides the freedom to accommodate a broader 
collection of self peptides. Comparisons of Ld and HLA-B structures containing Trp97 and Arg97, 
indicate that the results will translate to the HLA-B system. Thus, the result is consistent with a 
greater proportion of T cells being clonally deleted during negative selection against self-
peptide/MHC-R97 complexes. This would restrict the diversity of the T cell repertoire in the 
periphery and reduce the availability of T cells that could be effective against HIV (thereby 
leading to a “progressor” phenotype with the Arg97 alleles). 
 The fourth chapter in this thesis re-examines the naturally presented alloantigen that 
selected the mouse T cell clone called 2C. Thirty years ago, T cell clone 2C was raised against 
the Ld-expressing P815 mastocytoma cell line. About twenty years ago, a peptide called p2Ca 
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was identified by acid extraction from BALB/c thymus tissue as a peptide that mediated 
reactivity between the 2C T cell clone and Ld-expressing target cells. While p2Ca has been 
assumed to be the natural ligand for 2C, our lab had strong evidence to suggest that peptide 
p2Ca was not endogenously processed and presented on MHC Ld on the surface of P815 cells. 
Accordingly, peptide p2Ca could not have been the alloantigen against which the 2C T cell 
clone was raised. To search for the bona fide peptide(s), I obtained naturally derived peptides 
from BALB/c (Ld-positive) liver tissue, using either an acid extraction method or an affinity 
purification method (with an anti-Ld-monoclonal antibody). The resulting peptides were 
fractionated based on hydrophobicity using reverse-phase HPLC, and HPLC fractions were 
sampled in cytotoxicity assays using 2C T cells and the T2-Ld target cell line. Surprisingly, there 
appeared to be many more active fractions containing peptides than described previously, with 
a minimum estimate of at least 30 different active peptides. Thus, the alloreactive T cell clone 
2C has an even greater repertoire of ligands than thought. 
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CHAPTER ONE 
 
 
INTRODUCTION 
 
T Cells 
 The study of immunology has made great progress in understanding how an 
individual's immune system works to combat both infectious agents as well as cancer. 
The cell-mediated branch of the immune system is responsible for the recognition of 
virus-infected and transformed cells, such as cells that have undergone mutations 
resulting in aberrant expression of proteins and uncontrolled growth. The cell-mediated 
adaptive immune response is performed by the actions of T cells. T cells express a 
distinct heterodimeric T cell receptor (TCR) that is encoded by somatically rearranged 
genes containing variable and constant domains for each T cell receptor chain (1). The 
diversity of the T cell repertoire is responsible for surveillance of the entire human body, 
distinguishing healthy (called “self”) cells from cells that are transformed by viruses or 
that contain mutations.  
Various processes involved in the T cell-mediated immune system have been 
studied extensively at the molecular level. These include: T cell receptor recognition of 
peptide antigens on virus-infected or transformed target cells, the development of the T 
cell repertoire, the various effector functions that T cells perform such as killing and 
cytokine release, the processing and presentation of antigens, and T cell inactivation via 
anergic signaling mediated by tolerance mechanisms. 
 T cells are derived from the common lymphoid progenitor and develop in the 
thymus. A combination of signals drives differentiation of the T cell, among which are 
binding of interleukin-7 (IL-7) to the extracellular domain of the interleukin-7 (IL-7) 
receptor on the progenitor cell surface (2,3). This signal is required in order to initiate 
gene rearrangement processes that are required for formation of a functional T cell 
receptor on the surface of the cell. The process of gene rearrangement utilizes 
heptamer/nonamer recombinational signal sequences (RSSs) that flank the gene 
segments encoding the variable domain of the T cell receptor: the V (or variable) gene 
segment, J (or joining) gene segment in the case of either the alpha or gamma T cell 
receptor chains, and V, D (diversity), and J gene segments that form the variable domain 
of either the beta or delta T cell receptor chains (Figure 1.1) (4). Recombinase enzymes 
recognize these RSSs and facilitate the joining of TCR gene segments, and looping out 
the intervening DNA. After the gene rearrangement process, the rearranged V-J genes 
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or V-D-J genes are transcribed and spliced together with the transcripts of genes that 
encode the constant regions of the T cell receptor for the alpha, beta, gamma, or delta 
TCR chains (5). The variable domains of the TCR protein chains confer the specificity of 
the TCR for the antigenic complex, and are encoded by the rearranged V-J gene 
segments (α/γ chains) and rearranged V-D-J gene segments (β/δ chains) (6,7).  
At the junction points between gene segments there is the possibility to 
incorporate additional diversity with the addition of nucleotides by terminal 
deoxynucleotidyl transferase, or the removal of nucleotides by an exonuclease. The 
diversity in the variable regions of the TCR is greater in the beta and delta chains due to 
the incorporation of the D gene segment (8). T cells utilize allelic exclusion, which 
typically results in the expression of only one sequence of TCR on the cell surface. It has 
been estimated that the human repertoire of V, D, and J gene segments has the 
potential to encode a total of approximately 1012 different T cell receptors (Table 1.1). 
However, due to selection processes in the thymus, where T cells originate and develop 
(see below), the actual diversity of expressed TCRs in one individual may be closer to 3 
x 107 distinct TCRs (9).  
 There are two main classes of TCRs that can be expressed on the surface of the 
T cell- the αβ TCR and the γδ TCR. In humans, 95% of the T cells in the body display αβ 
TCRs on the surface, and the remaining 5% express γδ TCRs. The αβ TCRs are 
"restricted" by antigens displayed by products of the major histocompatibility complex 
gene, or MHC proteins (10,11). Conversely, γδ TCRS are not “restricted” to recognizing 
antigens in the context of an MHC molecule, and instead recognize non-peptide 
antigens such as lipids, amongst others (12). The antigens that are recognized by αβ 
TCRs are peptide fragments derived from proteins that are either synthesized and 
degraded by the proteosome, or extracellular proteins that have been endocytosed and 
degraded in endosomes (13). Peptides that are derived from intracellular proteins are 
cleaved into fragments of 8-10 amino acids and displayed on the heterodimeric MHC 
Class I protein that consists of a three-domain (α1, α2, α3) heavy chain, and an invariant 
light chain called beta-2-microglobulin (β2m) (14). For MHC Class I, the α1 and α2 
domains form alpha helices connected by a beta sheet beneath the helices that forms 
the floor of the peptide-binding groove, bound on either side by the alpha helices. The α3 
domain is mostly invariant among all the MHC alleles, and interacts with the light chain 
β2m (Figure 1.2A) (15,16).  
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On the Class I MHC product, the octamer-decamer peptide is displayed between 
the helices of the α1 and α2 domains, with anchor resides that typically are nearer to the 
ends of the peptide that insert into the peptide binding groove by forming charge-charge, 
hydrophobic, or aromatic stacking interactions with amino acids in the MHC alpha 
helices or beta sheet (17). The Class II MHC system is similar, in that the MHC product 
on the cell surface is comprised of similarly-sized alpha and beta chains, each 
containing two domains. The α1 and β1 domains form the peptide binding groove 
similarly to the groove formed in the MHC Class I system; the groove is formed by alpha 
helices as well as a beta sheet that forms the floor of the peptide binding groove (Figure 
1.2B). The peptides that load onto Class II MHC molecules are typically longer, between 
12 and 22 amino acids long, and are derived from endocytosed extracellular proteins 
(18). The peptides that are presented on MHC class II molecules typically have their N- 
and C-terminal ends protruding out of the end of the peptide binding groove, and also 
contain anchor residues that form various interactions within groove (19,20).  
 The two main classes of MHC proteins, I and II, have the potential to interact with 
T cells that express an αβ TCR that recognizes the displayed peptide, and in addition 
they interact with the co-receptors CD8 or CD4, respectively, expressed by the T cells 
(21).  Thus, T cells that express the CD8 co-receptor engage the peptide-MHC complex 
not only through the TCR-peptide/MHC interaction, but also through the interaction of 
the CD8 co-receptor with the α3/β2m interface of the peptide/MHC complex (Figure 
1.3A) (22). Conversely, T cells that express the CD4 co-receptor engage target cells via 
the specific TCR-peptide/MHC interaction, as well as the interaction between the CD4 
co-receptor and the interface of the largely invariant β2 domain of the MHC II molecule 
(Figure 1.3B) (23). The process of T cell development will be discussed later on in this 
chapter. For the purposes of this thesis, the following description of T cells, their 
interactions, their development, etc. will be pertaining specifically to αβ T cells, which 
express αβ TCRs, unless otherwise noted. 
 
Major Histocompatibility Complex 
 The MHC is the most polymorphic locus in the human genome. In humans, the 
MHC locus, also known as the HLA (human leukocyte antigen) locus contains three 
class I genes: A, B, and C. Each individual inherits one allele of each HLA gene from 
each parent. Because MHC Class I consists of only a heavy chain encoded by the 
inherited HLA alleles and the invariant chain β2m, each individual can express up to six 
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distinct MHC (or HLA) Class I products (17). Class I HLA products are expressed and 
displayed on the surface of all nucleated cells of the body. The Class II system in 
humans is more complex, although there are three gene regions called DP, DR, and DQ, 
within each region are the genes for both the alpha and beta chains that comprise the 
human class II MHC. An individual inherits one allele for each alpha and beta chain for 
each gene from each parent, and alpha allelematernal for one gene can pair with the beta 
allelepaternal for the same gene, and vice versa. This results in up to four distinct α/β pairs 
for each gene DP, DR, or DQ, resulting in a total of 12 possible HLA II protein products 
(24). Class II HLA products are expressed and displayed on the surface of antigen 
presenting cells, which include thymic epithelial cells, B cells, macrophages, and 
dendritic cells.  
The mouse MHC system is organized similar to the human system, and there are 
many parallels between them. The MHC class I alleles are of the same number as in 
humans- there are three genes known as K, D, and L for which the mouse can express 
up to two alleles each. The MHC class I products are denoted with K, D, and L 
(indicating the gene) and a superscript letter indicating the allele. The Class I products 
associate with the murine β2m protein on the surface of all nucleated cells of the body. 
The murine MHC class II system has two gene regions, IA and IE, each encoding an 
alpha and beta chain, and the alleles once again are denoted by a superscript letter (25). 
As in the human system, the alpha and beta chains encoded by the maternal and 
paternal alleles for one gene (IA or IE) can be mixed and matched to form a total of eight 
possible murine MHC class II products displayed on the surface of antigen presenting 
cells such as thymic epithelial cells, B cells, macrophages, and dendritic cells. 
Polymorphisms in the MHC loci are likely advantageous as a species. The 
polymorphisms are located primarily in the regions of the MHC that affect peptide 
binding, thus they also affect T cell recognition, which in turn affects one's ability to 
mount an effective immune response and eliminate an infectious agent (26). 
Polymorphisms in the MHC repertoire reduce the chances that one infectious agent 
could escape immune recognition by the entire population, thus providing an 
evolutionary advantage for a population. Even in one individual, the presence of up to six 
distinct MHC class I alleles with different specificities for binding peptides increases the 
breadth of self-peptide and foreign peptide presentation, thereby increasing the chances 
for detection of foreign agents (i.e. their peptides) by the adaptive immune system (19). 
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The numbers of known alleles for each Class I and Class II MHC genes are shown in 
Table 1.2. 
 The antigen processing pathways that result in the peptides that are presented 
on each class of MHC are different, as the peptides are derived from proteins in different 
intracellular trafficking routes. The processes that generate these MHC-binding peptides 
are the same in humans and mice. For binding to MHC class I, proteins that are 
synthesized within the cell (both self proteins and virus-encoded proteins) are degraded 
by the proteosome, which cleaves these proteins into peptide fragments of various sizes, 
including some that are eight to ten amino acids long, perfect for loading onto the class I 
MHC (27). The cleaved peptides are then shuttled by TAP (transporter associated with 
antigen processing) into the rough endoplasmic reticulum where empty (no bound 
peptide) MHC class I molecules are tentatively assembled with various chaperone 
proteins to stabilize them (28). MHC class I molecules are not stable in the absence of 
either peptide or invariant chain β2m (29). The chaperone-stabilized MHC class I 
molecule, upon interacting with TAP, is allowed to "try on" the candidate peptide and if 
the peptide binds with sufficient affinity and stabilizes the MHC class I molecule, the 
complete complex can be shuttled to the cell surface via the Golgi apparatus. If the 
peptide does not bind sufficiently well enough, the complex can be recycled, and another 
attempt at successful assembly can be made (24).  
The peptides that are loaded onto class II MHC molecules are derived from 
extracellular proteins that have been endocytosed and digested in endosomes, which 
contain enzymes that utilize the acidic environment to fragment the proteins. Similarly to 
class I MHC, the MHC II molecule is not stable in the absence of peptide, and so it is 
stabilized by a team of chaperone proteins, including a protein called "invariant chain" 
which binds in the peptide binding groove as well as outside the peptide binding groove, 
and allows the stabilized MHC class II molecule to be transported in a vesicle (30). 
When the endosome containing the digested peptides fuses with the vesicle containing 
the stabilized MHC class II molecule, the "invariant chain" protein is degraded in a step-
wise fashion and only a small fragment is left in the peptide-binding groove. Another 
chaperone protein removes this small fragment, also known as CLIP, and facilitates the 
binding or loading of peptides (12-22 amino acids long, on average) from the enzyme-
degraded proteins in the endosome. At this point, the assembled MHC class II molecule 
bound to a peptide can be displayed on the cell surface (31,32). 
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Class I MHC Allele Ld 
 As described in the section above, in mice there are three MHC class I genes: K, 
D, and L. Because the mouse strains used in immunological studies are inbred, they 
typically express one allele for each MHC gene (in the mouse, the MHC is known as H-
2). The main haplotypes discussed in this thesis are H-2k, H-2b, and H-2d. The 
superscript letter indicates the name of the allele that is expressed for each of these 
class I MHC genes; for example, the MHC class I alleles expressed in an H-2d mouse 
are Kd, Dd, and Ld, and the MHC class I alleles expressed in the H-2b haplotype are Kb, 
and Db (the L gene has been deleted in most H-2b strains) (33). The MHC allele Ld is a 
major topic of this thesis and is expressed in many mouse strains of the H-2d haplotype, 
including the often-used BALB/c strain. MHC Ld is a class I MHC allele, and like the 
others is comprised of a heavy chain encoding the α1, α2, and α3 domains. This heavy 
chain is likewise associated with the invariant β2m light chain (Figure 1.4A). 
 The so-called “anchor” residues predicted to be important in binding to the Ld 
allele were discovered by eluting peptides from cell surface peptide/Ld complexes and 
performing several rounds of N-terminal sequencing, or Edman degradation. The 
consensus, or lack thereof, of amino acids at each position of the eluted peptides 
revealed which positions of the peptide were likely to serve as “anchor” positions, and 
thus to facilitate binding to the Ld protein. These experiments revealed that potential 
anchor residues for binding to MHC Ld included a proline at position 2 of the peptide, and 
a leucine, isoleucine, valine, or phenylalanine at position 9 of the peptide (34-36). Self 
peptides that bind to the MHC Ld allele, but may not be endogenously processed (this 
will be described later), include peptide p2Ca (LSPFPFDL) and the longer variant QL9 
(QLSPFPFDL). A peptide derived from the murine cytomegalovirus (MCMV) with 
sequence YPHFMPTNL, as well as a peptide derived from a mutated protein in P815 
with sequence TQNHRALDL (known as tum-), were also found to bind MHC Ld (37,38).  
From these latter sequences of QL9 and tum- peptides that bind to Ld, it was 
apparent that the position 2 proline anchor residue identified initially was not absolutely 
required for binding to Ld. Additionally, the presence of anchor residues at positions 2 
(e.g. Pro) and 9 (e.g. Leu) of the peptide do not guarantee binding to the MHC. 
Compared to several other murine Class I MHC alleles (e.g. Kb), the presence of anchor 
residues within an octamer or nonamer peptide is far less predictive of binding to Ld 
(39,40).  
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The explanation for less strict peptide binding motifs may in part be revealed by 
structural studies. In addition, the Ld protein is notoriously unstable, making work with 
soluble forms of this particular MHC allele difficult (41,42). Many attempts have been 
made to crystallize the full length Ld protein in complex with both β2m and various Ld-
binding peptides; the MHC class I heavy chain is not stable in the absence of either one 
of those components. However, only one structure of full length Ld exists in complex with 
β2m and a peptide (Figure 1.4A) (43). The other full length Ld structure that was solved 
did not include just one peptide, rather the structure of the Ld protein was solved in the 
presence of a collection of different Ld-binding peptides (44). These structures revealed 
the overall shape and topology of the Ld heavy chain to be similar to that of the other 
known MHC class I complexes (16,20,26,45). The instability of the peptide-Ld complex 
made it difficult to solve as a ternary complex with a T cell receptor.  
To address the stability problem, Dr. Susan Brophy, a previous member of the 
Kranz Lab, used yeast display libraries (46) to engineer a more stable form of the Ld 
protein. An Ld mutant was identified that was expressed stably on the yeast surface, and 
further analysis revealed that the stabilized Ld variant was truncated and contained only 
the α1 and α2 domains of the Ld protein (47). The two-domain version of Ld was shown 
to be folded properly, as it would be in a full length Ld molecule on the surface of a cell, 
and for this reason further experiments were performed using this newly stable Ld 
variant, known as Ldm31. This variant contained a Trp97Arg mutation that resides in the 
floor of the peptide binding groove. This mutation was shown in the yeast-display system 
to provide additional stability to the Ld molecule, which was consistent with the results of 
earlier studies on impact of Trp97 versus Arg97 (48) (49).  
 The Ldm31 variant was able to be expressed on the surface of yeast, as well as 
in soluble form after being introduced into a pET28A expression vector and expressed in 
E. coli (47). When this variant of Ld was used for crystallization, it did not require 
expression as a complex with β2m, because β2m associates with the α3 domain of the 
class I MHC, which is absent in the Ldm31 variant. The structure of Ldm31 was solved in 
complex with peptide QL9 by Dr. Lindsay Jones, a previous member of the Kranz Lab, 
providing insight into the interaction of the QL9 anchor residues with the floor of the 
peptide-binding groove (50). The same QL9/Ldm31 complex was solved in a ternary 
complex with the 2C TCR (Colf et al., 2007), the T cell receptor expressed on the 
surface of the alloreactive 2C T cell clone that recognizes the Ld complex on the surface 
of target cells in biological assays ((51,52). The generation of the Ldm31 variant provided 
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a way to assess the soluble stability of peptide/Ld complexes that previously could only 
be evaluated on the surface of an Ld-expressing cell line, like the human TAP deficient 
cell line T2 that had been transfected to express Ld (53,54). In Chapter 3 of this thesis, 
various peptides are tested in both cell-based flow cytometry assays and soluble 
peptide/Ldm31 assays as two independent verifications of peptide/Ld stability, and the 
two assays were found to be in agreement, suggesting once again that the Ldm31 
variant has several applications experimentally that are consistent with in vitro cell-based 
assays using full length Ld(W97R). 
 
T Cell Development and Tolerance 
 T cells (αβ) develop in the thymus, where the processes of positive and negative 
selection that shape the ultimate diversity of the T cell repertoire occur. After these 
selection processes, surviving T cells exit the thymus and circulate to the periphery. It is 
thought that the selection processes occur sequentially, with positive selection taking 
place before negative selection (55). The process of positive selection is one in which T 
cells that are double positive for CD4 and CD8 co-receptors are screened for their 
binding to self-peptide/MHC complexes. If the T cell expresses a TCR that binds 
adequately to self-peptide/MHC class I complexes, the CD4 co-receptor genes are 
turned off, and only the CD8 co-receptor remains expressed (56). These CD8+ T cells 
differentiate into cytolytic or cytotoxic T cells which can directly kill or induce apoptosis in 
target cells- if the displayed antigenic peptide/MHC Class I complexes are recognized by 
the T cell's TCR with sufficient affinity, typically between 1μM and 300μM. If the T cell in 
question expresses a TCR that instead binds self-peptide/MHC class II complexes, the 
CD8 co-receptor genes are turned off, leaving only the CD4 co-receptor expressed on 
the T cell surface along with the TCR (57). These CD4+ expressing T cells differentiate 
into helper T cells which secrete cytokines that play major roles in activating and 
enhancing the responsiveness of both cytotoxic T cells as well as B cells, which mediate 
the humoral, or antibody branch of the immune response (9). Any T cells bearing TCRs 
that are unable to sufficiently bind the self-peptide MHC complexes are eliminated by 
clonal deletion, meaning that all T cells expressing that particular TCR would also be 
deleted (58).  
The process of negative selection, also known as tolerance induction, is also 
based on TCR-peptide/MHC affinity. In this process, T cells bearing TCRs that recognize 
self-peptide/MHC complexes too strongly are again eliminated by clonal deletion 
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(reviewed in (59-61). The combined process of positive and negative selection results in 
a T cell repertoire in which T cells only recognize peptide antigens presented in the 
context of the MHC protein, and are ideally not reactive against self-peptide/MHC 
complexes (reviewed in (62)). The resulting T cell population that is allowed to circulate 
the periphery outside the thymus is thus capable of detecting virally-infected self cells 
with CD8+ T cells, and mounting robust T cell and B cell-mediated immune responses 
using CD4+ T cells and professional antigen presenting cells. 
 Both positive and negative selection processes utilize thymic epithelial cells as 
antigen-presenting cells that display self-peptide/MHC Class I and self peptide/MHC 
Class II molecules on the cell surface (63). The self peptides that are displayed on the 
surface of thymic epithelial cells are processed differently than antigens in the periphery. 
Firstly, in the periphery, the antigens presented on MHC class I are derived only from 
proteins that are actively being synthesized and degraded in that particular cell, so only 
the genes that are "on" are expressed and result in proteins from which peptide 
fragments can be displayed. For example, peptides derived from heart-specific proteins 
are only presented on nucleated cells found in the heart. However, thymic epithelial cells 
express a gene product called AIRE (Autoimmune Regulator of Expression), which turns 
on many genes that are not normally expressed, at some low level (64). The level of 
these proteins is low enough that it does not affect the phenotype of the cell, but 
sufficient such that the resulting proteins can be effectively degraded into peptide 
fragments and displayed on the cell surface in the context of the MHC proteins. Thus, T 
cells can be “tolerized” against a large repertoire of peptides derived from a broad set of 
non-thymic (as well as thymic) proteins. Defects in AIRE can result in severe 
autoimmunity, as the resulting T cell repertoire has likely not been tolerized against the 
majority of peptides derived from proteins expressed in non-thymic cells. Thus T cells 
that leave the thymus are more likely to recognize self-peptide/MHC complexes in the 
periphery and react against them in a way that cannot be fully controlled by peripheral 
tolerance processes (65,66). The evolution of central tolerance (positive and negative 
selection in the thymus) is arguably most important in affecting T cell autoreactivity and 
the breadth of the T cell repertoire, and it impacts control or progression of multiple 
diseases.  
 
Relationship Between Self-Peptide/MHC Expression and Disease 
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 The somewhat speculative relationship between self-peptide presentation by 
MHC proteins and disease control and progression is examined further in Chapter 3 of 
this thesis, but will be discussed here briefly. Each individual expresses up to six distinct 
MHC class I products, and each can bind a different subset of peptides based on anchor 
residue compatibility. During the development process, the peptides of interest are self 
peptides that are derived from proteins expressed in the thymic epithelial cells as a 
result of AIRE activity. If an MHC allele that is expressed in an individual binds a narrow 
subset of self peptides due to the peptide-binding groove environment, there will be 
fewer distinct peptide/MHC complexes against which the T cell repertoire can be 
tolerized. This may result in a broader, more diverse T cell repertoire that may be more 
likely to detect a foreign peptide antigen displayed on an MHC protein, as hypothesized 
in (67). Similarly, an MHC allele which binds a broader subset of self peptides during T 
cell development in the thymus would result in a greater number of distinct peptide/MHC 
complexes on the thymic epithelial cell surface, and thus a greater diversity of 
peptide/MHC complexes against which to tolerize the premature T cell repertoire. The 
resulting T cell repertoire that leaves the thymus following negative selection is less 
diverse in nature, and T cells bearing TCRs that could have reacted against foreign 
antigenic peptide/MHC complexes may have been deleted in the thymus.  
It is possible that the MHC allele that binds a broader repertoire of self peptides 
might also bind a broader repertoire of foreign peptides, and this would actually result in 
a greater chance of recognition and reactivity by T cells. However, the negative effect of 
enhanced self peptide presentation on the T cell repertoire during development may be 
the more dominant player in mediating the breadth and reactive capability of the T cell 
repertoire, and thus also disease control or progression. It may be noted that 
susceptibility to disease can be mapped to the MHC locus, and in particular, is most 
associated with HLA-B class I products. This seems to be the case that is reflected in 
studies of disease control and progression focusing on both infectious diseases, such as 
HIV/AIDS, and autoimmune conditions such as psoriasis and ankylosing spondylitis 
(67,68). The same HLA-B alleles that are associated with HIV control (such as HLA-B57 
and HLA-B27) are also associated with increased susceptibility to psoriasis and 
ankylosing spondylitis (69). HLA-B alleles that are associated with HIV progression, such 
as HLA-B35, are also associated with decreased susceptibility to the listed autoimmune 
diseases (70). In Chapter 3, we discuss our findings regarding the presence of particular 
polymorphisms at position 97 of the murine class I MHC Ld on the breadth of peptide 
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binding, and relate these findings to the HLA-B system. My work on this project is 
detailed in (71). Structurally, Ld and HLA-B are homologous and the position 97 residue 
is similarly located in these proteins as shown in aligned peptide/Ld and peptide/HLA-B 
structures (Figure 1.8). This allows us to draw parallels between these systems and 
discuss the possible effects of position 97 MHC class I polymorphisms on the T cell 
repertoire. 
In the case of autoimmune disease, it is speculated that MHC alleles that display 
a smaller collection of self peptides during central tolerance result in a more diverse T 
cell repertoire, which has the possibility of reacting with self antigens against which T 
cells were not tolerized in the thymus. For example, these T cells might react with 
peptides that are derived from proteins for which expression was not induced by AIRE in 
thymic epithelial cells. The less diverse T cell repertoire, thought to be the result of MHC 
alleles that bind a broad variety of self peptides, would be less likely to be self-reactive. 
 
T Cell Reactivity 
 T cell reactivity in the periphery begins with TCR binding, above an activation 
threshold, to a peptide/MHC complex on the surface of a target cell or antigen 
presenting cell. In the case of CD8+ T cells, when the TCR binds an antigenic 
peptide/MHC class I complex on the surface of a target cell with sufficient affinity, the 
CD8 co-receptor, which is present in a lipid raft with other components, interacts with the 
mostly invariant interface between the MHC class I heavy chain and β2m. When CD8 
interacts with MHC/ β2m, the lipid raft containing accessory signaling components is 
brought in close proximity with the TCR. One of the signaling components in this raft is 
the kinase Lck. The Lck kinase phosphorylates tyrosine residues in the Immunoreceptor 
Tyrosine Activation Motifs (ITAMS) present on the intracellular regions of CD3 subunits 
that are associated with the TCR (72,73). When the ITAMs are phosphorylated by Lck, 
they provide a docking point for another kinase known as ZAP-70, which binds to the 
phosphorylated tyrosines. Kinase Zap-70 is then also phosphorylated by Lck, thereby 
activating it, and then ZAP-70 dissociates from the CD3 ITAMs and facilitates a kinase 
cascade with many downstream players (Figure 1.5). Ultimately, this ZAP-70 cascade 
alters gene expression in the T cell using the transcriptional regulators NF-kB, AP-1, and 
NFAT, and allows the T cell perform its effector functions (74,75). For CD8+ T cells, this 
includes the production and release of cytokines interleukin-2 and interferon-γ, perforin, 
and cytotoxic granules containing Granzyme-B (76,77). Beyond the TCR-peptide/MHC 
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specific interaction, and the CD8-MHC interaction, there are other players in the immune 
synapse between the two cells. Adhesion molecules play an important role in facilitating 
the interaction between the T cell and target cell, holding the target cell within the 
proximity the T cell's effector molecules can act. The ICAM adhesion molecules on the 
surface of the target cell interact with binding partner LFA-1 on the surface of the T cell, 
which allows the cytotoxic granules released from the T cells to be directed towards the 
target cell presenting the antigenic peptide/MHC (78). The perforin secreted by the T cell 
creates holes in the target cell membrane, beginning the process of lysis. Granzyme-B 
begins digesting proteins within the target cell, which can then be taken up by 
macrophages and processed for display on the class II MHC proteins (79). Another 
interaction between the CD8+ T cell and target cell utilizes Fas ligand on the T cell 
binding to Fas (the receptor) on the target cell surface. This interaction induces caspase-
mediated apoptotic signaling within the target cell, resulting in cell death (80). Once 
again, the resulting cellular debris can be taken up by phagocytes and processed for 
antigen presentation. 
 The reactivity of CD4+ T cells begins with the same recognition process 
described above for CD8+ T cells, except the peptide ligands in this case are presented 
by MHC class II molecules. If the TCR binds a particular peptide/MHC class II molecule 
on the surface of an antigen presenting cell with sufficient affinity, the CD4 co-receptor 
binds the more invariant regions of the MHC class II complex, bringing with it the lipid 
raft and additional signaling components like the Lck kinase (81,82). Lck phosphorylates 
the ITAMs of the TCR-associated CD3 subunits, resulting in the binding of yet inactive 
ZAP-70, which is located in the cytosol. Upon binding to the phosphorylated tyrosines in 
the CD3 ITAMs, ZAP-70 is phosphorylated by Lck and releases from CD3, then goes on 
to start a kinase cascade that results in the activation of transcriptional regulators NF-kB, 
AP-1, and NFAT (Figure 1.5). These in turn activate the expression of genes encoding 
cytokines interferon-γ (among others) which enhances the activity of cytotoxic T cells 
(83), or interleukin-4 (among others) which enhances the activity of B cells (84,85). 
 The TCR-peptide/MHC interaction has been examined through structural studies- 
since the mid 1990s. Many ternary complex structures have been resolved containing 
TCRs bound to peptide/MHC complexes. The first mouse structure solved was that of 
the 2C T cell receptor bound to the self peptide dEV8 (sequence EQYKFYSV) (40,86) in 
complex with syngeneic MHC allele Kb (murine MHC class I allele) (87). The term 
"syngeneic" refers to the fact that the mouse from which the 2C T cell clone (CD8+) was 
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isolated was of the H-2b haplotype, indicating that MHC alleles Kb was expressed on all 
nucleated cells in that mouse. In this 2C-dEV8/Kb structure and others with either mouse 
and human TCRs, docking on self peptide/MHC complexes or foreign peptide/MHC 
complexes, a similar diagonal TCR docking geometry was observed (88,89).  
The TCR contains hypervariable complementarity determining regions or CDR 
loops, that most mediate the specificity of the TCR for a peptide/MHC complex. The 
CDR loops perform the majority of the recognition of the peptide/MHC complexes, and 
there are three CDR loops in each chain of the TCR, and six CDR loops total interacting 
with the peptide/MHC complex forming the TCR docking “footprint” (90). The CDR3 
loops confer the most peptide specificity of the three from each chain, having been 
encoded by the junctions of the V and J genes in the TCRα chain, and the junctions of 
the V, D, and J genes in the TCRβ chain. The CDR3 loop from each chain is centered 
over the peptide in this canonical TCR docking footprint, with CDR loops 1 and 2 of each 
chain located over one of the MHC alpha helices (91). If one was to draw a line between 
the center of mass of each TCR variable domain (from Vα to Vβ), a diagonal would be 
formed between the two. This diagonal docking orientation is not rigid in that every 
docking diagonal is exactly the same; a range of approximately 100° has been observed 
in diagonal docking orientations (92-94). The variety of angles formed by the TCR 
variable regions can be affected by both the identity of the peptide as well as the MHC 
allele in the structure.  
To illustrate the topology of the TCR:pepMHC interaction, the 2C TCR can be 
seen in Figure 1.6 docking on two different peptide MHC complexes, one syngeneic 
complex and one allogeneic (MHC mismatched) complex (the significance is described 
further in the next section (52)). The syngeneic complex shows the binding of the 2C 
TCR on the dEV8-Kb complex (95), and the allogeneic complex shows the binding of the 
2C TCR onto the QLSPFPFDL-Ld complex (52). Only the variable regions of the TCR 
are shown in the side-view of the complex viewing through the peptide-binding groove. 
The orientation of the TCR on each peptide/MHC complex shows the Vα domain over 
the MHC α2 helix and the Vβ domain over the MHC α1 helix.  The top-down view of the 
individual CDR loops docking on each peptide/MHC complex shows the previously 
described orientation of CDR loops 1, 2, and 3 from each TCR chain. In both complexes, 
the CDR3 loops from each chain are interacting with the peptide in the center of the 
peptide binding groove. If a diagonal is drawn between the CDR2α and CDR2β in each 
complex, there is an approximately 23°difference between these diagonal lines (52). A 
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very similar docking orientation is seen between the 2C-dEV8/Kb and 2C-SIYRYYGL/Kb 
complexes, though the SIYRYYGL (SIY) peptide was identified from a synthetic peptide 
library (96). In soluble kinetic binding studies, the 2C TCR binds to the dEV8-Kb complex 
with an affinity of 85μM (97), to the SIY-Kb complex with an affinity of approximately 
30μM, and to the QL9-Ld complex with an affinity of 2μM. In biological T cell activation 
assays using 2C T cell hybridomas, 2C T cells were activated by antigen presenting cell 
line T2 displaying either SIY-Kb complexes or QL9-Ld complexes on the surface, 
suggesting that the observed range of diagonal docking is acceptable for mediating 
biological reactivity. 
 The requirement or lack of requirement for the co-receptor in facilitating T cell 
activation is a dynamic field of study with the potential to influence T cell-based therapies 
for cancer and infectious disease. The above description of T cell activation discussed 
the contribution of the co-receptor in bringing Lck kinase to the TCR/CD3 complex, and 
all αβ T cells in the periphery must express either the CD4 or CD8 co-receptor. 
However, the co-receptor is not required for activation of the T cell in response to every 
peptide/MHC complex. What has been deduced experimentally, is that there is an 
affinity threshold above which the TCR affinity for the peptide/MHC complex can drive T 
cell activation and effector function without the requirement of the co-receptor. The 
particular value of the threshold affinity varies from system to system experimentally- for 
example in the T cell hybridoma system, experimental data from our lab suggests that if 
the KD of a TCR-peptide/MHC interaction is less than 2μM, activation can occur in the 
absence of the co-receptor. This was determined by performing biological assays using 
T cell hybridoma cell lines (58-/-) that expressed one particular TCR, such as the 2C 
TCR, but were either positive or negative for the CD8 co-receptor (98,99). However, 
when similar T cell activation assays are performed using primary T cells, the threshold 
for CD8 independence is closer to 10μM.  
The nature of CD8 dependence and independence has been examined by the 
Kranz Lab extensively, due to findings using the 58-/- T cell hybridoma cell line 
(derivative of BW5147 parental cell line), which is negative for RAG (recombinase 
activating genes), the enzyme that is responsible for TCR gene rearrangement (100). 
Because 58-/- cells cannot rearrange the TCR genes, this cell line cannot produce any 
endogenous T cell receptors, and thus when these cells are transduced to express a 
TCR of interest, only the intended TCR is on the surface. The relationship between TCR-
peptide/MHC affinity and the requirement of CD8 for T cell activation was also examined 
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in experiments assessing the reactivity of T cell hybridomas transduced to express the 
42F3 TCR, which was identified from a CD8+ T cell clone by Dr. Ted Hansen and Dr. 
Janet Connolly (101,102). Chapter 2 of this thesis describes these findings and explores 
the nature of CD8-independence and CD8-dependence in the reactivity of 42F3-
expressing T cell hybridomas against novel peptide antigens that were identified using a 
yeast display peptide/MHC library system. 
 T cell-mediated transplant rejection is described in the field of molecular 
immunology as “alloreactivity”. This is a phenomenon in which an individual is the 
recipient of a transplant from a donor that is MHC mismatched, meaning that at least 
one of the six MHC class I alleles, for example, is not encoded in the genome of the 
recipient (53,103,104). Because of this, during development in the thymus, T cells are 
not screened for their reactivity against these foreign peptide/MHC complexes- thus 
leaving the donor tissue vulnerable to attack by the recipient’s T cells (105). Studies on 
the molecular basis of alloreactivity sought to address questions regarding the specificity 
of the recipient’s T cells for the peptide/MHC complexes on donor tissue. For example, 
were the recipient’s T cells recognizing every foreign MHC complex regardless of the 
presented peptide, or was there specificity for the peptide presented on the allo- MHC? 
The early studies of transplant rejection began with a technique known as the mixed-
lymphocyte reaction, in which T cells from two different mice were mixed together after 
cells from one mouse were treated with an agent to block cell proliferation (reviewed in 
(106,107)). The proliferation of the lymphocytes (proliferation is an indicator of T cell 
reactivity) from the other mouse was quantified by the incorporation of 3H-thymidine that 
was present in media into newly synthesized DNA in the proliferating cells. If proliferation 
was detected, this was an indicator of T cell alloreactivity. The alloreactivity of T cells in 
these mixed lymphocyte reactions increased with the level of MHC mismatch between 
the two varieties of lymphocytes tested, providing evidence that cell-mediated transplant 
rejection is based on histocompatibility, or matching of MHC products. Other preliminary 
studies of alloreactivity showed that alloreactive T cells were specific for certain peptides 
presented on these allogeneic MHC alleles, meaning that the TCRs specificity was not 
only MHC-dependent, but alloantigen-dependent as well (108). The study of 
alloreactivity contributed greatly to the many considerations taken when matching 
donors to recipients for tissue transplants, and as such has greatly increased the 
prospects for the success of transplant surgeries (reviewed in (109)). 
 
 
 
16 
The Mouse 2C T Cell System 
 The most well-characterized T cell clone is the murine 2C, and was identified in 
1984 as an alloreactive CD8+ T cell clone that was raised in a mouse of H-2b haplotype, 
meaning that the mouse expressed MHC class I products were of the "b" allele. The 
isolation of the 2C T cell clone is detailed in (110). This particular mouse strain did not 
express any L MHC class I gene products. The H-2b mouse was then injected with P815 
cells, mastocytoma cells of H-2d hapotype, meaning that the P815 cells expressed MHC 
class I gene products Kd, Dd, and Ld on the surface, each complexed with some 
endogenously processed peptide derived from proteins expressed in P815 (Figure 1.7). 
Because the implanted P815 tumor cell line was fully MHC mismatched as compared to 
the H-2b mouse, this system was analogous to a transplant recipient receiving a fully 
MHC mismatched donor tissue. Cytotoxic T cells reacted against the mismatched MHC 
molecules on the P815 surface, effectively eliminating those transplanted cells. As part 
of this reaction against P815, the T cells that recognized P815 proliferated, and were 
taken from lymphoid tissue (spleen, lymph nodes) of the recipient mouse and clones 
were isolated by culturing the cells using a limiting dilution strategy. The resulting clones 
were tested for reactivity against P815 cells in an in vitro cytotoxicity assay, and it was 
from these experiments that the 2C T cell clone was identified as an alloreactive T cell 
clone that recognized a peptide/MHC class I complex on the surface of P815. The TCR 
genes from the 2C T cell clone were isolated, and the genes were sequenced resulting 
in the first known sequence of a complete T cell receptor.  
Like all endogenous TCRs, the 2C TCR was positively selected in the H-2b 
mouse (Sha et al, Nature, 1988), Subsequently, 2C was predicted to have been 
positively selected by binding with low affinity to the dEV8/Kb complex (111,112). The 
restriction of the 2C T cell clone by the Ld MHC class I allele was discovered by 
performing cytotoxicity assays including blocking antibodies to each MHC class I allele 
expressed on P815. Only blocking the Ld molecules reduced cytotoxicity by the 2C clone 
(37). Further experiments were performed to identify the peptide endogenously 
processed by P815 cells that was displayed on Ld and recognized by the 2C TCR. 
Candidate peptides were identified using an acid extraction technique, in which P815 
cells were lysed in an acidic environment that facilitated the precipitation of large cellular 
proteins and solubilization of intracellular and cell surface peptides. The solubilized 
peptide fragments were separated using high performance liquid chromatography 
(HPLC) and hydrophobicity gradient; the resulting HPLC fractions were sampled in an in 
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vitro cytotoxicity assay using the 2C T cell clone and target cells that expressed MHC Ld. 
HPLC fractions that resulted in 2C cytotoxicity against the target cell contained a 
peptide(s) that mediated the interaction between 2C and Ld on the cell surface. A peptide 
called p2Ca (LSPFPFDL) was identified using this acid extraction method, and a 
synthetic version of this peptide was made and sampled again in in vitro cytoxicity 
assays, verifying that the 2C T cell clone did recognize and react against Ld-expressing 
cells displaying this peptide.  
Further studies evaluated the quantitative binding of the 2C TCR to peptides 
p2Ca and the N-terminal extended version QL9 displayed on Ld (113-115), and further 
characterization of the 2C TCR is detailed in (116). It must be noted that this peptide 
was identified using acid extraction, not an affinity purification of endogenously 
presented peptide/Ld complexes from the surface of P815 cells (37,117). This is 
important because the affinity purification method isolates only peptides that were 
endogenously presented, while acid extraction isolates peptide fragments derived from 
all cellular proteins, whether or not they were actually processed endogenously and 
presented on the MHC. The identification of this p2Ca peptide, as well as the search for 
the endogenously presented peptide ligand against which the 2C T cell was raised, is 
discussed at length in Chapter 4 of this thesis. 
 The 2C T cell system contains many "firsts" with regards to the field of 
immunology. The 2C T cell clone was the first alloreactive, "transplant specific" T cell 
clone that was isolated, and the 2C TCR was the first complete T cell receptor that was 
sequenced and identified. Additionally, the 2C TCR was the first mouse T cell receptor 
crystallized in complex with a peptide/MHC ligand (complexed with positive selecting 
ligand dEV8 presented by syngeneic MHC allele Kb) (95). The 2C TCR was the template 
for early T cell receptor engineering projects utilizing yeast display technology- 2C TCR 
variants were developed with high affinity for syngeneic peptide/MHC complex SIY/Kb as 
well as allogeneic peptide/MHC complex QL9/Ld and expressed in T cell hybridomas 
(118,119). Additionally, the 2C T cell hybridomas as well as the hybridomas expressing 
high affinity variants of the 2C TCR were used in studies concerning the nature of CD8-
independence and CD8-dependence in T cell activation as previously reported by the 
Kranz Lab (98,99).  
The 2C T cell system was utilized recently in a study concerning the nature of in 
vivo selection mechanisms with relation to TCR affinity for a particular peptide/MHC 
complex. In this study, H-2b mice were implanted with syngeneic tumors that had been 
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transduced to produce and present the SIYRYYGL peptide (detailed in (120) and (121)). 
Then primary T cells were transduced with a TCR library based on the 2C TCR (wild 
type affinity of 30μM for the SIY/Kb complex) or the 2C variant m33 which binds SIY/Kb 
with high affinity (30nM), with degeneracy in the TCR sequence at key residues in 
positions known to contact the SIY/Kb complex. The growth of the SIY/Kb+ tumors was 
monitored, and at the time of sacrifice, T cells were isolated from the spleen and lymph 
nodes. An RNA extraction and conversion to cDNA, and subsequent high-throughput 
sequencing, revealed the sequences of the TCRs expressed by those T cells. The TCRs 
that were variants of either the 2C or m33 TCRs were compared in terms of frequency of 
each amino acid at these key positions, and in terms of affinity of the TCR variants for 
the SIY/Kb complex. This compilation of data, as described in (122) and (121) revealed 
an affinity threshold of ≈ 3μM, above which deletion of adoptively transferred T cells can 
be observed. These findings using the 2C T cell system are fully relevant to the studies 
regarding engineering of human T cell receptors against common tumor antigens. In 
designing or optimizing a T cell receptor for a particular tumor antigen, the TCRs with the 
greatest affinity will not necessarily result in the greatest success of adoptively 
transferred T cells (see also (123,124) and (125)). Rather, studies using the 2C TCR 
suggested that an intermediate affinity of an engineered TCR for a particular tumor 
antigen may provide a greater anti-tumor effect. 
 The findings from studies using the 2C T cell clone and 2C TCR have informed 
the fundamentals of immunology- providing insights into T cell mediated transplant 
rejection, T cell development, and TCR engineering, among other things. These findings 
translate well into the study of human T cells and human T cell receptors, and for this 
reason the 2C T cell system remains an important tool to further understand complicated 
immunological concepts. 
 
The Mouse 42F3 T Cell System 
 The 42F3 T cell clone was isolated in a manner similar to that of 2C, in that it was 
isolated as a CD8+ alloreactive αβ T cell clone that was raised against the Ld-expressing 
P815 mastocytoma. An H-2d mouse in which the L gene had been deleted was injected 
with P815 cells similarly to the manner described above for the 2C T cell clone. Even 
though the haplotype of the mouse was H-2d, just like P815, the resulting T cell response 
is still considered alloreactive in nature because the T cells present in the mouse were 
never tolerized against peptide/Ld complexes during development due to the deletion of 
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the Ld gene (101). The TCR expressed on the surface of the 42F3 T cell clone is related 
to the 2C TCR and shares significant sequence identity in both the alpha and beta 
chains, and also recognizes the peptide QL9 (QLSPFPFDL) presented on MHC allele Ld.  
Of relevance to this thesis work, the 42F3 T cell clones isolated in the lab of 
Janet Connolly were frozen and stored, but were not hardy enough to survive thawing 
for use in in vitro assays. To address this, a previous member of the Kranz Lab, Dr. 
Natalie Bowerman, performed RNA extractions on the 42F3 T cell clones to identify and 
sequence the rearranged TCR genes that encoded the variable regions of the alpha and 
beta chains. The sequence of the 42F3 TCR, as well as the transduction of these TCR 
genes into the 58-/- T cell hybridoma cell lines that were either positive or negative for the 
CD8 co-receptor, is detailed in Chapter 2 of this thesis, as well as in published work 
(102). Experiments were performed using these CD8+ and CD8- 42F3 T cell lines to 
assess the reactivity of the 42F3 TCR against novel peptide/Ld antigens that were 
identified using yeast display, and resulted in further characterization of the 42F3 TCR. 
Figure 1.1. A schematic representation of V/J recombination in the TCRα chain and V/D/J 
recombination in the TCRβ chain. RAG recombinase facilitates the somatic rearrangement of V and 
J gene segments in the TCRα locus. In the TCR β, RAG first rearranges the D and J gene 
segments, and then rearranges the V gene segment to the already rearranged D-J segments. The 
resulting rearranged genes coding for the variable region of the TCR protein chains is transcribed, 
then spliced together with the transcript encoding the constant region of each TCR chain. The 
mRNA transcript for each TCR chain is then translated and the resulting chains are transported to 
the T cell surface and paired to form an αβ heterodimer. 
Figure 1.1 
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Figures and Tables 
Table 1.1 
Gene segment V D J C 
TCR α 70-80 ------- 61 1 
TCR β 52 2 13 2 
Table 1.2 
Number of known alleles 
MHC Class I 
A 2,365 
B 3,015 
C 1,848 
DP 37 190 
DR 7 1,456 
DQ 51 416 
MHC Class II 
α β    
Table 1.1. The number of each T cell receptor gene 
segment in the human genome. 
Table 1.2. The number of distinct alleles of MHC 
class I (HLA-A, -B, or –C) and MHC class II (HLA-DP, 
-DR, -DQ) that have been identified and sequenced 
from the human population. These values reflect the 
number of distinct alleles as of July 2013 that have 
been reported on the website of the IMGT 
(International ImMunoGeneTics information system). 
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Figure 1.2 
A 
B 
Side-view Top-down view 
Side-view Top-down view 
Human MHC I HLA-A2 
Human MHC II HLA-DR1 
Figure 1.2. A, Left: Side-view of class I MHC allele HLA-A2 in complex with beta-2-
microglobulin and Mart-1 peptide AAGIGILTV (PDB ID 3QFD). Blue, HLA-A2; 
orange, β2m; red, AAGIGILTV peptide. Right: Top-down view of the 
AAGIGILTV/HLA-A2/β2m complex, showing the peptide orientation in the peptide-
binding groove. B, Left: Side-view of class II MHC allele HLA-DR1 in complex with 
influenza derived peptide PKYVKQNTLKLAT (PDB ID 1DLH). Magenta, HLA-DR1 α 
chain; grey, HLA-DR1 β chain; cyan, PKYVKQNTLKLAT peptide. Right: Top down 
view of peptide PKYVKQNTLKLAT in the peptide-binding groove of HLA-DR1. 
α1 
α3 
α2 
β2m 
α1 
α2 
α1 
β2 
β1 
α2 
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HLA-A2 
β2m 
AAGIGILTV 
HLA-DR1 α 
HLA-DR1 β 
PKYVKQNTLKLAT  
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Figure 1.3 
A B 
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CD4 
Helper T cell 
Antigen-
presenting cell 
Figure 1.3. A, Schematic representation of the interaction between 
the αβ T cell receptor  on a cytotoxic T cell with a peptide (red circle) 
in complex with a class I MHC product and β-2-microglobulin on the 
surface of a target cell. The CD8 co-receptor of the cytotoxic T cell is 
shown interacting with the α3/β2m region of the peptide/MHC 
complex. B, Schematic representation of the interaction between the 
the αβ T cell receptor  on a helper T cell with a peptide (cyan circle) in 
complex with a class II MHC product on the surface of an antigen 
presenting cell. Also shown is the CD4 co-receptor of the helper T cell 
interacting with the relatively invariant β2 region of the MHC class II 
beta chain. 
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Figure 1.4 
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α2 
Figure 1.4. A, Side-view of the full length class I MHC Ld protein in 
complex with murine β-2-microglobulin and peptide p29 
(YPNVNIHNF) (PDB ID 1LD9). Grey, Ld heavy chain; lime green, 
murine β2m; purple, p29 peptide. B, Side-view of miniature Ld module 
Ldm31 in complex with peptide QL9 (QLSPFPFDL) (PDB ID 3ERY).  
Grey, Ldm31. Marine blue, QL9 peptide. C. Top-down view of peptide 
QL9 bound in the Ldm31 peptide binding groove, with the arginine 
residue at position 97 of Ldm31 highlighted in red. 
C 
α1 
α2 
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A 
B 
C 
D 
Figure 1.5 
Figure 1.5. A, Schematic representation of a T cell in a resting state, with the 
TCR/CD3 complex assembled and the co-receptor in a lipid raft with Lck kinase. 
CD3 ITAMs are un-phosphorylated, indicated by (    ). B, the T cell interacts with an 
antigen presenting cell, and TCR engages a peptide/MHC complex. The co-
receptor (CD4 or CD8) engages with the invariant region of the MHC, bringing Lck 
in close proximity to the CD3 ITAMs, which are then phosphorylated (    ). C, 
Kinase ZAP-70 binds to the phosphorylated ITAMs, and is itself activated by Lck 
phosphorylation (      ). D, Activated ZAP-70 detaches from the CD3 subunits and 
initiates a kinase cascade that ends in the activation of transcriptional regulators 
NF-κB, AP-1, and NFAT. These transcriptional regulators then translocate to the 
nucleus alter gene expression to mediate effector function. 
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Figure 1.6 
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Figure 1.6. A, Side-view of the structure of the 2C TCR binding to positive 
selecting peptide ligand dEV8 presented on syngeneic MHC class I allele Kb. 
Magenta, 2C Vα; lime green, 2C Vβ; grey, MHC Kb; yellow, dEV8 peptide. B, Side-
view of the structure of the 2C TCR binding to peptide ligand QL9 presented on 
allogeneic MHC class I allele Ld. Orange, 2C Vα; blue, 2C Vβ; grey, Ldm31; red, 
QL9 peptide. In A and B, the shown structures contain only the variable regions of 
the 2C TCR and the peptide-binding grooves of the class I MHC products Kb and 
Ld. C, Shown are the footprints of the 2C TCR CDR loops docking on either the 
dEV8/Kb complex or QL9/Ld complex. The diagonal line shown between the CDR2 
of each chain is representative of the canonical TCR docking diagonal. 
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Figure 1.7 
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Figure 1.7. A, Schematic representation of the isolation of the 2C T 
cell clone. Shown is a cartoon of an H-2b haplotype mouse, which was 
injected with cells of the P815 cell line, an Ld-expressing mastocytoma. 
T cells were then isolated from lymphoid tissue, including the spleen. 
B, schematic representation of the class I MHC products expressed on 
the surface of P815 cells. 
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Figure 1.8 
MHC Class I alleles with R97 
QLSPFPFDL-Ldm31 
Murine 
VPLRMPTY-HLA-B35:01 
Human 
Figure 1.8. Shown is a top-down view of the murine class I MHC allele 
Ld (Ldm31) (left complex), and human MHC class I allele HLA-35:01 
(right complex), each in complex with  the indicated peptide. Each 
displayed MHC class I allele contains an arginine at position 97 in the 
peptide binding groove, which is highlighted in red (Ldm31) or black 
(HLA-B35:01).   
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CHAPTER TWO 
 
NOVEL PEPTIDE ANTIGENS REVEAL THE IMPORTANCE OF CD8 AND T CELL 
RECEPTOR:PEPTIDE-MHC INTERACTION GEOMETRY ON T CELL ACTIVATION 
 
Introduction 
 The molecular basis of T cell recognition of antigens and the resulting effector 
function is a complex and interesting field of study. Major findings have revealed the 
mechanisms by which T cells in an individual’s T cell repertoire, expressing a diverse 
array of rearranged T cell receptors (TCRs), are able to recognize and distinguish 
foreign-derived antigens from normal self peptides within the context of the major 
histocompatibility complex (MHC). Approximately 95% of the T cells in a human 
individual are heterodimers of the α and β chains, each containing a constant domain 
and a variable domain, which contains hyper-variable regions known as complementarity 
determining regions or CDR loops. These αβ TCRs recognize peptides presented only in 
the context of an MHC product displayed on the surface of nucleated cells of the body.  
The peptides displayed on the MHC products can be derived from normally 
expressed self proteins, proteins that are encoded by viruses, or extracellular proteins 
that are processed after endocytosis (126). During development, T cells are screened for 
reactivity with self peptide-MHC complexes; T cells bearing TCRs that do not bind 
sufficiently well to self peptide/MHC complexes are clonally deleted, as are T cells 
bearing TCRs that bind too strongly to self peptide/MHC complexes (63,127-129). This 
process, known as central tolerance, results in a T cell repertoire that recognizes foreign 
peptide antigens presented on the MHC, but ideally does not react against self-
peptide/MHC complexes displayed on the surface of normal, healthy cells. Once out in 
the periphery, T cells react only when the TCR binds an antigenic peptide/MHC complex 
with sufficient affinity, typically on the order of 1-300μM (1,130,131). The term “MHC 
restriction” refers to the requirement of T cells to recognize antigen only in the context of 
the MHC product; no free peptide antigens will be recognized by the αβ T cell repertoire 
(11). The restriction of the TCR by the MHC product suggests a possible co-evolution of 
 
 
30 
these molecules, as there appear to be conserved contacts between conserved key 
residues in the T cell receptor variable regions and MHC helices (92,132,133).  
The hypothesis regarding the coevolution of the TCR and MHC proteins 
stemmed from the growing abundance of solved TCR-peptide/MHC structures (both 
human and murine), which show a consistent diagonal docking orientation of the TCR 
onto an antigenic peptide/MHC complex (88,134). The diagonal is drawn between the 
center of mass of each TCR variable region, in which the CDR3 loop from each chain is 
centered over the peptide, beta chain CDR loops 1 and 2 are located over the MHC α1 
helix, and alpha chain CDR loops 1 and 2 are located over the MHC α2 helix. The first T 
cell receptor structure that was solved in complex with a relevant peptide/MHC complex 
showed the docking of the well-characterized murine TCR known as 2C on self peptide 
EQYKFYSV (dEV8) displayed on syngeneic MHC allele Kb (135). The 2C TCR has also 
been crystallized in complex with synthetic peptide antigen SIYRYYGL (SIY) displayed 
on the Kb allele (136), as well as alloantigen QLSPFPFDL (QL9) displayed on allogeneic 
MHC allele Ld (52), and in all of these structures 2C docked with the same diagonal 
orientation on the peptide/MHC complex.  Because these crystallized complexes did not 
include any other components of the immune synapse where the T cell meets the target 
cell, such as co-receptor CD8, adhesion molecules, and signaling molecules, the 
conserved diagonal docking orientation was mediated only by the TCR and MHC 
proteins. 
Typically, the peptides included in these solved TCR-peptide/MHC structures 
resulted in some level of biological reactivity from T cells bearing these particular TCRs. 
Peptide dEV8 was identified as the endogenously Kb-presented peptide that resulted in 
positive selection of the 2C TCR during development (112); peptide QL9 was a naturally 
derived peptide identified as a potent alloantigen for 2C T cells when presented on Ld 
(37). Peptide SIY was identified from a synthetic peptide library, and when presented on 
Kb induces reactivity from 2C T cells (96). 
The 42F3 (Vα 3.3, Vβ 8.3) TCR is related to the 2C TCR (Vα 3.1, Vβ 8.2), and 
was raised in an H-2d haplotype mouse in which the L locus, which would have encoded 
the Ld product, had been deleted (101). For this reason, the T cells in this mouse were 
never tolerized against self peptide/Ld complexes, and thus Ld can serve as an 
allogeneic MHC allele for the 42F3 TCR. The 42F3 TCR was found to interact with 
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naturally derived peptide QL9 when displayed on the Ld allele. The 2C TCR was raised 
in a mouse of H-2b haplotype that had been inoculated with P815 cells (H-2d, and Ld+), 
and the isolation and identification of the 2C TCR is detailed in (137) and (51) and (138). 
In collaboration with K. Christopher Garcia’s lab at Stanford University, we 
utilized yeast display technology to identify novel peptide antigens to mediate reactivity 
between the 42F3 TCR and the allogeneic MHC allele Ld. In this system, a variant of the 
miniature Ld module Ldm31 was displayed on the surface of yeast via in-frame fusion 
with the yeast Aga2 protein, and a nonamer peptide was tethered to the C-terminal end 
of Ldm31 via a flexible linker. Three yeast display libraries were generated by introducing 
degeneracy in the DNA sequence encoding the nonamer peptide; two of the libraries 
used peptide QL9 as a template and degeneracy was introduced at positions that either 
contacted the TCR (TCR contacts library) or the MHC (MHC contacts library). One 
library was entirely randomized except for anchor positions 2 and 9 of the peptide.  We 
identified novel peptide antigens using this method and examined them in the context of 
biological assays (T cell activation assays, flow cytometry binding studies), kinetic 
binding studies (surface plasmon resonance), and crystallographic studies (crystal 
structures of each ternary TCR-peptide/Ld complex). We discovered one peptide, 
SPLDSLWWI (SPL), from the entirely random yeast display library, that failed to 
stimulate 42F3 T cells despite sufficient binding of 42F3 to the SPL/Ld complex. The 
solving of the crystal structure of 42F3 docking on the SPL/Ld complex revealed that 
42F3 docked with an orientation that deviated greatly from the canonical docking 
orientation previously described, and we propose that this unconventional docking 
orientation may prevent T cell activation signaling in response to binding this peptide/Ld 
complex. This collaborative work was written and published in the journal Immunity in 
2011 (102). 
 
Materials & Methods 
 
The following materials and methods have been adapted, in part, from the published 
manuscript that describes some of studies in this chapter (referenced in this chapter 
(102)): Adams, J.J., Narayanan, S., et al. 2011. T cell receptor signaling is limited by 
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docking geometry to peptide-Major Histocompatibility Complex. Immunity 35(5): 681–
693. 
 
Cell lines 
Parental 58-/- and 58-/- CD8αβ++ cell lines are non-adherent T cell hybridoma lines 
of BW5147 lineage. Cells were grown in complete RPMI 1640 containing 10% fetal calf 
serum and were maintained by splitting/passing the cells in a 1:10 ratio every two days. 
The LM1.8-LdW97R cell line was a generous gift from the lab of Dr. Janet Connolly at 
Washington University in St. Louis, MO. The LM1.8-LdW97R is an L-cell fibroblast cell 
line that is a TAP-competent with high levels of adhesion molecules, and was 
transfected to express LdW97R previously in the labs of Dr. Ted Hansen and Dr. Janet 
Connolly (101). These cells were grown in complete RPMI 1640 with 10% fetal calf 
serum and passaged every 3-4 days. G418 0.5mg/mL was added to LM1.8-LdW97R 
culture every third time the cells were passaged. 
 
Peptides 
All novel peptides used in this study were obtained from Genscript. Peptides QL9 
(QLSPFPFDL) and MCMV (YPHFMPTNL) were synthesized by the Protein Sciences 
Facility at the University of Illinois at Urbana-Champaign. For use in biological assays, 
the crude peptides were dissolved in sterile dimethylsulfoxide, or DMSO (Sigma), at a 
concentration of 50mM and stored at -20°C. Peptides were diluted for use in biological 
assays into complete RPMI containing 10% fetal calf serum. 
 
Sequencing the 42F3 TCR 
This work was performed by Dr. Natalie A. Bowerman, a previous member of the 
Kranz Lab, and the following description of the methods has been adapted from (102). 
Primary 42F3 T cells were mixed with 1mL TRIzol Reagent (Invitrogen) on ice, then 
incubated for 5 minutes at room temperature. 200 μL chloroform was added and mixed 
by shaking for 15 seconds followed by room temperature incubation for 2-3 minutes. 
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Treated cells were centrifuged at 12000g for 15 minutes at 4°C. Aqueous RNA phase 
was transferred to a fresh tube and 500 μL isopropyl alcohol/1mL TRIzol was added and 
the mixture was incubated for 10 minutes at room temperature. Sample was centrifuged 
for 10 minutes at 12000g at 4°C. 1mL 75% ethanol/1mL TRIzol was mixed with the 
precipitant and centrifuged for 5 minutes at 7500g at 4°C. Supernatant was removed and 
the pellet was allowed to air dry for 5-10 minutes. RNA was resuspended in 50 μL 
RNAse-free water and incubated for 10 minutes at 60°C. RNA concentration was 
quantified by analyzing by A260/A280. Total RNA was converted to cDNA using a 
SuperScript First-Strand Synthesis System (Invitrogen) creating heterogeneous cDNA. 
42F3 was cloned from bulk cDNA by nested PCR as previously described in (139) and 
cloned using a TOPO TA cloning kit (Invitrogen) using Vα fwd 5’ gctcagtcagtgacacagccc 
3’, and Vβ fwd 5’ gaggctgcagtcacccaaagc 3’ primers. 
 
Cloning of 42F3 genes into retroviral vector MSCV and generation of 42F3 T cell 
hybridoma cell lines 
This description of the methods was taken and adapted from (102). The 42F3 
alpha and beta V genes were synthesized in frame with the mouse TCR alpha and beta 
constant regions (Genscript) and cloned into retroviral transduction vector MSCV using 
restriction enzymes Age1 (5’) and Mlu1 (3’) using T4 DNA Ligase (Invitrogen). 
Constructs were verified by sequencing. 30μg 42F3- MSCV DNA and 60μg 
Lipofectamine 2000 (Invitrogen) were incubated at room temperature in 3ml Opti-mem 
media (Gibco #11058) for 20 minutes. After removing DMEM culture supernatant, 
DNA/lipofectamine mixture was incubated with 3x106 adherent Plat-E cells for 3 hrs at 
37°C. DNA/lipofectamine supernatant was removed and Plat-E cells were recovered 
overnight at 37°C in a poly-L-lysine coated 100mm tissue culture dish. DMEM media 
was removed and Plat-E cells were incubated in RPMI 1640 at 37°C overnight. T cell 
hybridoma 58-/- cell lines with and without CD8 (118)were transduced by centrifuging 
2x106 cells in a 24-well plate (Corning costar) with 1.5ml of filtered culture supernatant 
from transfected Plat-E cells for 45 minutes at 652g. Cells were incubated with Plat-E 
supernatant for 4hrs at 37°C prior to incubation with additional 1.5mL of filtered Plat-E 
supernatant. 1mL supernatant was removed, and cells were cultured overnight at 37°C. 
Transduced cells were transferred to T25 flask with 5mL RPMI 1640 and cultured at 
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37°C and 5% CO2. The brightest 1% of V positive cells was sorted by staining with 
10μg/ml biotinylated anti-Cβ antibody followed by 1.7μg/mL SA-PE. 42F3 cells were 
cultured in RPMI 1640 with 10% FCS and 0.5mg/mL G418. 
 
Peptide-Ldm31 libraries using yeast display and QL9 template 
This work was performed by Dr. Jarrett Adams in Dr. K. Chris Garcia’s lab at 
Stanford University. This description of the methods was taken and adapted from (102). 
H2-Ld was displayed on the surface of yeast as a minimal α1α2 variant of H2-Ld called 
m31 (47). The m31 used in this study was converted into a single chain pMHC with a C-
terminal tethered peptide (Aga2-LdW167A-pep) by incorporating the mutation W167A. The 
W167A mutation created an opening at the end of the Ld α2 helix for the peptide Gly-Ser 
linker to pass without influencing the binding of the TCR. Aga2-LdW167A-pep was cloned 
into the yeast display vector pCT302. A degenerate primer containing the peptide library 
annealing to the peptide-associated linker nucleotide sequence were used to PCR 
amplify combinatorial libraries. A second PCR was used to further amplify the total mass 
of DNA and to extend the 5’ and 3’ ends of the amplicon with 50bps complementary to 
the vector sequence. Libraries were then recombined into linearized vector using 
homologous recombination in yeast (140). Briefly, 1mL of electro-competent yeast was 
prepared as previously described and transformed with 100μg extended library amplicon 
and 20μg of linearized pCT302. Yeast cultures were allowed to recover in YPD for 1hr 
and grown in SDCAA media. Cultures were split twice to 107 cells/ml in SDCAA and 
grown for 24hrs shaking at 30°C. Transformants were calculated from the number of 
colonies formed on plates from a serial dilution of the recovered electroporated yeast 
cultures. The number of transformed yeast for each library were 1.8x108, 1.0x108 and 
5.7x107 for the Random, TCR contact and MHC contact libraries respectively. 
 
Selection of yeast clones using soluble 42F3 scTCR tetramers 
This work was performed by Dr. Jarrett Adams of Dr. K. Christopher Garcia’s 
laboratory at Stanford University. The following description of the materials and methods 
has been adapted from (102). Freshly cultured cells from each yeast library were 
resuspended in SGCAA pH 4.5 at a concentration 107 cells/mL and were grown shaking 
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at 20°C for 48 - 72 hours. After induction, the yeast cells were washed once with 
PBS+0.1%BSA (PBS/BSA) and incubated with 470nM preformed 42F3-tetramers 
assembled on SA-PE (Invitrogen) and 1:100 dilution of anti-HA-Alexa488 (Invitrogen) for 
3hrs at 4°C while slowly tumbling to maintain cells in suspension. After incubation cells 
were washed twice with PBS/BSA and resuspended in FACS buffer immediately before 
sorting on a FACS Aria (BD). During the first round of selections the brightest 2.5% of 
the 42F3-tetramer+/HA+ population was sorted into a single culture. The sorted cells 
were grown overnight at 30°C in SDCAA to a cell concentration of 5.0x107-1.0x108 
cells/mL before the yeast were induced again and the process repeated. After the first 
round of selection, the brightest 1% of 42F3-tetramer+/HA+ was sorted until greater than 
10% of the yeast population could be resolved from the unstained population by flow 
cytometry. Each selection oversampled the total number of selected clones from the 
previous round by at least 10-fold to maintain diversity throughout the enrichment. 
Enriched populations were serially diluted to individual clones and grown on SDCAA 
plates. Individual yeast colonies were picked and grown in 1mL SDCAA in a 96 deep 
well block for 36hrs, shaking at 30°C. Yeast clones were induced by resuspending 107 
cells in 1mL SGCAA pH4.5 in a 96 deep well block and grown for 48hrs, shaking at 
20°C. Yeast cultures were stained with 100nM preformed 42F3-tetramers while rocking 
on ice for three hours in a 96 well plate. Fluorescence was detected and analyzed using 
a C6 flow cytometer with an autosampler (Accuri). Data analysis was carried out on 
Flowjo and CFlow software. Individual plasmids from yeast clones were harvested using 
the Zymoprep yeast plasmid mini-prep II kit (Zymo Research) and sequenced 
(Sequetech). 
 
42F3 T cell activation assays using LM1.8-LdW97R APCs 
T2-Ld or LM1.8-LdW97R target cells (1x105) and peptides were diluted in RPMI 
and incubated in a 1:1 effector-to-target ratio with CD8αβ+ or CD8αβ- 42F3 T cells for 20 
hrs at 37°C. For a negative control, target cells and T cells were incubated in the 
absence of peptide (no peptide). For a positive control, T cells only (1 x 105) were 
incubated in wells that had been previously immobilized with 10μg/mL anti-CD3 mAb 
(clone 145-2C11). For the inhibition experiments performed for Figure 8B, 42F3 CD8+ T 
cells were incubated with LM1.8-LdW97R target cells and 30nM QLSDKPVDL alone, or 
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30nM QLSDKPVDL mixed with various concentrations of SPLDSLWWI or MCMV 
peptide, and incubated at 37°C for 20 hours. The resulting cell supernatants were 
analyzed for IL-2 using an ELISA format (BD Pharmingen).  
Alternatively, recombinant H-2Ld:Ig fusion protein (BD Biosciences) was loaded 
with exogenous peptides by incubating 100nM H2-Ld:Ig in the presence of 10μM peptide 
overnight at 37°C. Peptide-loaded H2-Ld:Ig dimers (50μL) were immobilized overnight at 
4°C in a 96-well tissue culture plate (Corning Costar) (98). CD8αβ- 42F3 T cells (105) 
diluted in RPMI were incubated for 20hrs at 37°C in wells with immobilized pep/H2-Ld:Ig. 
Supernatants were assayed for cytokine release by IL-2 ELISA (BD Pharmingen). 
Experiments were done in duplicate in two independent experiments. 
 
Flow cytometry staining of 42F3 58-/- cells and peptide-loaded LM1.8-LdR97 cells with 
soluble PE-conjugated tetramers 
LM1.8-LdW97R cells (2x105) were incubated on ice for 3hrs with 10μM peptide 
(MCMV, QL9, SPLDSLWWI, QLSDRPVDL or FLSPFWFDI) and 470nM preformed 
42F3- tetramers diluted in PBS/BSA. After incubation, cells were washed twice with cold 
PBS/BSA to remove unbound tetramer. Cells were analyzed for PE fluorescence on a 
C6 flow cytometer (Accuri).  
Likewise, washed 42F3 T cells (1x106) were incubated on ice for 3hrs with 
470nM preformed single-chain pMHC-tetramers encoding QL9, SPLDSLWWI, 
QLSDVPMDL, and FLSPFWFDI diluted in PBS/BSA. After incubation, cells were 
washed twice with cold PBS/BSA to remove unbound tetramer. Cells were analyzed for 
PE fluorescence on a C6 flow cytometer (Accuri). For both of these types of 
experiments, data was analyzed using the flow cytometry analysis software FCS 
Express. 
 
Competitive peptide binding assays using QL9 and scTCR 2C-m6 
 58-/- cell lines transduced to express MHC LdW97 or LdR97 were incubated with 
50nM QL9 alone, or various competitor peptides (QLSDVPMDL, FLSPFWFDI, 
SPLDSLWWI) titrated in the presence of 50nM QL9 peptide. After a three hour peptide 
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loading period at 37°C, the cells were washed with PBS/BSA and incubated with 
10μg/mL biotinylated 2C-m6 scTCR, which binds with high affinity to QL9-LdW97 and 
QL9-LdR97 complexes. After another wash with PBS/BSA, the cells were incubated with 
Streptavidin conjugated to the phycoerythrin fluorophor (SA-PE). The cells were washed 
again with PBS/BSA and fixed with 1% paraformaldehyde in PBS and fluorescence was 
analyzed using the Accuri C6 flow cytometer. Data were analyzed using FCS Express 
and graphed using Graphpad Prism. Data was indicated as MFU0, which designates the 
mean fluorescence units (MFU) of cells incubated with 50nM QL9 alone, and MFU1, 
which designates the MFU of cells incubated with 50nM QL9 and one concentration of 
competitor peptide. The MFU1/MFU0 for each peptide concentration was plotted versus 
log of peptide concentration, and the resulting non-linear regression curves provided 
BD50 values to quantifiably compare the affinity with which peptides L
dW97 or LdR97. 
 
Cloning and expression of soluble 42F3 scTCR for use in SPR and crystallographic 
studies 
This work was performed by Dr. Jarrett Adams of Dr. K. Christopher Garcia’s 
laboratory at Stanford University. The following description of the materials and methods 
has been copied and adapted from (102). The V regions of the α and β chain were 
spliced by overlapping extension to form a Vα-(Gly4Ser)4-Vβ scFv. The scFv fragments 
were cloned in frame with a C- terminal 6xHis-tag into pET22b to allow for periplasmic 
secretion in BL21-Codon Plus E. coli (Stratagene). Two mutations in the Vα3.3 (W82R 
and L44P) and five mutations in the Vβ8.3 (G17E, G42E, H47Y, L175T, and L177S) 
were made using the QuickChange Site-Directed Mutagenesis method (Stratagene) to 
create the 42F3 Mut7 scFv TCR as previously described for 2C (52). 
The wt Vα3.3 and Vβ8.3 regions of the 43F3 TCR were also fused in frame with 
human constant domains containing engineered stabilizing cysteines to form the 42F3 
VmCh TCR (141). 42F3 VmCh was ligated into pAcGP67a vector encoding a C-terminal 
acidic GCN4 zipper-BAP-6xHis tag (α) or a C-terminal basic GCN4-zipper-6xHis tag (β). 
The 42F3 VmCh regions were also cloned into pET28a for expression as inclusion bodies 
as previously described (141). 
 For the single-chain 42F3 scFv used in the QL9 complex, BL21 E. coli were 
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transformed with 42F3 “Mut7.” Single colonies grown in 50ml overnight cultures were 
used to inoculate 1L cultures of LB broth at 30°C for 12hrs. Cell cultures were 
centrifuged at 4500g for 15min and transferred to 1L TB media at 
21°C. Cells were allowed to recover for 1hr before induction with IPTG and incubated at 
21°C for 5 hours. The scFv TCR was harvested by a sucrose/EDTA osmotic shock 
method (47,52) and dialyzed against 10mM TRIS pH8 and 200mM NaCl. Protein was 
purified by Ni-NTA chromatography (Qiagen) followed by Superdex 75 size exclusion 
chromatography (Amersham). The H2-Ld class I MHC platform (SBM2) was expressed, 
purified and refolded as previously described (47,52) with exogenous peptides QL9, 
p4B10, p5E8 and p3A1 (Genscript). 
 Biotinylated VmCh chimeric TCRs were expressed in Hi5 insect cells by baculovirus 
coinfection of α chain and β chains in the presence of secreted BirA ligase and 50μM 
biotin. Cells were pelleted by centrifugation and the cell media was primed for Ni-NTA 
capture by the addition of 100mM Tris pH8.0, 1mM NiCl2 and 5mM CaCl2. Precipitate 
from the media was removed by centrifugation and TCRs were captured by batch Ni-
NTA purification and further purified by Superdex 200 (Amersham) size exclusion. Biotin 
incorporation was assayed by band shift using SDS-PAGE in the presence of saturating 
streptavidin. 
For the p3A1 complex ,the 42F3 VmCh and β chains were co-infected into insect 
cells in the presence of 4μM kifunesine and cleaved with EndoH to produce partially 
deglycosylated 42F3 TCR for crystallography. Insect expressed 42F3 TCR used for 
crystallography and SPR were cleaved with 3C protease to remove zippers and further 
purified by size exclusion. 42F3 VmCh was also produced in E.coli by refolding from 
inclusion bodies by methods previously described (142), and purified by ion exchange 
on DE52 resin followed by 60% ammonium sulfate precipitation and Superdex 200 
(Amersham) size exclusion. N-terminal 6xHis-tags were removed by thrombin (GE 
healthcare) digest overnight at RT. 
 
Kinetic binding studies of 42F3 binding to novel pep/Ldm31 complexes 
This work was performed by Dr. Jarrett Adams of Dr. K. Christopher Garcia’s 
laboratory at Stanford University. The following description of the materials and methods 
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has been copied and adapted from (102). Binding affinities and kinetics of purified 42F3 
VmCh with the different single- chain pMHC were determined by surface plasmon 
resonance on a Biacore T-100 (GE). Yeast displayed clones were amplified from 
pCT302 and cloned into the pETDuet1 (Novagen) bicistronic vector with an N-terminal 
biotin acceptor peptide (BAP) tag (BAP-LdW167A-pep) and co-expressed with BirA ligase 
with the addition of 100μM biotin upon induction. Inclusion bodies were purified and 
refolded as previously described (47,52). Refolded biotinylated BAP-LdW167A-pep was 
coupled to a Streptavidin-chip (GE Healthcare) and association and dissociation was 
measured at concentrations of 0-100μM 42F3 VmCh at 25°C with a flow rate of 50μL/min 
without regeneration between injections. Resonance curves were fit to a 1:1 Langmuir 
steady-state model and affinities were calculated for each Bap-LdW167A-pep measured. 
Kinetic parameters kon and koff were also calculated for several pMHC, however koff 
values often fell well outside the limits of detection for this instrument (>0.5s-1) or poorly 
fit the data based on the residual analysis and therefore the 3D kinetics were considered 
only qualitatively. Kinetics fits for two pMHC complexes resulted in KD and Rmax values 
that converged with the values derived from steady-state fits. 
 
Structural Analyses 
 The following are Protein Database (PDB) IDs corresponding to each 42F3-
peptide/Ldm31 complex: 42F3-QL9/Ldm31, 3TF7; 42F3-QLSDVPMDL/Ldm31, 3TFK; 
42F3-SPLDSLWWI/Ldm31, 3TJH; 42F3-FLSPFWFDI/Ldm31, 3TPU (102). Pymol was 
used to visualize the coordinates of the various structures. 
 
Results 
Cloning and T cell expression of the TCR from mouse T cell clone 42F3 
The mouse CTL clone 42F3 was generated originally against the P815 
mastocytoma, and was discovered to recognize peptide p2Ca (and its single-amino acid 
extension called QL9), in the context of the allogeneic class I MHC Ld. My efforts in this 
work were to generate T cell sublines of 42F3 that would facilitate the analysis of peptide 
specificity, and the role of CD8 in T cell activation. 
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To accomplish this, the genes encoding the full length 42F3 TCR (Vα3.3, Vβ8.3) 
were obtained from Genscript and cloned into the retroviral vector murine stem cell virus 
(MSCV) using 5’ restriction site Age1 and 3’ restriction site Mlu1, and the sequence of 
the full length 42F3 TCR, including leader sequences and constant regions, is displayed 
in Figure 2.1. Retroviral packaging cell line Plat-E was transfected with 42F3-MSCV 
DNA and culture supernatant containing packaged 42F3-MSCV particles was used to 
transduce BW5147 cell lines 58-/- (CD8-) and 58-/- (CD8αβ++) (118). These parental cell 
lines do not express endogenous TCRs or CD3 on their surface. Transduced cell lines 
were sorted using an anti-Cβ antibody and PE-conjugated secondary antibody.  Flow 
cytometry analysis of 58-/- parental cell lines, 42F3-transduced cell lines pre-sorting, and 
42F3 cell lines after sorting using an anti-TCR-Cβ antibody revealed enrichment of the 
42F3+ population of transduced T cell hybridomas , both CD8- (Figure 2.2A) and 
CD8++ (Figure 2.2B), after sorting. These 42F3 T cell hybridoma cell lines were stable 
transductants that did not require additional selecting reagents during growth to maintain 
surface expression levels of the 42F3 TCR and grow robustly in complete RPMI 1640 
media containing 10% fetal calf serum. 
  
Activity of the 42F3 T cell lines with peptide QL9. 
 
Because the 42F3 T cell clone was previously found to recognize the QL9 
(QLSPFPFDL) peptide in complex with allogeneic MHC allele Ld, I performed T cell 
activation assays using the two 42F3 T cell lines I generated using retroviral 
transduction. 42F3 T cells that expressed CD8αβ, or did not express CD8αβ, were 
incubated with various concentrations of the QL9 peptide and two different Ld-expressing 
target cell lines (Figure 2.3). After a twenty hour incubation at 37°C, the culture 
supernatants were analyzed by ELISA for the presence of interleukin-2 (IL-2), which is 
released from the T cell hybridomas in response to T cell activation signaling. Two 
different target cell lines were used in these IL-2 release activation assays. The T2-Ld 
cell line, which is a human cell line transfected to express the murine MHC allele Ld, is 
deficient in TAP (transporter associated with antigen processing) and cannot process 
peptides for MHC presentation endogenously. The LM1.8-LdW97R cell line is a murine 
cell line transfected to express the W97R variant of the MHC allele, and is fully capable 
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of processing and presenting peptides on surface MHC class I molecules; this cell line 
has also been found to express high levels of the ICAM surface adhesion molecule 
which interacts with the LFA-1 adhesion molecule on T cells.  
To examine function of the transduced T cells, 42F3 T cell hybridoma activation 
was stimulated with immobilized anti-CD3 monoclonal antibody (mAb) 145-2C11 (Figure 
2.3). Anti-CD3 mAb cross-links the CD3-ε subunits associated with the TCR and initiates 
T cell activation signaling, resulting in the production and release of IL-2 from the T cell 
hybridomas. Both 42F3 and 42F3/CD8 T cell hybridomas were capable of being 
activated through the TCR as judged by the release of IL-2.  In contrast, activation of 
42F3 T cells by QL9 peptide presented by the T2-Ld target cell line was only observed at 
the 1μM concentration and required the presence of the CD8 co-receptor (Figure 2.3A). 
No activation was seen from 42F3 CD8- T cells in response to 1μM QL9 on T2-Ld target 
cells. The activation of 42F3 T cells by the QL9 peptide presented on LM1.8-LdW97R 
required CD8αβ as well, but activation of 42F3 CD8αβ was seen with QL9 
concentrations as low as 0.1μM, 10-fold lower than the minimal [QL9] required for 
activation of 42F3 CD8αβ on T2-Ld (Figure 2.3B). These T cell activation assays verified 
that the 42F3 T cell lines generated by retroviral transduction were capable of 
recognizing the known ligand QL9, albeit weakly, and that they were efficiently activated 
by positive control immobilized anti-CD3 mAb. Thus these 42F3 cell lines were suitable 
for assessing the recognition of other Ld-bound peptide ligands by the 42F3 TCR, and 
thus could provide biological data regarding CD8-dependence and activation 
requirements of 42F3. 
 
 
Generation of alternative peptide ligands to the 42F3 TCR 
We embarked on a project in collaboration with Dr. Jarrett Adams of Dr. K. 
Christopher Garcia’s lab to examine the breadth of degeneracy by T cells in their 
recognition of diverse peptide/MHC ligands, using the 42F3 T cell system. All previous 
studies regarding the diversity of peptide ligands that can be recognized by a TCR used 
functional T cell activity assays to screen for such peptides. This approach generally 
requires the contribution of CD8 and these screening assays do not have the potential to 
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identify ligands that could bind the TCR but have no T cell stimulatory activity. 
Accordingly, peptides were isolated and identified in these methods with T cell reactivity 
as a criterion for further study; thus kinetic binding studies, crystallographic studies, 
MHC-binding studies, etc. were only pursued with peptide ligands that were known to 
mediate biological reactivity. Using soluble 42F3 and a yeast display system, Dr. Adams 
was able to identify novel Ld-bound peptide ligands for 42F3 outside the context of T cell 
reactivity, and without the complication of the CD8 co-receptor synergizing with the TCR 
for enhanced interactions with each peptide/Ld ligand. The goal of this study was to 
examine the interactions of the 42F3 TCR with these novel peptide ligands for MHC Ld 
and LdW97R using biological, kinetic, and crystallographic approaches. 
 The 42F3 TCR is known to recognize peptide QL9 (QLSPFPFDL) presented by 
allogeneic MHC Ld with low affinity, which can explain the low activity observed in the 
assays described above.  Based on the QL9 peptide sequence, yeast display libraries 
were generated using the Ld platform Ldm31 expressed as a fusion with the Aga2 yeast 
mating protein and N-terminal hemagglutinin (HA) expression tag (Figure 2.4A). The 
libraries were constructed such that Ldm31 (containing the W97R mutation as described 
in (47) was tethered to a nonamer peptide via a flexible linker, in which the peptide 
contained degeneracy at positions known to point towards the TCR (positions 4,5,7,8 as 
described in (143)), positions known to point toward the MHC  (positions 1,2,3,6,9 as 
described in (102)), or was fully degenerate at all positions of the peptide except for 
anchor positions 2 (PQL) and 9 (FILV)(Figures 2.4B and 2.4C).  This system provided 
display platform from which novel peptide antigens could be identified purely on the 
basis of binding to the TCR, without the biological requirement for T cell responsiveness 
at the peptide selection stage. In order to further study the identification and subsequent 
reactivity of these novel peptide antigens with T cells expressing the 42F3 TCR, Dr. 
Adams subjected the yeast display library to fluorescence activated cell sorting (FACS) 
with soluble PE-conjugated TCR 42F3 tetramers and an Alexa488-conjugated antibody 
to the N-terminal HA tag. The brightest dual stained (HA+/42F3+) populations were 
sorted and the process was repeated until the population of yeast expressing stably-
expressed, 42F3-binding peptide-Ldm31 complexes was enriched significantly (Figure 
2.4C). DNA was extracted from yeast cells isolated from the FACS sorts and sequenced 
to reveal the identity of the peptide-Ldm31 complex on the surface that was bound by the 
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soluble 42F3 TCR.  The peptides, and the libraries they were obtained from, are listed in 
Table 2.1. 
 
Analysis of alternative peptide ligands for T cell activity. 
To examine their stimulatory ability, the 42F3 T cell hybidoma cell lines were 
incubated with target cells expressing wild type LdW97 (T2-Ld) or LdW97R (LM1.8-
LdW97R) in the presence of the peptides (10μM) identified from the yeast libraries, and 
the resulting interleukin-2 (IL-2) released into the culture supernatant was analyzed by 
ELISA.  
Peptides identified from the TCR contacts library resulted in CD8-independent 
activation of 42F3 cells when presented on both T2-Ld and LM1.8-LdW97R and cell lines 
(Figures 2.5 and 2.6, respectively). All of these peptides (QLSDRPVDL, QLSDRPIDL, 
QLSDRPFEL, QLSDKPVDL, QLSDVPMDL) resulted in similar levels of IL-2 release 
from 42F3 T cell lines with and without CD8 co-receptor in response to high 
concentrations of peptide (10uM), and these were the most potent peptide antigens 
identified through this yeast display method.  
In contrast, peptides identified from the MHC contacts library resulted in CD8-
dependent activation of 42F3 T cells only when presented on LM1.8-LdW97R cells 
(Figure 6); no activation of 42F3 T cells (with or without CD8) was evident when these 
peptides were displayed on T2-Ld (Figure 2.5). Of the peptides from the MHC contacts 
library, peptide EENPFWFDI was the strongest agonist for 42F3, followed by 
FLSPFWFDI (further referred to as FLS) and DYNPFWFDI, and peptide EYNPFWFDI 
was the weakest peptide agonist for 42F3 according to the IL-2 release activation assay 
using LM1.8-LdW97R target cells.  
One peptide, SPLDSLWWI (further referred to as SPL) was identified from the 
fully degenerate peptide library.  This peptide did not result in activation of 42F3 T cells 
(with or without CD8αβ co-receptor) when loaded on either antigen presenting cell line, 
T2-Ld or LM1.8-LdW97R (Figures 2.5 and 2.6, respectively). 
 
Binding affinity of soluble TCR for various peptide-Ld complexes 
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 Our collaborators used surface plasmon resonance (SPR) to measure the kinetic 
binding affinities of 42F3 binding to LdR97 in complex with each peptide tested in the IL-
2 release activation assays, including the peptides for which ternary complexes were 
solved as described later: QL9, QLSDVPMDL, FLS, and SPL. The KD values for 42F3 
binding to these linked peptide-Ldm31 complexes are as follows: QL9, 40μM; 
QLSDVPMDL, 9.7μM, FLS, 48μM; SPL, 3.9μM (Full panel of KD values can be found in 
Table 2.1). In comparing 42F3 activation to the KD values obtained by SPR, the 
activation assays using LM1.8-LdW97R target cells are most relevant as the Ldm31 
construct used in SPR contains the W97R mutation. As described in Chapter 3 of this 
thesis and (71), the W97R mutation was shown to affect peptide binding, and wild type 
Ld (W97) showed inferior binding to many of the peptides tested from this panel. The KD 
for 42F3 binding QL9 and FLS fall greater than the approximate threshold of 2μM for 
CD8-independent T cell activation (indicating an interaction with lower affinity than is 
required for CD8-independence), and this was reflected in the IL-2 release assays 
shown in Figure 2.6.  
 The affinity of 42F3 for the QLSDVPMDL-LdR97 complex was lower than the 
threshold of CD8-independent T cell activation in the 58-/- system; however, 42F3 was 
activated by QLSDVPMDL in a CD8-independent manner, reflected in the IL-2 release 
assays shown in Figure 2.6. The same CD8-independence was observed for the 
activation of 42F3 T cells in response to LM1.8-LdW97R cells presenting peptides 
QLSDRPVDL (KD 6.4μM), QLSDRPIDL (KD 7.7μM), and QLSDRPFEL (KD 8.2μM), for 
which the affinities are all below the threshold of CD8-independence. Kinetic binding 
experiments shows that 42F3 bound SPL-LdR97 with a KD of 4μM, well within the range 
of CD8-independent T cell activation, yet no activation of 42F3 T cells was seen, even in 
the presence of the CD8 co-receptor. Along the same lines, the activation of 42F3 T 
cells in response to peptides DYNPFWFDI (KD 5.1μM) and EENPFWFDI (KD 3.4μM) 
was CD8-dependent. This is an interesting finding because the affinity of 42F3 for the 
DYNPFWFDI (DYN) and EENPFWFDI (EEN) peptides in complex with LdR97 is greater 
than the affinity of 42F3 for QLSDVPMDL in complex with LdR97, yet the activation of 
42F3 T cells in response to DYN and EEN peptides required CD8.  
 An interpretation of the relationship between the apparent requirement of CD8 in 
42F3 T cell activation and the measured affinity values must be accompanied by a few 
caveats regarding the systems used for this investigation. For example, the reported KD 
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values were obtained using a peptide/LdR97 complex in which the peptide was 
covalently linked to Ld as a single chain molecule; IL-2 release activation assays were 
performed in a non-covalent system in which peptides were free to diffuse away from the 
MHC depending on the strength of that peptide/MHC interaction. The use of the linked-
construct SPR to determine the affinity of the TCR for binding to peptide/MHC did not 
take into account the binding of the peptide to the MHC protein, and this is examined 
next. There are other possible explanations for the discrepancies between the reported 
affinity measurements and CD8-dependence of 42F3 activation, and these are 
examined in the discussion. 
 
Peptide binding to Ld is a critical component of the TCR-pep/MHC interaction 
 One caveat that should accompany the discussion of the relationship between T 
cell activation (as seen in the IL-2 release activation assays of Figures 2.5 and 2.6) and 
the soluble kinetic binding data (discussed above and shown in Table 2.1), is that there 
are two main interactions that contribute to T cell activation. First, there is the interaction 
between the peptide and the MHC protein itself. This particular component is a major 
factor in determining T cell activation by a specific peptide/MHC complex; if the peptide 
of interest binds poorly to the MHC, the number and density of that specific peptide/MHC 
complex on the target cell surface decreases, thus decreasing the likelihood that a T cell 
can be efficiently stimulated by it. Strong binding of antigenic peptides to MHC leads to 
an increased number of MHC complexes containing those antigenic peptides on the cell 
surface. An increased surface density of antigenic peptide/MHC complexes would better 
allow the clustering of TCR-peptide/MHC complexes at the immunological synapse 
between T cell and target cell, which is known to be required for T cell activation 
signaling.  Secondly, there is the interaction between the TCR on the T cell and the 
antigenic peptide in complex with the MHC protein on the target cell, in which the TCR 
must form contacts with both the MHC alpha helices and peptide via CDR loops for 
effective binding to the complete peptide/MHC complex. The CDR 3 loop of each TCR 
chain typically forms the most contacts with the peptide bound in the MHC peptide-
binding groove, and as the most diverse region in a TCR repertoire, provides the 
greatest peptide specificity. Both of these key interactions contribute to the magnitude 
and sensitivity of T cell activation in response to specific antigenic complexes.   
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 The peptide interaction with Ld is not addressed by the SPR approach because of 
the use of the linked peptide-Ld construct. To address this, we compared: 1) the binding 
of each of the listed peptides to either LdW97 or LdR97 on the surface of 58-/- cell lines 
transduced to express one or the other Ld variant (Figure 2.7A), and 2) the activation of 
42F3 CD8αβ T cells in response to peptides QLSDVPMDL, FLSPFWFDI, and 
SPLDSLWWI displayed on target cells T2-Ld (LdW97) and LM1.8-LdW97R (Figure 
2.7B). A competitive binding assay was performed to quantitatively assess the binding of 
each of these peptides to cell surface Ld (either the wild type W97, or the R97 variant). In 
this assay, 58-/- cells expressing LdW97 or LdR97 were incubated with a mixture 
containing 50nM QL9 peptide and a competitor peptide (QLSDVPMDL, FLSPFWFDI, or 
SPLDSLWWI) at various concentrations. Then these cells were incubated with soluble 
biotinylated scTCR 2C-m6, which binds with high affinity to the QL9/LdW97 and 
QL9/LdR97 complexes, but does not bind to any of the competitor peptides in complex 
with either of the Ld variants. A decrease in 2C-m6 staining indicated that the competitor 
peptide bound to the cell surface Ld molecule, by effectively competing with QL9 peptide. 
By performing this type of assay with various concentrations of the listed competitor 
peptides and using a non-linear regression, we were able to derive BD50 values, which 
represent the concentration of peptide at which 50% maximal Ld-binding is observed 
(Figure 2.7A). A lower BD50 value indicates higher affinity of the peptide for L
d, and vice-
versa.  Of the novel peptides tested, only QLSDVPMDL detectably bound LdW97; 
QLSDVPMDL showed the strongest binding to LdR97, followed by FLSPFWFDI, and 
lastly SPLDSLWWI.  
 IL-2 release activation assays were performed to assess T cell reactivity against 
these peptides in the context of each Ld variant (W97 versus R97). 42F3 CD8+ T cells 
were activated by QLSDVPMDL presented on T2-Ld; no activation was seen in response 
to either the FLSPFWFDI or SPLDSLWWI peptides. When presented on LM1.8-LdW97R 
target cells, peptide QLSDVPMDL resulted in the greatest activation of 42F3 CD8+ T 
cells, FLSPFWFDI followed with moderate activation of 42F3 CD8+ T cells, and lastly 
SPLDSLWWI resulted in no activation of 42F3 CD8+ T cells (Figure 2.7B).  
 According to the competitive binding assay shown in Figure 7A, peptides 
FLSPFWFDI and SPLDSLWWI did not detectably bind to LdW97 (BD50 values ≥ 200μM, 
the highest concentration tested). Thus, the lack of activation of 42F3 CD8+ T cells by 
these peptides displayed on T2-Ld at a 10μM concentration may be due to the very low 
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abundance of peptide/Ld complexes that contain these peptides. Peptide QLSDVPMDL 
bound to wild type Ld (W97) with an average BD50 of just less than 100μM, and when 
presented on T2-Ld cells, resulted in modest activation of 42F3 CD8+ T cells as shown in 
Figure 2.7B. All three of these peptides bound to LdR97 enough to obtain a true 
quantitative BD50 value for each; QLSDVPMDL bound with the highest affinity, followed 
by FLSPFWFDI, and lastly SPLDSLWWI bound with the lowest affinity (Figure 2.7A). 
Likewise, 42F3 CD8+ T cells were most sensitive to activation by QLSDVPMDL, followed 
by FLSPFWFDI, and lastly, no activation was observed in response to SPLDSLWWI 
when presented on LM1.8-LdW97R target cells. The lack of 42F3 T cell activation in 
response to the SPLDSLWWI peptide may be partially explained by the relatively poor 
binding of the peptide to LdR97 on the target cell surface, although the observation that it 
was only marginally lower than FLSPFWFDI, which did activate 42F3 cells, suggests 
other explanations are possible (see below). 
 
SPLDSLWWI is not an inhibitor of 42F3 activation 
 The lack of activation of 42F3-expressing T cells in response to the SPLDSLWWI 
peptide might also be due to the possibility that it acts as an antagonist rather than 
agonist of 42F3. To determine if SPLDSLWWI could act as an antagonist of 42F3 T 
cells, an IL-2 release activation assay was performed to assess the ability of this 
peptide, compared to the known null peptide MCMV, to decrease activation of 42F3 T 
cells in response to strong agonist peptide QLSDKPVDL. These experiments rely on the 
following principle: inhibition can be observed due to competition for Ld binding, as would 
be seen with MCMV, or due to true antagonist activity. Antagonist activity would be 
observed at low peptide concentrations where competition for Ld would not be observed.  
 An initial experiment was performed with various concentrations of QLSDKPVDL 
peptide in an activation assay using CD8+ 42F3 T cell hybridomas and LM1.8-LdW97R 
target cells. From this assay, an SD50 value of 34nM was determined, indicating the 
concentration of QLSDKPVDL peptide that resulted in 50% maximal 42F3 activation 
(Figure 2.8A). The SD50 represents the concentration of agonist peptide QLSDKPVDL 
that would provide the most sensitive assessment of T cell activation in subsequent 
inhibition experiments. For these experiments, 42F3 CD8+ T cells were incubated with 
LM1.8-LdW97R cells in the presence of 30nM QLSDKPVDL only, or 30nM QLSDKPVDL 
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mixed with various concentrations of SPLDSLWWI and MCMV peptides (Figure 2.8B). 
The activation of 42F3 T cells by 30nM QLSDKPVDL in this assay was significantly 
inhibited by MCMV peptide at concentrations of 10μM, 3.3μM, and 1μM, due to 
competitive binding by MCMV, which is known to bind well to Ld. 
 In contrast, 42F3 CD8+ T cells were fully activated by 30nM QLSDKPVDL in the 
presence of 10μM SPLDSLWWI, indicating that the SPLDSLWWI peptide, even at this 
high concentration, was unable to inhibit 42F3 T cell activation. This can perhaps be 
addressed using the BD50 values obtained in competitive peptide binding assays 
(described in Figure 2.7A) that represent the quantitative binding of each peptide to 
LdR97. Compared to SPLDSLWWI, peptide MCMV bound approximately 100-fold better 
to LdR97. In the T cell inhibition assay described above, significant inhibition of 42F3 
activity against QLSDKPVDL/LdR97 complexes was detected at a concentration as low 
as 1μM MCMV. Taking this peptide-binding data into account, we might expect to see 
some level of 42F3 inhibition at a minimum concentration of 100μM SPLDSLWWI. 
Peptide concentrations higher than 10μM were not tested in this assay, and thus we can 
speculate that some inhibition of 42F3 might have been observed had the SPLDSLWWI 
peptide been tested at a concentration of 100μM or greater.  This result supports the 
idea that the SPLDSLWWI peptide does not send antagonist signals through the 42F3 
TCR. It is possible that the SPLDSLWWI peptide does not engage the 42F3 TCR in 
such a way as to effect signaling, and that will be explored in further sections of this 
chapter from a structural standpoint. 
  
Flow cytometric-based binding assays of SPLDSLWWI/Ld binding to 42F3 TCR  
To further verify that the SPLDSLWWI/Ld complex was engaging the 42F3 TCR, 
an independent approach was taken. Soluble biotinylated 42F3 single chain TCR 
(scTCR) was expressed, purified, and tetramerized using Streptavidin PE, and used in a 
flow cytometry experiment to determine the binding of the 42F3 TCR to LM1.8-LdW97R 
cells loaded with the following peptides: QL9, QLSDRPVDL, FLS, and SPL. The 
resulting histograms independently verified the hierarchy of binding seen in SPR 
experiments. 42F3 scTCR showed the greatest binding to LM1.8-LdW97R cells loaded 
with 10μM SPL, followed by QLSDRPVDL (KD 6.4μM), then FLS, and lastly QL9 resulted 
in the lowest levels of 42F3 binding (Figure 2.9A). As expected, incubation with null 
 
 
49 
peptide MCMV (YPHFMPTNL) did not result in detectable staining by soluble 42F3 TCR 
tetramers. The reciprocal experiment was also performed, in which 42F3 CD8- 58-/- cells 
were incubated with pre-formed peptide/Ldm31/PE tetramers (Figure 2.9B), but instead 
of peptide QLSDRPVDL, peptide QLSDVPMDL (KD 9.7μM) was sampled. In looking at 
the staining of 42F3 T cells by agonist peptide/Ldm31 complexes, QLSDVPMDL/Ldm31 
tetramers showed the greatest binding to 42F3 T cells, followed by QL9/Ldm31, and 
lastly FLS/Ldm31. In a sharp contrast to the 42F3 staining of SPL-loaded LM1.8-LdW97R 
cells, there was no detectable binding of fluorescent SPL/Ldm31 tetramers to 42F3 T 
cells. This data more closely mirrored the hierarchy of 42F3 T cell activation seen in the 
IL-2 release assays (shown in Figure 2.6), and was a better correlate to the 2D binding 
experiments described in (102). 
 
Structural studies of 42F3 TCR in complex with peptide/Ld ligands 
Soluble 42F3 TCR was expressed and purified for use in a structural examination 
of TCR interactions with peptides QL9, QLSDVPMDL, FLS, and SPL in complex with 
LdW97R; the W97R mutation was present in the yeast display tethered-peptide form of 
Ldm31 used to select these peptides, and is present in the form of Ldm31 used for 
crystallization as well. Crystal structures of the 42F3 TCR in complex with these peptide-
Ldm31 complexes were solved and structures were visualized and depicted in cartoon 
format using Pymol (Figure 2.10) (102). When one takes a side view of the 42F3 Vα and 
Vβ docking on each peptide/Ldm31 complex, looking directly through the peptide-binding 
groove (MHC α1 on the left, MHC α2 on the right), the V regions shown in structures that 
include peptides QL9, QLSDVPMDL, and FLSPFWFDI sat distinctly over the MHC α1 
helix (42F3 Vβ) or MHC α2 helix (42F3 Vα) (Figure 2.10A). In contrast, the 42F3 V 
regions shown in complex with SPL/Ldm31 complex were not oriented in the same way; 
the V regions were instead rotated such that they were nearly parallel to the peptide-
binding groove, rather than orthogonal as seen in the structures containing agonist 
peptides. A top down view of these newly solved structures showed that 42F3 bound 
QL9-, QLSDVPMDL-, and FLSPFWFDI-Ld complexes with the canonical docking 
orientation seen in all solved TCR-pepMHC structures, and all of these peptides resulted 
in some level of 42F3 T cell activation when presented on LdW97R (Figure 2.10B). 
However, 42F3 bound the SPL-LdW97R complex with an entirely unconventional 
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orientation, a 38° clockwise rotation from the canonical docking orientation (Figure 
2.10B). This peptide, with sequence SPLDSLWWI, was the only peptide identified from 
the yeast display platform that did not result in activation of 42F3, even in the presence 
of the CD8 co-receptor, on either Ld-expressing antigen presenting cell line.  
  
Discussion 
 This report details the utilization of yeast display technology to develop a library 
system in which novel peptide antigens can be selected in the context of one particular 
MHC allele by a TCR restricted by that MHC allele. In this case, the selecting TCR was 
the 42F3, a close relative of the very well characterized 2C TCR, which, like 2C, was 
raised against the allogeneic MHC allele called Ld (51,101,137). The novel peptide 
antigens for the 42F3 TCR were variants of known 42F3 antigen QL9 (QLSPFPFDL) 
and were identified based only on the requirement of binding to the TCR, and reactivity 
with 42F3 T cells was evaluated using IL-2 release activation assays. Peptides identified 
from the library in which TCR-contacting residues of QL9 were degenerate resulted in 
peptide antigens that activated 42F3-transduced T cell hybridomas in a CD8-
independent manner. Peptides identified from the library in which MHC-contacting 
residues were degenerate resulted in peptide antigens that activated 42F3 T cells only in 
the presence of the CD8 co-receptor. One peptide, SPL, was identified from the fully 
degenerate peptide-Ldm31 library, and it did not result in any activation of 42F3 T cells 
(with or without CD8) even at the high concentration of 10μM. 
 The panel of peptides identified from the nonamer peptide-Ldm31 yeast display 
libraries revealed the nature of CD8-dependence in the activation of T cells that express 
the 42F3 TCR. The various yeast display libraries contained degeneracy in the 
sequence of the peptide, the template for which was the known 42F3 agonist peptide 
QL9 (sequence QLSPFPFDL). Degeneracy was introduced at: all positions of the 
peptide except for anchor residues (Pro at 2; Phe, Ile, Leu, Val at 9), positions of the 
peptide that contact the T cell receptor (positions 4,5,7,8), or positions of the peptide that 
contact MHC Ld (positions 1,2,3,6,9). The resulting peptides were sampled in IL-2 
release T cell activation assays using two different target cell lines (T2-Ld expressing 
wild type LdW97, and LM1.8-LdW97R), and T cell hybridomas that expressed the 42F3 
TCR in the presence or absence of the CD8 co-receptor. The resulting data showed that 
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peptides that were isolated from the TCR contacts library (QLSDRPVDL, QLSDRPIDL, 
QLSDRPFEL, QLSDKPVDL, QLSDVPMDL) activated 42F3 T cells in a CD8-
independent manner when presented on either T2-Ld or LM1.8-LdW97R cells. Peptides 
that were isolated from the MHC contacts library (EYNPFWFDI, FLSPFWFDI, 
DYNPFWFDI, EENPFWFDI) activated 42F3 T cells in a CD8-dependent manner 
(activation required the presence of CD8), and activation was only observed when 
peptides were presented on LM1.8-LdW97R cells, which contained the W97R mutation 
in Ld that was also contained within the Ldm31 construct. One peptide, SPLDSLWWI, 
was identified from the fully degenerate library (with the exception of Ld anchor 
residues), and this peptide did not activate 42F3 T cells with or without CD8, regardless 
of the target cell line used. 
Surface plasmon resonance experiments evaluated the binding of soluble 42F3 
scTCR to each immobilized peptide-Ldm31 complex, and revealed kinetic KD values for 
each TCR-peptide/Ldm31 interaction. In the 58-/- system, TCR-peptide/MHC interactions 
with KD values less than or equal to 2μM correlate with CD8-independent T cell 
activation, and TCR-peptide/MHC interactions with KD values greater than 2μM correlate 
with T cell activation that requires the CD8 co-receptor. None of the peptides from the 
yeast display library, in complex with Ldm31, were bound by soluble 42F3 TCR with a KD 
less than or equal to 2μM. Ldm31 complexes containing TCR contacts library peptides 
QLSDRPVDL, QLSDRPIDL, QLSDRPFEL, and QLSDVPMDL were all bound by soluble 
single chain 42F3 TCR with KD values between 5μM and 10μM, below the threshold for 
CD8-independent T cell activation. However, 42F3 T cell hybridomas were activated 
independent of CD8 in response to these peptides. Soluble 42F3 bound Ldm31 
complexes containing MHC contacts peptides (DYNPFWFDI and EENPFWFDI) with KD 
values of 5.1μM and 3.4μM, respectively, yet 42F3 T cells were only activated in 
response to these peptides in the presence of CD8, and only on the target cell lines 
expressing the LdW97R variant. MHC contact library peptide FLSPFWFDI in complex 
with Ldm31 was bound by 42F3 TCR with a KD value of 48μM, which is a value known to 
correlate with CD8-dependent T cell activation, which is consistent with what was 
observed in IL-2 release activation assays. The SPR experiments showed that 42F3 
bound SPL-Ldm31 with fairly high affinity (3.9μM), which was the closest measurement 
to the threshold of CD8 independence of all the novel peptide-Ld complexes tested, yet 
no activation of 42F3 T cells was observed.  
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 The nature of CD8 dependence and independence depends on many factors, 
such as the TCR affinity, peptide affinity for the MHC, the level of ICAM surface 
adhesion molecules on target cells, and the docking of the TCR on the peptide/MHC 
complex. As discussed earlier in the results section, there is an affinity threshold of 
approximately 2μM in the 58-/- system, above which the CD8 co-receptor is not required 
for T cell activation. 42F3-transduced 58-/- T cell hybridomas did not follow the 2μM CD8-
dependence convention in IL-2 release activation assays- none of the peptides that 
resulted in CD8-independent 42F3 activation, in complex with Ldm31, was bound by 
soluble 42F3 with a KD of less than 2μM.  
In this case, the reported KD values came from SPR experiments using soluble 
scTCR 42F3 and a covalently-linked construct of peptide/Ldm31 that was immobilized on 
the SPR chip. The local concentration of the peptide was artificially high, and likely drove 
the formation of complete peptide/Ldm31 complexes. If a peptide bound weakly, the 
covalent construct could increase the likelihood that the peptide would rebind to the 
MHC, compared to a system in which a non-covalently bound peptide is allowed to 
diffuse away from the MHC. One would expect this linked construct to result in a higher 
apparent affinity, thus lower KD value, than if the peptide/MHC complex had not been 
linked as is the case in the IL-2 release T cell activation assays.  
 It is important to note that while the linked construct likely affected the apparent 
KD values obtained through SPR, this does not account for the differential activation of 
42F3 in response to peptides from the TCR contacts library (activation was CD8-
independent) versus the MHC contacts library (activation required CD8 co-receptor). 
The reported affinity values take into account both the on-rate and off-rate of TCR 
binding to each peptide/Ld complex. It is possible that the intermolecular contacts 
between the 42F3 TCR and peptides derived from the TCR contacts library in complex 
with MHC Ld may contribute to a more optimal “dwell time” or period of interaction 
compared to peptides from the MHC contacts library, between the TCR and 
peptide/MHC at the immunological synapse. This time period is related to the off-rate of 
TCR binding, and can affect the sensitivity and magnitude T cell activation. As discussed 
in (144), these interactions should be long enough such that T cell activation signaling 
can be completed, but not so long that the TCR is unable to interact serially with many 
antigenic peptide/MHC complexes. This so-called “serial triggering” of T cells is thought 
to contribute to the magnitude of activation as well. The off-rates for interactions with all 
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of the peptides from the TCR and MHC contacts libraries were too long to be accurately 
measured by SPR, and so the implication of off-rates in affecting the differential 
activation in response to peptides from these two different libraries is purely speculative. 
  The effects of the affinity of the peptide for the MHC were explored 
experimentally, which proved useful in addressing the discrepancies between the SPR 
binding data and the CD8-dependence observed in T cell activation assays using 
LdW97R-expressing target cells. One peptide from each peptide/Ldm31 library was 
sampled using a competition assay format. All of the peptides that were tested (MCMV, 
QLSDVPMDL, FLSPFWFDI, and SPLDSLWWI) bound more strongly to LdW97R than to 
wild type Ld. The binding of peptides in order of highest affinity for LdW97R to lowest 
affinity was MCMV (null)>QLSDVPMDL>FLSPFWFDI>SPLDSLWWI and this hierarchy 
was also reflected in the requirement of CD8 for the activation of 42F3 T cells in 
response to these peptides presented on LdW97R target cells. 
The binding of the peptide to the MHC is an integral part of the T cell- target cell 
interaction, because if an antigenic peptide is not displayed at a high enough density, T 
cells do not become efficiently activated. Surprisingly, peptide FLSPFWFDI, which was 
thought to have been isolated from the MHC contacts library due to superior binding to 
the LdR97 surface protein, showed inferior binding to the MHC compared to peptide 
QLSDVPMDL that was isolated from the TCR contacts library. What this finding 
suggests, is that the MHC-contacting residues in the template peptide QL9 were likely 
superior for MHC binding compared to the predominant motif identified in the MHC-
contacts library. The peptides that were identified from this MHC-contacts library 
overwhelmingly contained the C-terminal motif PFWFDI, while the same region of the 
peptide in QL9 (residues 4-9) has the sequence PFPFDL. There is one key difference 
between these C-terminal sequences; the wild type proline at position 6 has been 
mutated to a tryptophan. Additionally, all of the peptides isolated from the TCR contacts 
library contained a glutamine residue in the first position, which has also been previously 
shown to positively impact Ld binding. The motifs identified from the MHC-contacts 
library may have negatively affected the binding of these peptides to the MHC, thus 
affecting density of antigenic peptide/Ld complexes on the cell surface and the sensitivity 
of 42F3 T cell activation in response. Peptide QLSDVPMDL, and the other peptides from 
the TCR-contacts library that contained the same MHC-binding residues including the 
position 1 glutamine and position 6 proline, bound more strongly to the MHC and 
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perhaps formed a more dense collection of antigenic complexes. For this reason, we 
hypothesize that the activation of 42F3 in response to peptides from the MHC contacts 
library could have occurred independent of the CD8 co-receptor if the peptide 
concentration was higher than 100μM and drove the formation of a greater number of 
complete peptide/Ld complexes on the target cell surface; however, in these assays one 
cannot drive the peptide concentration much higher than this.  
The affinity ranges associated with CD8-dependent or CD8-independent T cell 
activation may depend on the T cell system being studied. The 2C T cell hybridoma 
system showed CD8-independent activation of T cells interacting with complexes with KD 
values less than 2μM (119), but there are systems using primary T cells for which 
detectable CD8-independent T cell activation can occur even when the TCR binds 
peptide/MHC complexes with kinetic KD values of 100μM, as described in (145) and 
further reviewed in (144). Thus, the TCR density and the nature of the T cells could 
influence the threshold for CD8-independent activity. 
Another component of the T cell- target cell interaction involves adhesion 
molecule LFA-1 on the T cell interacting with adhesion molecule ICAM on the target cell 
surface, which acts synergistically to allow for prolonged interaction between the two. 
The LM1.8-LdW97R target cell line has higher ICAM surface levels compared to T2-Ld. 
The differences in cell surface adhesion molecules were may have been involved in 
affecting the differences in magnitude and sensitivity of 42F3 activation in response to 
peptides presented by each target cell line. We suspect that LM1.8-LdW97R was a 
stronger antigen presenting cell line than T2-Ld in these IL-2 release assays, able to 
display each novel antigenic peptide at a higher density at the cell surface due to 
enhanced affinity of peptides for the LdW97R variant, and higher levels of the ICAM 
surface adhesion molecule. 
The lack of activation of 42F3 CD8+ T cells by peptide SPLDSLWWI presented 
on LdW97R (KD 3.9μM), was further explored by performing a series of flow cytometry 
experiments in which 42F3 T cells were stained with fluorescent peptide/Ldm31 
tetramers, or LM1.8-LdW97R cells were incubated with peptide and stained with 
fluorescent 42F3 TCR tetramers. Soluble 42F3 TCR tetramers were able to bind the 
SPL-loaded LM1.8-LdW97R antigen presenting cells, which were used in the biological 
assays for T cell reactivity, confirming the ability of the SPL peptide to be displayed on 
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the cell surface in the context of the restricting MHC, and thusly bind the T cell receptor. 
This indicated that the lack of activation of 42F3 T cells in the IL-2 release activation 
assays was probably not due to the inefficient presentation of the SPL peptide on the 
target cell surface; the lack of T cell activation may be attributed to the way the 42F3 
TCR binds SPL/LdR97, and the effect of that novel docking orientation on activation 
signaling. This will be explored next. 
 Structural studies suggested that the explanation for the binding of the 42F3 TCR 
to the SPL-LdR97 complex, but lack of activation of 42F3 T cells by this same complex, 
may lie in the unconventional docking orientation of the TCR on the SPL-LdR97 complex 
(Figure 2.10). The canonical docking orientation was seen in 42F3/LdR97 complexes 
containing peptides QL9 (template peptide), QLSDVPMDL (TCR contacts library), and 
FLSPFWFDI (MHC contacts library) with the Vβ region centered over the C-terminus of 
the peptide and the α1 helix of LdR97, and the Vα region centered over the N-terminus of 
the peptide and α2 helix of LdR97. In all of these canonical docking structures, the CDR3 
loops were centered over the peptide and the diagonal between the center of mass of 
each V region conformed to the diagonal docking angle seen in previously solved TCR-
pep/MHC complex structures such as 2C-dEV8/Kb, 2C-SIY/Kb, 2C-QL9/Ld, among others 
(50,52,95). The germline 42F3 Vα residues Lys48α, Tyr31α, Tyr50α and Ser51α were 
utilized in contacting these agonist peptide/Ldm31 complexes, though the MHC residues 
contacted by these varied from complex to complex. Similarly, 42F3 Vβ germline 
residues Tyr50β and Asn31β played a role in the binding of 42F3 to each peptide/Ldm31 
complex, though these Vβ residues interacted with differing residues in each structure. 
This observation suggested that the “germline codon” hypothesis discussed in 
(88,92,146,147) may not be as rigid in terms of specific TCR-MHC contacts as a 
requirement for a stimulatory TCR interaction.  Rather, germline residues of the TCR can 
possibly adapt their contacts for interactions with novel peptide/MHC complexes in such 
a way that may alter the specific intermolecular interactions between the TCR and MHC, 
while still resulting in the general canonical TCR docking diagonal and T cell stimulation.  
The diagonal between the V regions of 42F3 docking on SPL/Ldm31 deviated 
from the canonical docking diagonal by 38° in a clockwise direction, if one is looking 
down on the pep/MHC complex from the point of view of the TCR (Figure 2.10B). 
Additionally, 42F3 docked approximately 7Å from the center of the peptide binding 
groove, with the CDR loops from both the Vα and Vβ of 42F3 found interacting with the 
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Ldm31 α1 helix and the SPL peptide, with fewer contacts to the MHC α2 helix as 
compared to the canonical docking orientation in structures that included stimulatory 
peptides QL9, QLSDVPMDL, and FLS. We suggest that despite the sufficient affinity of 
42F3 for the SPL-Ldm31 complex, the unconventional docking orientation of the 42F3 
TCR on this non-stimulatory ligand prevented the proper assembly of the TCR-
associated signaling components, and thus prevented T cell activation in response. 
 There are many proximal components aside from the TCR-peptide/MHC 
interaction that are involved in the initial recognition signaling within a T cell, including 
the co-receptor (in this case, CD8), as well as intracellular signaling molecules that are 
brought into proximity of the TCR-pep/MHC complex by association of the co-receptor 
with the MHC. The canonical TCR docking orientation may play a significant role in 
assembling these components for activation signaling (148,149). Another explanation 
may lie in the requirement for, at least, a dimer of peptide/MHC to result in stimulation of 
the T cell via TCR (150,151); the unconventional docking orientation with which 42F3 
interacts with SPL-LdR97 may prevent the formation of a functional stimulatory 
peptide/MHC dimer on the cell surface. While these explanations for the lack of 
activation of 42F3 by the SPL/LdR97 complex remain speculative, some contribution of 
the unconventional docking orientation to this phenomenon seems likely. A further study 
that includes the crystallization of the entire biologically relevant complex involved in the 
TCR-pep/MHC interaction, including the co-receptor and proximal signaling components, 
would likely illuminate how the TCR docking geometry influences the participation of 
these other key players of T cell activation signaling. 
The SPL peptide would not have been identified via previously utilized 
techniques for identifying peptide antigens for specific T cell clones. The closest 
approximation to this yeast display method might be the screening of synthetic peptide 
libraries, such as the one that resulted in the identification of the SIYRYYGL peptide 
antigen recognized by the 2C TCR when presented by syngeneic MHC allele Kb (96). 
However, this method used 2C T cell reactivity as the selecting criterion, and in this way 
fundamentally differs from the technique we describe here. The yeast display technique 
we have described utilizes a flexible linker to tether the peptide library to the restricting 
MHC of interest, and it is important to recognize that it is possible for this linker to 
influence the nature of peptides identified from this library setup. The linker increases the 
local concentration of completed peptide/MHC complexes, driving the formation of 
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peptide/MHC complexes that may not otherwise associate well on the surface of antigen 
presenting cells. Additionally, in using soluble scTCR to select positive-binding peptide-
linker-MHC complexes, the linker may participate the interaction between the TCR and 
peptide/MHC on the yeast surface and result in the identification of peptide antigens that 
alone cannot mediate binding between the TCR and MHC of interest; this was the case 
for one non-stimulatory peptide identified from a similar scTCR selection of Ldm31-
expressing yeast using the m33 TCR (variant of the 2C TCR with high affinity for the 
SIY-Kb complex described in (118) (data not shown).  
Additional peptides were identified using a subsequent variant of the covalently-
linked peptide/Ldm31 yeast display system, that instead contained the wild type residue 
tryptophan at position 97 (Ldm31R97W). The yeast libraries were similarly sorted with 
42F3/PE tetramers and another panel of novel peptides was identified. These peptides 
mediated greater and broader reactivity from 42F3 T cell hybridomas as compared to the 
peptides from the Ldm31R97 library when presented on T2-Ld cells, which express the 
wild type Ld molecule (W97) on the cell surface, as well as LM1.8-LdW97R target cells 
(data not shown).  
This project examining the binding, reactivity, and structural interactions of the 
42F3 TCR with novel peptide antigens provided characterization of this murine T cell 
receptor that is a close relative of the well studied 2C TCR. The generation of a novel 
42F3 T cell hybridoma cell line allowed for in vitro assays of reactivity against peptides in 
complex with an allogeneic MHC allele, which was previously unable to be examined 
due to the poor recovery of primary 42F3 T cell clones. This combination of structural 
studies and biological assays has added to the broad study of T cell alloreactivity and 
raised more questions regarding the requirements of the CD8 co-receptor in T cell 
activation and its role in the assembly of T cell signaling components. Future 
experiments and crystal structures of the entire TCR-signaling complex would add to the 
already vast collection of data regarding T cell reactivity and signaling. 
Table 2.1 
Peptide Library KD (SPR) 42F3 T cell 
activation 
QLSPFPFDL (QL9) Template peptide 40μM CD8-dependent 
SPLDSLWWI (SPL) Random 3.9μM None 
QLSDRPVDL TCR contacts 6.4μM CD8-independent 
QLSDRPIDL TCR contacts 7.7μM CD8-independent 
QLSDRPFEL TCR contacts 8.2μM CD8-independent 
QLSDKPVDL TCR contacts ---------- CD8-independent 
QLSDVPMDL TCR contacts 9.7μM CD8-independent 
EYNPFWFDI MHC contacts ---------- CD8-dependent 
FLSPFWFDI (FLS) MHC contacts 48μM CD8-dependent 
DYNPFWFDI MHC contacts 5.1μM CD8-dependent 
EENPFWFDI MHC contacts 3.4μM CD8-dependent 
Table 2.1. Peptides identified by Ldm31 yeast display libraries after sorting 
with soluble 42F3 TCR tetramers. Peptide sequences are shown with 
underlined residues indicating residues that were products of degeneracy in 
the library, along with the library the peptide was derived from, the kinetic 
KD value obtained by surface plasmon resonance, and the class of 
activation of 42F3 T cell hybridomas, as measured by IL-2 release ELISA, 
in response to each peptide (10μM) loaded on LM1.8-LdW97R target cells.  
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Figures and Tables 
Figure 2.1 
42F3 full length sequence with underlined P2A linker 
Figure 2.1. Sequence of the full length 42F3 TCR protein (capital letters). Displayed 
sequence shows the 5’ AgeI restriction site, spacer DNA bases before the start codon 
that encodes the N-terminal methionine (M), and 3’ MluI restriction site used to clone the 
full DNA insert into the MSCV retroviral vector.  Orientation of the encoded 42F3 TCR 
includes, in this order: Alpha chain leader sequence, Vα, Jα, murine Cα, P2A linker, beta 
chain leader sequence, Vβ, Dβ, Jβ, Cβ, stop codon. The regions of each TCR protein 
chain are labeled in the above sequence: Vα, Variable α domain; Cα, constant region of 
the α chain; Vβ, Variable β domain; Cβ, constant region of the β chain. Also indicated 
are the leader sequences for each TCR chain required for good cell-surface expression. 
The sequence of the P2A linker between the two TCR chains is indicated; the p2A linker 
is cleaved after expression and before surface display. 
accggtcgccgccMLLALLPVLGIHFVLRVAQAAQSVTQPDARVTVSEGASL 
 
QLRCKYSYSATPYLFWYVQYPRQGLQMLLKYYSGDPVVQGVNGFEAEF 
 
SKSDSSFHLRKASVHWSDSAVYFCAVSAKGTGSKLSFGKGAKLTVSPDI 
 
QNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDM 
 
KAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFET 
  
DMQLQFQNLSVMGLRILLLKVAGFNLLMTLRLWSSGSGATNFSLLKQAG 
 eeeeeeee                                            
DVEENPGPMSNTAFPDPAWNTTLLSWVALFLLGTKHMEAAVTQSPRNKV 
 
TVTGGNVTLSCRQTNSHNYMYWYRQDTGHGLRLIHYSYGAGNLQIGDV 
 
PDGYKATRTTQEDFFLLLELASPSQTSLYFCASSDAPGQLYFGEGSKLTV 
 
LEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVN 
 
GKEVHSGVSTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQF 
 
HGLSEENKWPEGSPKPVTQNISAEAWGRADCGITSASYHQGVLSATILY 
 
EILLGKATLYAVLVSGLVLMAMVKKKNS-(stop)-acgcgt 
AgeI restriction site 
MluI restriction site 
       TCRα   leader   sequence   _   Vα           
 Cβ      
 Cα 
P2A linker 
 Vβ              TCRβ leader sequence_        _  ___    P2A link r   
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Figure 2.2 
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Figure 2.2. Enrichment of 42F3-expressing T cell hybdridoma populations after 
retroviral transduction and one round of FACS using an anti-TCR Cβ antibody and 
PE-conjugated secondary antibody. T cell hybridoma cell lines 58-/- (A) and 58-/- 
CD8αβ++ (B) were transduced via packaged retrovirus to express the 42F3 TCR 
on the surface. Parental cells (untransduced, black trace), cells that were 
transduced but unsorted (red trace), and retroviral transductants that were sorted 
one time (blue trace) were stained with biotinylated anti-TCR Cβ and Streptavidin 
PE to detect the levels of TCR (in this case, 42F3) on the cell surface using flow 
cytometry. 
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Figure 2.3 
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Figure 2.3. Interleukin-2 release from 42F3 T cell hybridomas that express 
CD8αβ (lime green squares), or do not express CD8αβ (red triangle), in response 
to incubation with the indicated concentrations of peptide QL9 (QLSPFPFDL) and 
either T2-Ld target cells (A), or LM1.8-LdW97R target cells (B). Also shown is the 
interleukin-2 release in response to incubation with anti-CD3 mAb (145-2C11 
clone) from 42F3 T cells in the presence of CD8αβ (open black squares), or in the 
absence of CD8αβ (blue circles). 
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Figure 2.4 
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Figure 2.4. A, Schematic representation of the extracellular fusion protein containing 
Ldm31 linked to the nonamer peptide, the N-terminal expression tag hemagglutinin (HA), 
and the yeast mating protein Aga2. B, Schematic representation of the extracellular fusion 
protein in which Ldm31 is linked by flexible linker to hemagglutinin, and a flexible linker 
tethers the nonamer peptide to Ldm31 which contains only the α1 and α2 domains. The 
peptide shown is representative of QL9 (QLSPFPFDL) and arrows indicate the pointing of 
each residue towards the TCR (up arrows) or towards the MHC (down arrows). C, Flow 
cytometry data showing the dual staining (anti-HA/Alexa488 and 42F3/PE tetramers) of 
populations after several rounds of enrichment using FACS, and the positions of 
degeneracy introduced in the nonamer peptide in each library (Random, TCR contacts, or 
MHC contacts). C is shown with permission from (102). 
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Figure 2.5 
Figure 2.5. Relative IL-2 release from 42F3 T cell hybridomas in response 
to novel peptide antigens loaded onto Ld-expressing target cells. 42F3 T 
cells with CD8αβ co-receptor (grey bars) or without co-receptor (black 
bars) were incubated with T2-Ld target cells in the presence of 10μM 
peptides (from indicated yeast display libraries, R indicating Random) 
diluted in RPMI, and supernatants were analyzed by ELISA for the 
presence of interleukin-2 (IL-2). 
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Figure 2.6 
Figure 2.6. Relative IL-2 release from 42F3 T cell hybridomas in response 
to novel peptide antigens loaded onto Ld-expressing target cells. 42F3 T 
cells with CD8αβ co-receptor (grey bars) or without co-receptor (black 
bars) were incubated with either LM1.8-LdW97R target cells in the 
presence of 10μM peptides (from indicated yeast display libraries, R 
indicating Random) diluted in RPMI, and supernatants were analyzed by 
ELISA for the presence of interleukin-2 (IL-2). 
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Figure 2.7 
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Figure 2.7. A, BD50 values for each indicated peptide binding to L
dW97 (black 
bars) or LdR97 (grey bars) on the surface of 58-/- cell lines transduced to express 
each Ld variant. B, Activation, as indicated by interleukin-2 release, of 42F3  
CD8αβ+ T cell hybridomas in response to the indicated peptides at 10μM 
displayed on T2-Ld (black bars) or LM1.8-LdW97R (grey bars) target cells.  
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Figure 2.8 
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Figure 2.8. A, Activation, as indicated by interleukin-2 release, of 42F3 CD8αβ+ T cell 
hybridomas in response to the indicated concentrations of peptide QLSDKPVDL (black 
circles), MCMV (YPHFMPTNL, lime triangle), or SPLDSLWWI (orange inverted triangle) 
displayed on LM1.8-LdW97R target cells. Also included is the activation of 42F3 CD8αβ+ 
T cell hybridomas in response to  LM1.8-LdW97R cells alone (no peptide, black diamond), 
or stimulation with the anti-CD3 antibody (145-2C11 clone, red squares). B, Activation of 
42F3 CD8αβ+ T cell hybridomas in response to 30nM QLSDKPVDL only (red bar), or the 
indicated concentrations of SPLDSLWWI or MCMV peptide in the presence of 30nM 
QLSDKPVDL (black bars).  
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Figure 2.9 
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Figure 2.9. Flow cytometry staining using soluble 42F3 TCR/PE  tetramers and soluble 
peptide/Ldm31/PE tetramers. A, LM1.8-LdW97R cells were loaded with 10μM of indicated 
peptides prior to staining with soluble 42F3biotin/SA-PE tetramers and analysis via flow 
cytometry. B, 42F3 58-/- (no co-receptor) were incubated with tetramers comprised of 
peptide-Ldm31biotin and SA-PE prior to analysis via flow cytometry. Red trace indicates no 
activation of 42F3 by the peptide, cyan indicates CD8-dependent activation of 42F3, and 
lime green CD8-independent activation of 42F3 when the peptide is displayed on LM1.8-
LdW97R target cells.  
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Figure 2.10 
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Figure 2.10.  A, Side-view of aligned crystal structures of 42F3 variable regions docking on Ldm31 
displaying QL9 and the indicated novel peptide antigens QLSDVPMDL, FLS, and SPL. B, Top-
down view of the docking of 42F3 CDR loops onto agonist peptide/Ldm31 complexes (black CDR 
numbers) or the SPL/Ldm31 (red CDR numbers). Red/pink toned loops indicate CDR loops from 
the 42F3 α chain, blue/grey toned loops indicate CDR loops from the 42F3 β chain, and 
representative MHC α-helices and peptide are shown from the 42F3-QL9/Ldm31 structure. 
Diagonal lines were manually drawn between the CDR2α and CDR2β loops of the agonist 42F3-
pep/Ldm31 complexes (solid black line) or 42F3-SPL/Ldm31 (dashed red line). 
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CHAPTER THREE 
 
 
THE SAME MHC POLYMORPHISM INVOLVED IN CONTROL OF HIV INVFLUENCES 
PEPTIDE BINDING IN THE MOUSE H-2Ld SYSTEM 
 
 
Introduction 
 
Human leukocyte antigens (HLA) encoded by the major histocompatibility complex 
(MHC) are among the most polymorphic genes in the population (152). Class I MHC 
gene products display short peptides of eight to ten amino acids on the surface of all 
nucleated cells (126), and these complexes are recognized by the αβ T cell receptors 
(TCR) on the surface of T cells. TCR binding of peptide/MHC molecules above a 
minimal threshold results in T cell activation and effector function such as target cell lysis 
(1,130,131).  
The MHC locus has been shown to be associated with protection from or 
susceptibility to various diseases, including infectious diseases of viral origin such as 
HIV, as well as autoimmune conditions (67,68,70,153-156).  Ultimately the MHC-
associated control or progression of diseases is related to the presence of functional T 
cells that express TCRs that bind to antigenic (or self) peptide-MHC complexes. The 
presence of functional T cells, and the breadth of the TCR repertoire, is controlled both 
by thymic selection processes that occur during development of a T cell, and peripheral 
processes that regulate mature T cell activity (157).  In the thymus, positive and negative 
selection operates on T cells through the αβ TCR and the CD4 and CD8 co-receptors. T 
cells that have TCRs with a low affinity for self-peptides presented on self-MHC 
molecules are positively selected, yet T cells that express TCRs with higher affinity for 
self-peptide-MHC complexes are clonally deleted (63,127,128).  
It is widely hypothesized that the diversity of an individual’s peripheral T cells 
correlates with the effectiveness of the adaptive immune system in eliminating viral 
infections, and that the breadth of the TCR repertoire correlates in turn with the diversity 
of self peptides presented by an individual’s MHC alleles during development (158). 
Thus, self-protein antigen processing pathways are critically linked to immune potential 
(128,159-161). Importantly, the peripheral regulatory processes are also influenced by 
interactions of T cells with self pep-MHC complexes, which can control functional T cell 
activity by promoting the deletion or anergy of particular T cells, (as reviewed in (162-
164)).  
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Recent studies have implicated several positions of the human MHC locus HLA-B in 
the control and progression of HIV infection. Positions 67, 70, and 97 of HLA-B, all 
located in the peptide-binding groove, showed the strongest associations with 
differences in the frequency of HIV controllers and progressors (67). It has been 
hypothesized that these amino acid positions in HLA-B could contribute to disease 
control or progression by affecting the ability of either foreign peptides or self-peptides to 
bind the different alleles; the former could operate by inducing favorable immunity, and 
the latter could operate by influencing thymic selection (as reviewed in (165)).  However, 
biochemical and structural explanations for these effects remain unknown, and thus a 
mechanistic explanation of the polymorphisms is yet to be developed.  
The mouse MHC (known as H-2) represented the first system to reveal the 
properties of polymorphism and the process of T cell recognition that required MHC 
“restriction” of the antigen (166).  The class I H-2 molecule Ld has been well studied and 
is known to exhibit lower stability than many other class I products such as Kb 
(41,42,167-169).  In addition, it appears that peptides that bind to Ld may be influenced 
by more of their individual residues than peptides that bind to Kb, which appear to have 
dominant anchor residues (143). Relevant to recent information about HIV and HLA-B 
polymorphisms are previous studies showing that two alleles called Lq and Ld contained 
the same polymorphism at residue 97 as in the HLA-B studies, and these alleles 
exhibited differences in stability between the ternary complexes (peptide, H-2L heavy 
chain, and beta-2-microglobulin) (49). In an independent approach, the W97R 
substitution was identified in a “needle in a hay stack” experiment in which more stable 
Ld mutants were identified because they conferred higher surface levels of the protein in 
a yeast display system (47). Thus, completely different approaches have revealed the 
importance of position 97 in Ld stability. The crystal structures of Ld complexes with the 
Trp (43,44) and the Arg (52,102,170) have also been solved, providing additional 
mechanistic insight.  
To examine more fully the hypotheses regarding the impact of the position 97 
polymorphisms on peptide binding, here we introduced the two variants, LdW97 and 
LdR97, into an antigen-processing competent mouse cell line and examined various 
aspects of peptide binding and stability of the complexes. The binding analysis was 
facilitated by the use of a high-affinity, soluble TCR that was available against the 
specific peptide complex called QL9-Ld, allowing a quantitative assay of binding by a 
panel of peptides. The results showed that LdR97, compared to LdW97, conferred a 
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greater average stability to peptide-Ld complexes and resulted in a broader repertoire of 
peptide binding from the panel of peptides. The peptides included in the panel were 
identified either through a yeast display library displaying a miniature module of LdW97 
or LdR97, or from a collection of peptides that were affinity purified from endogenously 
presented peptide/Ld complexes. Half of the tested peptides bound preferentially to 
LdR97, and only a few peptides bound preferentially to LdW97. The remaining one third 
of peptides bound both Ld variants without a clear preference for one variant over the 
other.  
The structures of several different peptides bound to one or the other Ld variants 
suggested that the Arg97 residue acts not by having increased flexibility itself, but by 
tolerating more side-chain flexibility in the vicinity of the peptide and adjacent MHC 
residues, compared to Trp97. Overall, these findings are consistent with the hypothesis 
that many self-peptides will be presented at physiological higher levels by an allele with 
Arg97, compared to an allele with Trp97.  Thus, our results support the notion that Arg97 
alleles exhibit a preference for a progressor phenotype in HIV patients because 
potentially effective T cells in these individuals have been deleted by negative selection 
in the thymus. It is also possible that these self-peptide-Arg97 allele complexes may be 
capable of driving enhanced peripheral T cell anergy (as reviewed in (162)). 
 
 
Materials and Methods 
 
Cell lines and Ld transfectants 
A derivative of BW5147, a mouse T cell thymoma (AKR mouse, H-2k), was used for 
the Ld studies because it is readily transduced by the pMP71 retroviral vector, and it is 
capable of normal antigen processing of self and foreign peptides (e.g. it is TAP 
sufficient). The BW5147 subline called 58-/- was used to generate Ld-transfectants, as 
described below. BW5147 cell lines and the hybridoma 30-5-7 that secretes an anti-Ld 
monoclonal antibody (against the α2 domain) were cultured in RPMI 1640 media 
containing 10% fetal bovine serum at 37°C with 5% CO2. RMA and RMA/S cell lines 
were cultured in complete RPMI containing 10% fetal bovine serum at 37°C with 5% 
CO2. 
The gene encoding the full-length murine MHC allele heavy chain LdW97, residues 
1-338 with a 24 amino acid leader sequence, was cloned into retroviral vector pmp71 as 
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a NotI-EcoRI fragment. The LdW97-pMP71 ligation product was obtained and a single-
site mutation was made using the Stratagene QuikChange Lightning kit to generate a 
pMP71 construct containing the gene for LdR97. 58-/--LdW97 and 58-/--LdR97 cell lines 
were generated by retroviral transduction (102).  Briefly, 20μg Ld-pMP71 DNA was 
incubated with 60μg Lipofectamine 2000 (Invitrogen) in 3mL of Opti-mem media (Gibco) 
for 20 minutes at room temperature. DMEM culture supernatant was removed from 3 x 
106 adherent Plat-E retroviral packaging cells and 1.5mL of the DNA/Lipofectamine/Opti-
mem mixture was added.  Plat-E cells were incubated with the DNA mixture for 3 hours 
at 37°C, then the DNA mixture was removed.  Plat-E cells were washed with 7mL RPMI 
1640 media, then incubated with 6.5mL RPMI 1640 media for 48 hours at 37°C. Parental 
58-/- cells (2 x 106) were transduced by centrifuging the cells in a 24-well plate (Corning 
costar) at 652g for 45 minutes with 3mL of supernatant from transfected Plat-E cells.  
Transduced 58-/- cells were cultured overnight at 37°C before being transferred to a T25 
flask with 5mL RPMI 1640 media and cultured at 37°C with 5% CO2.  L
d-positive 
populations of 58-/- cells, expressing LdW97 or LdR97, were enriched by staining with a 
saturating amount of 30-5-7 anti-Ld monoclonal antibody (20μg/mL; purified from ascites 
fluid) followed by PE-conjugated goat F(ab)’2 anti-mouse IgG secondary antibody 
(1.25μg/mL; Southern Biotech) (171). The most fluorescent 1% of the stained 58-/- Ld-
transductants was isolated and collected by fluorescence activated cell sorting (FACS). 
Isolated cells were cultured in RPMI 1640 at 37°C with 5% CO2. The same transfection 
and transduction procedure was performed on cells from the RMA and RMA/S cell lines, 
but were unsuccessful and thus these cells were not submitted for FACS and not used in 
the remainder of the project. 
 The LM1.8-LdW97R cell line is an adherent, antigen-processing competent 
murine cell line that expresses the full length LdW97R variant on the surface. These cells 
were cultured in complete RPMI 1640 containing 10% fetal bovine serum, at 37°C with 
5% CO2. They were passaged to one tenth of their density every three days. 
 
Soluble high-affinity T cell receptor 
The soluble TCR called 2C-m6 binds to the QL9/Ld complex with high affinity (KD 
value 5 nM) (172). A single-chain form of the 2C-m6 TCR (scTCR) was expressed in E. 
coli, refolded from inclusion bodies, and purified as described previously (47). Purified 
2C-m6 scTCR was biotinylated using the EZ-Link Micro Sulfo-NHS-Biotinylation Kit 
(Thermo Scientific) and stored at 4°C (173). 
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Measurement of cell-surface Ld levels 
Cell surface levels of Ld variants were evaluated using transduced 58-/- cells and 
anti-Ld antibody. 58-/- cells (2 x 105) expressing LdW97 or LdR97 were incubated with 
RPMI alone or with peptides at various concentrations in RPMI for 3 hours, then washed 
and incubated with 20μg/mL 30-5-7 anti-Ld mAb followed by goat F(ab)’2 anti-mouse IgG 
secondary antibody. Samples were washed, fixed with 1% paraformaldehyde in PBS, 
and analyzed for PE fluorescence using an Accuri C6 flow cytometer.  Data was 
analyzed using FCS Express. 
 
Ld upregulation assays 
 Upregulation or stabilization assays were performed by first incubating the 58-/- 
cells transduced to express the Ld variants with various concentrations of peptides 
diluted in RPMI for 2.5 hours at 37C. Cells were harvested, washed with PBS/BSA, and 
then stained with 20μg/mL 30-5-7 anti-Ld mAb followed by goat F(ab)’2 anti-mouse IgG 
secondary antibody. Samples were washed again with PBS/BSA, then fixed with 1% 
paraformaldehyde in PBS, and analyzed for PE fluorescence using an Accuri C6 flow 
cytometer. Data was analyzed using FCS Express. Mean fluorescent units were plotted 
using GraphPad Prism. 
 
Source and synthesis of Ld-binding peptides 
The following Ld-binding peptides were used in this study:  QLSPFPFDL (called 
QL9); YPHFMPTNL (called MCMV); TQNHRALDL (called tum-); QLSDVPMDL, 
SPLDSLWWI, FLSPFWFDI, MPKPLSL, QPQHTVRSL, QFTTLPAGL, ANPSFYFDI, 
VPYMAEFGM, MPDSAGWSL, ALGPFPFDL, APWNPAMMI, MPGEASFML, 
MPAGRPWDL, WPAEGGFQL, SPAPRPLDL, and SPAEAGFFL.  Peptides 
QLSDVPMDL, SPLDSLWWI, FLSPFWFDI (called FLS), ANPSFYFDI, ALGPFPFDL, 
and APWNPAMMI were identified using a yeast display system as described previously 
that contained the Ldm31 module that contained the W97R mutation (102). Peptides 
VPYMAEFGM, MPDSAGWSL, MPGEASFML, MPAGRPWDL, WPAEGGFQL, 
SPAPRPLDL, and SPAEAGFFL were identified using a yeast display system very 
similarly to the one described in (102), the difference being that the Ldm31 module 
contained the wild-type Trp97 residue. The remaining peptides, MPKPLSL, 
QPQHTVRSL, and QFTTLPAGL, were identified by mass spectrometry from HPLC 
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fractions that contained peptides obtained from BALB/C liver tissue using an anti-Ld 
affinity purification scheme. The details of their isolation will be described in a separate 
report.  
 Peptides were synthesized either by the UIUC Protein Sciences Facility (MCMV, 
SPLDSLWWI, MPKPLSL, QPQHTVRSL, QFTTLPAGL) or by Genscript (QL9, tum- 
QLSDVPMDL, FLSPFWFDI, ANPSFYFDI, ALGPFPFDL, APWNPAMMI, VPYMAEFGM, 
MPDSAGWSL, MPGEASFML, MPAGRPWDL, WPAEGGFQL, SPAPRPLDL, and 
SPAEAGFFL) and stored in dimethylsulfoxide (DMSO) at 50mM at -20°C.  
 Biotinylated peptide QLSDKPVDL was obtained from the laboratory of Dr. K. 
Chris Garcia and was stored in 100% DMSO at a concentration of 50mM. The position 5 
lysine was biotinylated after synthesis, prior to being provided to our laboratory. 
 
Preliminary competitive Ld-binding assay using biotinylated QLSDKPVDL 
 58-/- cells transduced to express either LdW97 or LdR97 were incubated in a 96-
well plate (Corning) for 10 minutes at 37°C with 25μL of 5μM biotinylated QLSKPVDL 
before the addition of 25μL of 2X competitor peptides. Cells were incubated with the 
mixture of peptides for 2.5 hours at 37°C, then cells were harvested and washed. Cells 
were then stained with 2.5μg/mL phycoerythrin-conjugated Streptavidin (SA-PE). 
Fluorescence was analyzed by flow cytometry on the Accuri C6 cytometer. Data was 
analyzed using FCS Express and the geometric mean fluorescent (MFU) of each sample 
was determined. The MFU of cells incubated with biotinylated peptide only prior to 
staining with SA-PE is indicated as MFU0, and the MFU of cells incubated with both the 
biotinylated peptide and competitor peptide prior to staining with SA-PE is indicated as 
MFU1. MFUno peptide indicates the MFU of cells incubated without peptide prior to staining 
with SA-PE. The value reported as “MFU1/MFU0 corrected for MFUno peptide” was 
calculated as shown below: 
 
(MFU1 – MFUno peptide) 
(MFU0 – MFUno peptide) 
 
MFU1/MFU0 values were graphed using Graphpad Prism. 
 
Assessing the binding of m6 scTCR to Ld-expressing cells loaded with various candidate 
peptides 
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 Synthetic peptides were assayed to assess binding of soluble single-chain 2C-
m6 to each peptide-Ld complex. 58-/--LdW97 or 58-/--LdR97 cells (2 x 105) were incubated 
with 100μM peptide diluted in RPMI for 3 hours at 37°C.  Peptide QL9 was sampled in 
this experiment at 50nM or 100nM. Cells were washed and incubated with 10μg/mL 
soluble biotinylated 2C-m6 scTCR for 40 minutes on ice. Cells were washed and 
incubated with 2.5μg/mL phycoerythrin-conjugated Streptavidin (Streptavidin-PE, BD 
Pharmingen) before fixing with 1% paraformaldehyde.  Samples were analyzed by flow 
cytometry on an Accuri C6 cytometer, and data was analyzed using FCS Express.  
 
 
Competitive Ld-binding assay using high affinity m6 scTCR for detection 
Because initial studies with a reference biotinylated peptide yielded very low signal-
to-background, we developed a novel competition assay to evaluate the relative strength 
of each peptide in binding to LdW97 and LdR97. 58-/- cells (2 x 105) expressing LdW97 or 
LdR97 were incubated with a mixture containing 50nM QL9 and various concentrations 
of competitor peptides in RPMI (note that these competitor peptides were not detectably 
bound by the soluble TCR). After 2.5 hrs at 37°C, cells were washed and incubated with 
10μg/mL biotinylated 2C-m6 scTCR. After washing, cells were incubated with 2.5μg/mL 
Steptavidin-PE (BD Pharmingen).  Samples were fixed with 1% paraformaldehyde in 
phosphate-buffered saline and analyzed for PE fluorescence using an Accuri C6 flow 
cytometer.  Data was analyzed using FCS Express.  Mean fluorescence units (MFU) of 
samples incubated with competitor peptide and QL9 (MFU1) was divided by mean 
fluorescence units of samples incubated with QL9 alone (MFU0). BD50 values were 
obtained using non-linear regression analysis (GraphPad Prism). 
Peptides identified from the Ldm31 Trp97 yeast display library (VPYMAEFGM, 
MPDSAGWSL, MPGEASFML, MPAGRPWDL, WPAEGGFQL, SPAPRPLDL, and 
SPAEAGFFL) as well as additional Ldm31 Arg97-selected peptides (ANPSFYFDI, 
ALGPFPFDL, and APWNPAMMI) were also assessed in competitive binding assays as 
described above, but with a slightly modified protocol. Instead of mixing the various 
concentrations of the listed competitor peptides with an equal volume of 100nM QL9 
prior to incubation with the LdW97 and LdR97 58-/- transfectants, the Ld-variant-
expressing cells were first incubated with 25μL of 100nM for 10 minutes at 37°C, and 
then 25μL of the competitor peptide (at a 2X concentration) was mixed in by pipet. The 
cells were then incubated with the mixture of peptides for the 2.5 hours at 37°C and then 
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stained the same way described above, run on the Accuri C6 flow cytometer. Data was 
once again analyzed by FCS Express and MFU0 and MFU1 values were calculated the 
same way described above, graphed in GraphPad Prism, and BD50 values were once 
again obtained using a non-linear regression analysis.  
 
Soluble LdR97 stability assay 
The stabilized Ldm31 form (Arg97, 21 kDa) of MHC Ld was expressed in E. coli as 
inclusion bodies and refolded as described previously (47,170). Briefly, 3μM Ldm31 
inclusion bodies was refolded with 30μM, 6μM, or 1.2μM dimethylsulfoxide-dissolved 
peptide (MCMV, FLS, or tum-) in 25mL buffer containing 100mM Tris pH 8.0, 400mM L-
arginine, 2mM ethylenediaminetetraacetic acid (EDTA), 0.2mM phenylmethylsulfonyl 
fluoride (PMSF), 5mM reduced glutathione, and 0.5mM oxidized glutathione for 48hrs at 
4°C, without stirring. Refolded mixtures were filtered 
SDS- -20% 
gradient polyacrylamide gels (Bio-Rad) were run for 45 minutes at 120V, and stained 
with Coomassie Blue.   
Scanned gel images were subjected to analysis using the ImageJ public domain 
Java image processing program- first by converting the scanned image into 16-bit 
grayscale, and then by obtaining the area of each band and the average intensity of the 
band.  The average intensity of each band was multiplied by the band’s area, to 
generate overall intensity. These values were considered proportionate to the yield of 
each peptide-Ld complex.  The overall intensity value of the band corresponding to 
Ldm31 refolded in the absence of peptide (no peptide) was set to 1, and all protein yield 
values were calculated relative to this. 
 
Peptide-MHC structure analysis 
Structures of the following peptide-Ld complexes were analyzed QLSDVPMDL-
LdR97 (PDB ID 3TFK), FLSPFWFDI-LdR97 (PDB ID 3TPU), SPLDSLWWI-LdR97 (PDB 
ID 3TJH), and peptide LdW97 structures (PDB IDs 1LDP, 1LD9). In some cases, 
structures were aligned and highlighted for presentation using Pymol. Peptide-HLA-B 
structures examined were: RRRWRRLTV-HLA-B*14:02 (PDB ID 3BVN), VPLRPMTY-
HLA-B*35:01 (PDB ID 1A1N), KGFNPEVIPMF-HLA-B*57:03 (PDB ID 2HJK), 
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GRFAAAIAK-HLA-B*27:05 (PDB ID 1JGE), TAFTIPSI-HLA-B*51:01 (PDB ID 1E28), 
RPHERNGFTVL-HLA-B*07:02 (PDB ID 3VCL). 
 
HLA-B sequence analysis 
HLA-B sequences were obtained from the International ImMunoGeneTics (IMGT) 
Information System, and aligned using the IMGT alignment tool.  Truncated HLA-B 
sequences were not included in the tabulation of the amino acid identity at positions 114, 
116, and 156 of the full-length protein. 
   
 
 
 
Results 
 
Complexes of self-peptide/LdR97 are expressed at higher levels on cells than complexes 
of self-peptide/LdW97 
A previous study showed that the two H-2 alleles Ld and Lq differed at six positions, 
including position 97 (Trp in Ld and Arg in Lq) (48,49), the same single-site polymorphism 
shown to be involved in HLA-B control of HIV (67). Experiments performed with single-
site mutants of Ld(W97R) and Lq(R97W) on the surface of DAP-3 cells using antibodies 
against assembled and empty Ld or Lq molecules suggested that R97 may contribute to 
greater cell surface stability, stronger binding to endogenous peptides, and higher  
affinity for β2-microglobulin compared to W97 (48).  
To determine if this observation extended to different cell lines with varying levels of 
antigen-processing capability, we transduced the 58-/-, RMA, and RMA/S cell lines with 
wild-type Ld (Ld-W97) and the single-site mutant Ld-R97, using these genes inserted into 
the pMp71 retrovirus vector (124). The sequence of the full length wild type Ld protein, 
as well as the N-terminal leader sequence and restriction sites used for cloning into the 
pMp71 vector, is indicated in Figure 3.1A. The sequences of the PCR primers used to 
introduce the tgg (Trp)agg (Arg) point mutation in the codon for the position 97 residue 
are indicated in Figure 3.1B. Both the cloning into pMp71 and the introduction of the 
point mutation using the QuikChange Lightning PCR kit resulting in the W97R mutation 
were successful. LdW97-pMp71 and LdR97-pMp71 constructs were transfected into the 
Plat-E retroviral packaging cell line to generate retroviral particles containing the Ld-
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pMp71 constructs that could be transduced into immortalized cell lines, which included 
RMA (murine, TAP-sufficient), RMA/S (murine RMA lineage, TAP-deficient), and 58-/- 
(BW5147 lineage, TAP-sufficient). RMA and RMA/S cell lines were unable to be 
transduced, which was indicated by the lack of staining with anti-Ld monoclonal antibody 
30-5-7 following transduction (data not shown). For this reason, RMA and RMAS cell 
lines were not pursued any further in this project. However, surface Ld protein was 
detected on the surface of transduced 58-/- cells (H-2k haplotype) transduced to express 
either LdW97 or LdR97, and transduced 58-/- were enriched for an Ld+ phenotype using 
FACS. To assess the enrichment of Ld+ transductants, surface Ld expression was 
detected on cells that were untransduced, transduced and un-sorted, or transduced and 
sorted once using 30-5-7 and a fluorophor-conjugated secondary antibody (Figures 
3.2A and 3.2B). Prior to sorting, 21% of 58-/- cells transduced to express LdW97 were 
Ld+; after one round of sorting for Ld expression, 97% of transduced cells were positive 
for LdW97 (Figure 3.2A). Conversely, only 11% of LdR97-transduced 58-/- cells were Ld 
positive prior to sorting; after sorting 97% of transduced cells were Ld+ (Figure 3.2B). 
The experiments shown in Figures 3.2A and 3.2B indicated that the transduction of 58-/- 
with retroviral particles encoding LdW97 and LdR97 was successful, and that the Ld 
proteins were successfully displayed on the cell surface. Additionally, these experiments 
showed that the FACS-isolated transductant population was nearly entirely Ld+. The 
transduced 58-/- lines expressing LdW97 and LdR97 were ready to be used to further 
understand the effects of the W97/R97 MHC Ld polymorphism.  
Surface levels of LdR97, as judged by the mean fluorescent units (MFU) with anti-Ld 
staining were consistently twice as high as surface levels of LdW97 (Figure 3.2C). As it 
is well known that the surface levels of MHC are controlled in part by the stability of the 
peptide-class I heavy chain/β2m complex, this finding suggests that either there are 
many more endogenous self-peptides that can associate well with LdR97, or there is a 
smaller subset of abundant self-peptides that bind better to LdR97, or both. We chose to 
address this issue of the repertoire of peptide binding by each Ld variant using a series 
of flow cytometry based assays and a panel of peptides containing both known Ld-
binding species and novel peptide candidates. 
In the Ld system, “upregulation” assays dependent on the ability of an exogenous 
synthetic peptide to stabilize the pep-Ld/β2m complex and thus increase its total surface 
levels have often been performed to determine Ld-binding abilities (174). To examine if 
Ld-binding peptides could further increase the levels of LdW97 and LdR97 on 58-/-, four 
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peptides were examined in this assay. Cells were incubated with various concentrations 
of peptides QL9 (QLSPFPFDL), MCMV (YPHFMPTNL), FLS (FLSPFWFDI, and tum- 
(TQNHRALDL) and the surface levels of LdW97 and LdR97 were detected with the 30-5-
7 anti-Ld monoclonal antibody. The MHC upregulation on the surface of LdW97 and 
LdR97 58-/- transductants in response to incubation with MCMV peptide is shown in 
Figure 3.3A; the term “upregulation” indicates the increase in Ld surface levels in the 
presence of exogenous peptide relative to the Ld surface levels in the absence of 
exogenous peptide. The data from the other peptides tested (QL9, FLS, and tum-) was 
also obtained using the same assay, the “percent upregulation” values were determined 
similarly, and data was plotted in the same manner. The level of upregulation in 
response to incubation with each peptide concentration was determined relative to Ld 
surface levels in the absence of peptide, and the concentration of peptide resulting in 
50% maximal upregulation (SD50) was determined (Figure 3.3B). Peptide MCMV 
induced upregulation of LdW97, with an SD50 value of approximately 0.12μM.  Peptide 
FLS induced modest upregulation at only the highest concentration, 100μM, whereas 
neither QL9 or tum- exhibited any detectable upregulation.  Conversely, peptides QL9, 
MCMV, and FLS induced significant upregulation of LdR97 on the 58-/- cell surface, with 
SD50 values in the order of MCMV < QL9 < FLS (Figure 3.3B).  Thus, the addition of 
exogenous peptides enabled the cell surface levels of LdR97 to be increased more 
effectively than the levels of LdW97. LdW97 levels were able increased only by the 
presence of MCMV peptide (a known strongly-binding peptide for LdW97), indicating that 
this assay was sensitive enough only to detect binding by peptides that bind the MHC 
very strongly.  
A more sensitive assay was required to probe the preferential binding of a panel of 
peptides to each Ld variant, and attempts were made to increase the sensitivity of the Ld 
upregulation assay itself. While the inability of Ld (especially LdW97) cell surface levels to 
be increased in the presence some peptides, is in part likely to be related to the 
expression of TAP and hence self-peptide complexes, we reasoned that Ld levels could 
be enhanced at lower temperatures or in the presence of β2-microglobulin (β2m). 
Previous studies using the RMAS cell line (175,176) showed that lower temperature 
(26°C) allowed enhanced accumulation of empty MHC molecules at the cell surface, 
while addition of β2m during peptide-loading also increased MHC surface levels on 
RMAS cells (177). However, neither incubation of the transduced 58-/- cells at a lower 
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temperature (26°C), nor inclusion of β2m during peptide loading, increased surface 
levels of LdW97 or LdR97 (data not shown).  
 
Competitive peptide binding assays using a biotinylated reference peptide showed poor 
sensitivity 
 A competitive peptide binding assay was performed that utilized peptide 
QLSDKPVDL that had been previously biotinylated at the position 5 lysine. The 
biotinylated peptide (2.5μM) was pre-loaded for a short time onto the 58-/- Ld 
transductants, then various concentrations of competitor peptides were added. The 
peptide/Ld complexes containing the biotinylated QLSDKPVDL peptide were detected 
with PE-conjugated Streptavidin. Fluorescent signal was analyzed by flow cytometry and 
change in mean fluorescent units of each sample was indicative of the level of 
competition from each competitor peptide. A decrease in fluorescent signal from cells 
that had been incubated with a mix of competitor peptide and biotinylated peptide, 
compared to cells that were incubated with biotinylated peptide only, indicated that the 
competitor peptide had effectively bound to the MHC. Various concentrations of peptides 
SIYRYYGL (SIY, negative control for Ld binding), MCMV (positive control for Ld binding), 
and APWNPAMMI (APW, test peptide) were sampled in such an assay and the mean 
fluorescence (MFU) of LdW97 and LdR97-expressing cells were plotted against 
competitor peptide concentration (Figure 3.4A). The difference in fluorescence (MFU) 
between cells that were incubated with biotinylated QLSDKPVDL alone, and cells that 
were not incubated with any peptide, was very low, thus creating a very narrow dynamic 
range (as seen in Figure 3.4A). In order to more clearly observe the competition 
between competitor peptides and the biotinylated peptide, all samples were corrected by 
subtracting the “no peptide” MFU values from each sample prior to calculating the ratio 
(Figure 3.4B). When the data was analyzed this way, peptide MCMV proved to be the 
strongest LdR97-binding peptide of the group, followed by the APW peptide. Peptide SIY 
was included in this assay as a negative control, and did not show significant binding to 
LdR97, even at the highest concentration. One caveat of this experimental setup is that 
in order to see staining with Streptavidin-PE, the biotinylated reference peptide 
QLSDKPVDL had to be used at the very high concentration of 2.5μM. A peptide 
concentration of approximately 200μM was considered saturating for this system, which 
meant that the concentration of the competitor peptide could be, at its maximum, eighty 
fold in excess of the reference peptide. This compounded the poor sensitivity of this 
 
 
81 
assay, along with the small range of fluorescence observed using these reagents, and 
made it unlikely to obtain BD50 values relaying the quantitative binding for even 
moderately-binding peptides to Ld.  
 
 
LdR97 binds some, but not all, peptides better than LdW97 
As indicated, the higher levels of self-peptide LdR97 complexes shown here (Figure 
3.2C) and in a previous study could be due to a few abundant self peptides that bind to 
LdR97 better, or to a large fraction of self-peptides that bind better (48).  Because the Ld-
upregulation assay and competitive binding assay using the biotinylated peptide 
provided only a semi-quantitative assessment of Ld-binding ability for some peptides, we 
developed a competition assay that took advantage of a unique soluble TCR reagent, 
called 2C-m6, that detects complexes of QL9/LdW97 and QL9/LdR97. Based on peptide 
titrations (Figure 3.5A), we estimated that the QL9 peptide binds approximately 2 to 3-
fold better to LdR97 than to LdW97 (BD50 values of 85nM on L
dW97 and 17nM on 
LdR97).   
To examine additional Ld-binding peptides, we used a panel of peptides that had 
originally been isolated by one of several methods: previously characterized foreign 
peptides (tum- and MCMV), peptides derived from a yeast-display library screen 
involving a single-chain form of LdR97 or LdW97 ((102) and unpublished), or peptides 
eluted from Ld as part of an anti-Ld affinity purification from BALB/c (LdW97+) tissue.  
Thus, these peptides had been isolated based in part on their ability to associate with Ld. 
Most of these peptides, when bound to LdW97 or LdR97, are not detected by the soluble 
2C-m6 TCR, although weak binding was detected with peptide FLSPFWFDI and 
ALGPFPFDL at very high concentrations. The panel of peptides from three distinct 
sources and selection criteria allowed us to determine quantitatively the binding affinity 
of the collection of peptides for LdW97 and LdR97, using the high affinity m6 scTCR to 
detect QL9/Ld (both Trp97 and Arg97) complexes.  
In the competition assay format, cells bearing either LdW97 or LdR97 were 
incubated with synthetic peptides that were titrated in the presence of 50nM QL9, 
followed by staining with the 2C-m6 TCR. Decreased fluorescent signal indicated that 
the competitor peptide effectively competed for binding to the MHC, thus decreasing the 
2C-m6 scTCR binding and fluorescent signal.  The mean fluorescent units (MFU) for 
cells incubated with 50nM QL9 alone prior to m6 staining is referred to as MFU0, and the 
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MFU for cells incubated with 50nM QL9 and a competitor peptide is referred to as MFU1. 
The ratio of MFU1/MFU0 is indicative of the ability of the competitor peptide to compete 
with QL9 for binding to the surface Ld variant. An MFU1/MFU0 value approaching 1 
indicates poor binding or the lack of binding to Ld; an MFU1/MFU0 value less than 1 
indicates binding of the competitor peptide to the surface Ld variant. Curves were 
generated using data for each concentration of competitor peptide, and BD50 values 
were obtained (Table 3.1). These values indicate the concentration of competitor 
peptide at which 50% maximal binding was observed. The data from this assay is 
detailed in figures 6, 7, and 8. In total, 18 peptides were evaluated for binding to LdW97 
and LdR97 using the same peptide binding competition assay (Table 3.1). Peptides 
MCMV and tum- (shown in Figure 3.6) are previously identified foreign peptides known 
to bind Ld, and have been examined previously by Dr. Ted Hansen’s research group to 
assess their relative binding to LdW97 or LdR97. The MCMV peptide bound more 
strongly to LdR97 compared to LdW97, and the tum- peptide bound more strongly to 
LdW97 compared to LdR97. Both of these results were consistent with those shown from 
Ted Hansen’s research group, validating the use of this assay in examining the binding 
of the remaining panel of peptides to each Ld variant. Also shown in Figure 3.6 is Ld 
binding data for peptides MPKPLSL, QPQHTVRSL, and QFTTLPAGL, which were 
identified through an anti-Ld affinity purification process described in detail in Chapter 4 
of this thesis. Heptamer peptide MPKPLSL showed preferential binding to LdW97, while 
nonamer peptides QPQHTVRSL and QFTTLPAGL showed preferential binding to 
LdR97.  
Figure 3.7 contains Ld binding data for peptides that were isolated from the yeast 
display method described in (102) using the LdR97 selection platform. All of these 
peptides bound LdR97 more strongly than they bound LdW97 (See BD50 values in Table 
3.1). Two of the peptides tested, QLSDVPMDL and ALGPFPFDL, were pulled from 
LdR97 yeast display libraries that contained degeneracy at peptide positions that were 
directed away from the MHC according to the structure of QL9/Ldm31 as solved by Dr. 
Lindsay Jones, a previous member of the Kranz lab (170). Peptides FLSPFWFDI and 
ANPSFYFDI were identified from LdR97 libraries that contained degeneracy at positions 
that were known to contact the MHC, and thus would be expected to form stronger 
interactions with LdR97 compared to LdW97, considering that the position 97 residue is 
in the center of the peptide binding groove in a prime location to impact peptide binding. 
The remaining peptides, SPLDSLWWI and APWNPAMMI, were identified from LdR97 
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libraries that contained degeneracy at all positions except for position 2 (proline, leucine, 
or serine) and position 9 (leucine, isoleucine, methionine, and phenylalanine).  
Figure 3.8 contains Ld binding data for the seven peptides that were identified from 
the LdW97 yeast display libraries, all of which contained degeneracy at all positions 
except the anchor residue positions 2 and 9. Position 2 was restricted to proline, leucine, 
or serine, and position 9 was restricted to leucine, isoleucine, phenylalanine, or 
methionine.  One of these peptides, VPYMAEFGM, bound preferentially to LdR97. 
Peptide SPAEAGFFL bound preferentially to LdW97; the remaining peptides 
MPDSAGWSL, SPAPRPLDL, WPAEGGFQL, and MPAGRPWDL bound both Ld variants 
equally well (See BD50 values in Table 3.1).  
All of the LdW97-selected peptides, as well as ALGPFPFDL, ANPSFYFDI, and 
APWNPAMMI from the LdR97 selection, were sampled using a slightly modified protocol 
of the peptide binding assay. Instead of mixing the competitor peptide and QL9 prior to 
incubation with the Ld cell lines, the cells were first pre-loaded with 100nM QL9 for 10 
minutes. Then the 2X concentrations of competitor peptide were mixed in such that the 
final concentration of QL9 was 50nM. The incubation period was 2.5 hours long, just as 
in the published method. This method with the QL9 pre-incubation somewhat 
complicated the system of competitor peptide/QL9 competition for Ld binding. Instead of 
a direct competition between the two peptide species present in the culture supernatant, 
the on-rates and off-rates of QL9 binding to each Ld variant may have affected the ability 
of each competitor peptide to bind. I examined this by testing a few of these competitor 
peptides in a side-by-side assay in which the cells were either loaded with pre-mixed 
QL9 and competitor peptides, or pre-loaded with QL9 prior to addition of the competitor 
peptides. There was no significant difference in BD50 values from these side-by-side 
assays (data not shown), and for this reason we believe the BD50 values from assays 
performed using either method can be fairly compared against each other. 
In this competitive peptide binding assay, peptide QLSDVPMDL competed with QL9 
peptide on LdW97 and LdR97 with an average difference in BD50 of 14.7 (Figures 3.7 
and 3.9). In contrast, peptide tum- (TQNHRALDL) competed with the reference peptide 
QL9 on LdW97 and LdR97 with an average difference in BD50 of 0.11 fold (L
dW97/LdR97) 
(Figures 3.6 and 3.9). Heptamer peptide MPKPLSL competed with QL9 peptide on 
LdW97 and LdR97 with an average difference in BD50 of 0.54 (Figures 3.6 and 3.9). 
Peptide MPGEASFML competed well on both LdW97 and LdR97, resulting in a BD50 ratio 
of 1 which indicated that this peptide did not show preferential binding to either Ld variant 
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(Figures 3.8 and 3.9). The value of “average difference” listed here was calculated by 
taking the ratio of the BD50 value for each peptide binding to L
dW97 compared to the 
BD50 value for binding to L
dR97.  
Peptide binding curves were used to calculate BD50 values, and the relative peptide 
binding to LdR97 compared to LdW97 was determined by the ratio of BD50 (L
dW97)/BD50 
(LdR97). The results of this analysis indicated that nine of the eighteen peptides (MCMV, 
QPQHTVRSL, QFTTLPAGL, FLSPFWFDI, QLSDVPMDL, SPLDSLWWI, ALGPFPFDL, 
ANPSFYFDI, and VPYMAEFGM) bound better to LdR97 compared to LdW97, whereas 
the three others (TQNHRALDL, MPKPLSL, and SPAEAGFFL) bound better to LdW97 
compared to LdR97. Peptide FLS (FLSPFWFDI) showed the greatest disparity in binding 
LdR97 versus LdW97 (Figure 3.9 and Table 3.1) with a BD50 (W97)/BD50 (R97) ratio of 
approximately 38. Six of the eighteen peptides tested (APWNPAMMI, MPDSAGWSL, 
SPAPRPLDL, WPAEGGFQL, MPAGRPWDL, and MPGEASFML) did not show a clear 
preference for one particular Ld variant; they appeared to bind equally well to both 
LdW97 and LdR97. 
Peptide APWNPAMMI, though selected on the LdR97 yeast display platform, 
surprisingly did not show a clear preference for one Ld variant or the other. It must be 
noted that this peptide was a very poor binder to LdR97. This peptide was the subject of 
further unpublished study as part of a project conducted by our collaborator Dr. Jarrett 
Adams in the laboratory of Dr. Christopher Garcia. The peptide, identified from a 
peptide-linker-LdR97mini yeast display library, was examined from a structural 
perspective. The linked peptide/LdR97mini construct was expressed and refolded, and 
resulted in a successful crystallization and a solved crystal structure (unpublished, data 
not shown). The crystal structure showed that the APWNPAMMI peptide alone was not 
included in peptide-binding groove; a series of three glycine residues at the C-terminal 
end of the linker region was observed taking part in mediating the binding of the peptide 
to the peptide binding groove. The true sequence of the peptide interacting with LdR97 
for this yeast clone was not APWNPAMMI, but rather GGGAPWNPAMMI. The 
orientation of this longer peptide in the LdR97 groove did not form close contacts with the 
group, and its identification was likely an artifact of the peptide-linker-LdR97 yeast 
display system in which the linked constructs may drive the formation of peptide/Ld 
complexes that would otherwise not associate well on their own. 
An important note must be included in this description of the results from this 
competitive binding assay and the full panel of eighteen peptides. As mentioned 
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previously, the peptides in this panel were identified through a variety of means. 
Peptides MCMV and tum- were previously identified foreign (not endogenously 
presented) peptides known to bind to the wild type Ld protein. The naturally derived 
peptides identified through the anti-Ld affinity purification process detailed in chapter 4 
were also identified in part due to their ability to bind to MHC Ld (wild type) as well. 
However, the non-naturally derived peptides identified from the yeast display selection 
strategy using either the LdW97 or LdR97 platforms provided some very valuable insights 
into the effect of the position 97 residue on preferential binding to the MHC.  For 
example, all of the peptides identified from the LdR97 libraries bound more strongly to 
the R97 Ld variant, with the exception of APWNPAMMI which was a poorly binding 
peptide overall. Peptides FLSPFWFDI and ANPSFYFDI were isolated from LdR97 
libraries with degeneracy at MHC-contacting residues, and as predicted, these were 
peptides that bound more strongly to the R97 variant. Peptide SPLDSLWWI was 
identified from an LdR97 library in which only anchor residues were invariant, and this 
peptide did not detectably bind LdW97 at all, though significant binding to LdR97 was 
observed. Peptides identified from a similar anchor-residues-only LdW97 library did not 
prefer as a group to bind to LdW97 over LdR97. Instead, the majority of these peptides 
did not show a clear preference to bind to either variant, and all of them bound to both Ld 
variants quite strongly. This suggested that the majority of peptides that bind well to 
LdW97 also bind well to LdR97, though the reciprocal of that statement was not true in 
this study. In observing the full group of eighteen peptides, we conclude that 
approximately half of the peptides that load onto LdR97 show inferior binding to LdW97. 
A minority of those peptides may bind equally well to LdW97, and an even smaller 
fraction may prefer binding to LdW97. In any collection of peptides containing anchor 
residue motifs for Ld-binding, we suggest that there will be far fewer distinct peptide 
species that will bind preferentially to LdW97, and that the majority of peptides will bind 
equally well or better to LdR97. 
 
Peptide stabilization of soluble Ld correlates with the cell surface Ld binding assay 
To determine if the results of the cell-based assays extended to a cell-free system, 
we used a soluble form of the LdR97 molecule called Ldm31 (47). Ldm31 contains only 
the α1 and α2 domains and the W97R mutation, thus eliminating effects due β2m 
association. Ldm31 was originally selected by yeast display of a library of Ld mutants in 
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order to overcome problems with the use of full-length Ld, which has been difficult to 
express in soluble form in E. coli.  
Thus, to assess peptide stability, inclusion bodies of the Ldm31 (21 kDa) molecule 
(3μM) were refolded in the presence of three different concentrations of the peptides 
MCMV, FLS, and tum-. Samples from each refold were concentrated and analyzed by 
SDS-PAGE to determine amounts of refolded complexes as a measure of stability 
(Figure 3.10A). As expected, Ldm31 refolded in the absence of peptide resulted in a low 
yield of soluble 22 kDa protein. In contrast, Ldm31 refolded in the presence of all 
concentrations of MCMV peptide had the largest yields of peptide-Ldm31 complexes, 
followed by FLS-Ldm31 complexes, and tum-Ldm31 complexes.   
The yields of peptide-Ldm31 complexes, as determined by quantitative image 
analysis of gel bands (Figure 3.10B), showed that MCMV at 1.2 μM peptide was more 
stable than either FLS or tum- at 30μM, consistent with the results of the cell-based 
competition assay (Figures 3.6, 3.7, 3.9 and Table 3.1).  The 30μM concentration of 
peptide was in ten-fold excess compared to the concentration of the Ldm31 in the 
refolding mixture, and thus drove the reaction toward the formation of peptide/Ldm31 
complexes. A comparison of the yields at 1.2 μM peptide in the refolding mixtures 
showed that the hierarchy of stability of MCMV, FLS, and tum- as soluble Ldm31 
complexes (Figure 3.10B) correlated directly with the BD50 values of the competition 
assay (Figure 3.10C and Table 3.1) and the SD50 values of the upregulation assay, 
each with cell surface Ld-R97 (Figures 3.3B and 3.10D). The refolding mixtures 
containing peptides at the 1.2μM concentration were more telling of the relative stability 
of the various peptide/LdR97 complexes. Thus, we conclude that the cell-based 
competition assay is a valid surrogate for measuring actual stability of peptides with Ld.   
 
Arg97 tolerates greater side-chain flexibility of adjacent residues than Trp97 
The results above showed that all the peptides tested have shown variation in their 
preference for binding to one particular Ld variant, and more peptides resulted in superior 
binding to LdR97 compared to LdW97. Only three of the eighteen peptides tested 
showed preferential binding to LdW97 compared to LdR97 in our competitive binding 
assays, which led us to embark on a structural study of various peptide/Ld complexes. In 
order to explore the possible role of the position 97 residue on structural features of 
peptide binding, we were in the unique position of having high-resolution crystal 
structures of several of the peptides bound to either LdW97 (Figure 3.11A) or LdR97 
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(Figure 3.11B) ((43,44,52,102)). Three other adjacent residues, Y156, F116, and E114 
are also known to be polymorphic in the human HLA-B gene, although these 
polymorphisms appeared to be less associated with HIV immunity than the position 97 
polymorphisms (67,154,178-180). In the LdW97 complexes, W97 formed aromatic 
stacking interactions with F116 and Y156, and these three side chains were in similar 
spatial orientations regardless of the peptide sequence.  Although these residues do not 
appear to interact directly with peptide, they could present a steric barrier that enforces 
bulging of the peptide backbone. This might be particularly the case when aromatic 
residues exist at positions 7 and 8 of the peptide (Figure 3.11A). Our collaborator, Dr. 
Jarrett Adams in Dr. Christopher Garcia’s laboratory, solved the structures of the 
miniature LdW97 module that was modeled after the Arg97-containing Ldm31 protein in 
complexes with five of the peptides identified from the LdW97 yeast display selections. 
These structures will be detailed in a separate publication from the Garcia lab, and are 
not shown here. In these novel LdW97 structures, regardless of the peptide sequence, 
the interactions between W97, F116, and Y156 were identical. There was no observed 
flexibility in the Y156 sidechain in any plane, providing further evidence that the aromatic 
stacking interactions between these three key residues provide a rather rigid steric 
barrier in the center of the peptide binding groove.  
In contrast to the LdW97 structures, in the LdR97 structures R97 was in a position to 
mediate strong electrostatic interaction with E114 (Figure 3.11B). In addition, in the 
absence of W97, Y156 and F116 reside too far apart to form pi-pi stacking interactions 
with each other.  Perhaps as a consequence of the absence of such interactions, in each 
peptide-LdR97 structure, Y156 was observed in a different spatial orientation, oriented 
toward the peptide, or away from the peptide, with various degrees of rotation in any 
plane.  
Interestingly, in the peptide-LdR97 structures, the R97 side chain does not 
apparently use additional flexibility to accommodate different peptides in the binding 
groove, as has been proposed in the HLA-B system (181). Rather, the absence of the 
tryptophan at position 97 allowed Y156 to exhibit additional flexibility and thus to assume 
a variety of orientations. Accordingly, in LdR97 complexes, Y156 is free to stack or 
interact with aromatic residues of the peptide, such as aromatic residues at position 5 as 
found in both QL9 and FLSPFWFDI.  Two possible reasons for the rigidity of the R97 
side chain are evident from existing peptide-LdR97 structures.  Electrostatic interactions 
between side chains of R97 and E114, as well as pi-pi stacking interactions between 
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R97 and F116 may contribute to holding R97 in the same position regardless of the 
peptide sequence.  The corresponding plasticity of residue 156 may allow some 
peptides, including self-peptides, to interact more favorably with alleles that contain R97. 
An interesting finding that was highlighted by these peptide/LdR97 and peptide/LdW97 
structures was that there did not appear to be any peptide motif observed that might 
dictate better binding to one Ld variant or the other.  
While we believe the combination of W97, F116, and Y156 in LdW97 might provide 
a steric barrier that has the potential to block the binding of peptides with hydrophobic C-
terminal residues, peptide SPAEAGFFL bound preferentially to the LdW97 variant. In this 
case, the solved crystal structure of this peptide in complex with the miniature LdW97 
showed that the phenylalanine residues at positions 7 and 8 were able to form aromatic 
stacking interactions with Y156, above the peptide binding groove. Conversely, peptide 
SPLDSLWWI was unable to effectively bind this Ld variant, although it also contained 
aromatic residues at the C-terminal end in the same positions 7 and 8. This suggests 
that the size of the tryptophan residues compared to the phenylalanine residues might 
have contributed to the lack of association of the C-terminal end of the SPLDSLWWI 
peptide with the LdW97 MHC, and thus negatively affected binding. These peptides, 
SPAEAGFFL and SPLDSLWWI were fairly similar in their N and C terminal ends in 
terms of amino acid character, yet the difference in preferential binding to LdW97 and 
LdR97 respectively was interesting. Both peptides contained known Ld anchor residues 
(position 2 proline and position 9 leucine or isoleucine), acidic residues at position 4, and 
the large aromatic residues at the C-terminal end. What we and others have found is 
that it is difficult to take any peptide sequence and correctly predict its compatibility with 
binding to MHC Ld. I found this to be the case in my work that is detailed in Chapter 4 of 
this thesis. Part of this may have to do with the somewhat unusual peptide binding 
groove of this MHC allele and the preference for the unusual proline position 2 anchor 
residue, which might assist the peptide in associating higher over the peptide binding 
groove rather than forming close contacts with other residues within the groove. 
Additionally, in interacting with wild type Ld (W97), peptides have to accommodate the 
large hydrophobic barrier near the center of the groove, and thus predicting the effects 
on Ld binding of the interior four peptide residues has not been accurate. We suggest 
that the differential binding of the diverse collection of peptides to LdW97 and LdR97 
cannot be explained from the perspective of particular binding motifs. 
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HLA-B polymorphic variants have similar structural features with Ld-W97 and Ld-R97 
The frequency of HLA-B alleles that contained R97 was found to be 1.7-times 
greater in HIV progressors, compared to controllers (67). Conversely, the frequency of 
HLA-B alleles that contained W97 was 2-times greater in HIV controllers, compared to 
progressors. W97 and R97 are positioned in the floor of the HLA-B peptide binding 
groove (Figure 3.12A), in the same position as residue 97 in Ld. Position 156 in HLA-B 
alleles with W97 (40 total alleles) are overwhelmingly skewed toward leucine (97.5%), 
thus preventing aromatic interactions as seen in the Ld system with Y156. In HLA-B 
alleles that contain R97 (1360 total alleles), there is greater diversity at position 156 (e.g. 
67.5% leucine, 14.3% aspartic acid, 14% tryptophan, etc). Based on our analysis of the 
Ld system, this feature alone may allow additional plasticity in the binding of peptides by 
the R97 alleles. 
In HLA-B alleles with W97, the majority contained asparagine at position 114 and 
phenylalanine at position 116 (Figure 3.13A). Thus, like Ld, the W97 HLA-B alleles likely 
promote aromatic interactions within the peptide-binding groove, reducing the plasticity 
associated with binding of some peptides. In HLA-B alleles with R97, the majority 
contained an aspartic acid residue at position 114 and a serine residue at position 116 
(Figure 3.13B). As in the Ld system, R97 and D114 likely form electrostatic interactions 
that accommodates more flexibility in the pocket created at residues in positions 156 and 
116 (178). Thus, collectively, the R97 alleles are able to bind a larger collection of 
peptides, as observed in the Ld-R97 results here. 
 
Discussion 
 
The results of the recent International HIV Controllers Study suggested that the 
polymorphic position 97 of HLA-B was the most significant residue that correlated with 
HIV disease control or progression. While much has been learned about aspects of the 
HLA-B alleles in terms of disease association and structure, little attention has been paid 
to a mouse MHC system (H2-L) that has structural and genetic similarities to the HLA-B 
system, and that could inform HIV immunity studies.  Notably, these genetic similarities 
include two alleles, Ld and Lq, which express the W97 and R97 polymorphisms, 
respectively (49). Furthermore, the R97 substitution has been shown, by a completely 
independent approach, to stabilize the peptide/H-2Ld complex (47). 
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Our conclusions here are that: 1) Ld-R97 allows a greater repertoire of self-peptides 
to be bound more stably, compared to Ld-W97, 2) the structural correlate of these 
peptide-binding properties appears to involve increased plasticity in the class I pocket. 
The plasticity is enabled by the arginine at position 97 but it is not due directly to 
flexibility of R97 (181), but rather that R97 allows adjacent residues the freedom to move 
in the pocket. We suggest that these same conclusions likely hold true for the HLA-B 
alleles, given the striking structural similarities between the two systems. 
What is the structural basis for why a substantial number of the individual peptides 
bound better to LdR97 than to LdW97?  Our analysis of the sequences of these peptides, 
and the structures of several of them in complex with Ld-R97 (Figure 3.11B), does not 
reveal any obvious residue or motif shared among them (note that for Ld, the anchor 
residues are thought to be a preferred proline at position 2, and a leucine or isoleucine at 
the C-terminus). Thus, rather than pointing toward a specific structural feature of these 
peptides, the more general basis for their enhanced binding appears to be the nature of 
the pocket near residue 97.   
Residue 97 is centrally located in the peptide-binding groove between the α1 and α2 
domains of the Ld heavy chain, with the side chain directed into the groove (Figure 
3.12B).  A bulky tryptophan at that position forces the neighboring residues, including 
the side chains of residues 114, 116, and 156, into relatively invariant positions. This 
pocket cannot accommodate peptide variability to the same extent as an allele with R97 
at that position. This is because R97 allows some of these same neighboring side chains 
(and residue 156 in particular) the flexibility to accommodate alternate peptides (Figure 
3.12B). For example, the structure of peptide QLSDVPMDL showed that the hydroxyl 
group of Y156 side chain was displaced by 9.1 Å and a 106° vertical angle compared to 
the complex with peptide FLSPFWFDI; among the 8 peptides, peptide QLSDVPMDL 
had significant differential binding to R97 versus W97, binding approximately 14 fold 
better to the Arg97 variant (Figure 3.9). In contrast, Y156 showed no measurable 
vertical shifts within the peptide-LdW97 structures, but the side chain was observed 
within a modest 36° rotational angle range; the tyrosine side chains in both structures 
held both their direction from the backbone and position of the hydroxyl constant. These 
results also suggest that R97 does not act directly in allowing flexibility of peptide 
binding, as has been suggested. Rather, the negatively charged residue at position 114 
(Glu in Ld and Asp in HLA-B) creates a stable electrostatic interaction that locks R97 into 
the same position in different structures (Figure 3.12B), moving it out of the way of other 
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side chains in the pocket (179). A comparison of two HLA-B complexes (B*14:02 and 
B*35:01) with either W97 or R97 also shows the close proximities of this same group of 
residues (Figure 3.12B), suggesting the critical importance of their interactions in 
peptide binding. 
To further explore the possible structural parallels with our findings involving Ld, and 
the HLA-B system, we examined in more detail the co-expressed polymorphisms in 
residues 97, 114, and 116 among the position 97 alleles that operated either as “HIV 
controllers” (Figure 3.13A) or “HIV progressors” (Figure 3.13B). We also examined a 
structural representative of each position 97 allele to gain further insight into the 
positions of these key residues, and the bound peptides. The analysis included four 
HLA-B alleles associated with HIV control (HLA-B*14:02 (W97), HLA-B*57:03 (V97), 
HLA-B*27:05 (N97), HLA-B*51:01 (T97)) and two alleles associated with HIV 
progression (HLA-B*35:01:01:01 (R97), HLA-B*07:02 (S97) (Figure 3.13).   
The frequency analysis of all position 97 alleles (V97, 82 alleles; N97, 118 alleles; 
T97, 491 alleles; and S97, 549 alleles), in addition to W97 and R97 alleles described 
above, revealed a clear predominance of commonly associated residue pairs at 
114/116.  For example, the majority of alleles with valine at position 97, which exhibited 
the highest ratio (5.5) of controllers-to-progressors, contained an Asp at 114 and a Ser 
at 116. These exact two amino acids were also the predominant residues found in the 
R97 alleles, which exhibited the HIV progressor phenotype. Thus, it is reasonable to 
predict that the combination of residues at these positions impact immune status, 
presumably by affecting the ability to associate with different numbers or types of self-
peptides.  
Inspection of the positioning and structures of the various peptides from complexes 
of the controller or progressor alleles did not provide evidence for a common motif. While 
it is interesting that both progressor alleles (HLA*B35:01 with Arg 97 and HLA*B07:02 
with Ser 97) have an unusual position 2 anchor (proline), it remains to be seen if this 
provides some biochemical feature that enables such peptides to bind more effectively 
to these alleles.  In this regard, it has been suggested previously that there are fewer 
self-peptides in the human proteome with binding motifs of the controller alleles 
HLA*B57:01 (Val 97) and HLA*B27:06 (Asn 97) than there are self-peptides with binding 
motifs of the progressor alleles HLA*B35:01 (Arg 97) and HLA*B07:02 (Ser 97) (158). 
Likewise, the size of the self-peptide repertoire for an allele might not only impact CD8+ 
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T cell capacity (e.g. through negative selection in the thymus), but could of course be 
related to the association of some alleles with autoimmunity. 
While the original observations showed an association between position 97 alleles 
of HLA-B and HIV immunity, the lack of a strict correlation implies that other factors also 
impact immunity. In this regard, a more recent study revealed disparate effector 
functions of T cells from controllers versus progressors that all expressed the “control-
associated” allele HLA-*B27 (182). T cells from the controller population were more 
potent and cross-reacted with variants of the HIV gag epitope. However, there was no 
evidence presented on the binding affinities and kinetics of the TCRs from the 
corresponding T cells. We speculate that the TCRs from the controllers exhibited higher 
affinities/longer off-rates, which would explain both their potency and cross-reactivity 
(172). If so, the question remains why the HLA-*B27-positive progressors did not elicit T 
cells with TCRs of similar functional capacities? We speculate that the answer could 
either be that these individuals had some polymorphic self-peptides that deleted these T 
cells, or that these individuals had been exposed to foreign peptides (infectious or 
normal flora) that regulated the peripheral activity of these T cells. A mouse system, for 
example Ld/Lq or HLA*B transgenic mice, could provide models with more limited 
variables (e.g. same repertoire of self peptides) to examine some of these issues. 
Our findings within the Ld system do not support the view that W97 alleles confer 
greater immunity because they are capable of mounting a more robust response against 
some HIV peptide/HLA-B complexes. In this scenario, particular HIV antigenic peptides 
would bind better to W97 allele products than R97 allele products. Contrary to this 
notion, our data suggest that a substantial fraction of peptides actually bind better to Ld-
R97, while fewer peptides bind preferentially to LdW97. Of course, we can’t definitively 
rule out that there isn’t some unique peptide from HIV, not yet mimicked in our H-2L 
study that binds better to a W97 allele and mediates an enhanced anti-HIV immune 
response. 
Based on our results, we favor the possibility that a subset of self-peptides bind 
better to R97 alleles, and that these complexes operate in a tolerance mechanism to 
eliminate or suppress potential HIV-reactive T cells (154,179,180,183,184). These self-
peptides may be predominantly those that have very weak binding to the W97 alleles, 
and thus one might speculate that this increase in binding ability for R97 sufficiently 
stabilizes the complexes such that they can operate in either central or peripheral 
selection processes. In principle, the repertoire of self-peptides with enhanced binding to 
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the R97 alleles includes among them some that could have interacted with CD8+ T cells 
during thymic development, resulting in deletion. Furthermore, this premise would 
require that some of these T cells would have been effective against HIV epitopes. 
It is possible that these self-peptide/R97 complexes function mechanistically not by 
inducing T cell deletion or peripheral anergy but by stimulating T regulatory cells, which 
then suppress the HIV response. This mechanism cannot be ruled out. Another recent 
finding suggested that the peripheral immune repertoire of both HIV progressors and 
HIV controllers contained CD8+ T cells with TCRs capable of binding to HIV/HLA-B, but 
the T cells from the HIV progressors were less active. While no mechanism was 
revealed to account for these findings, the enhanced self-peptide binding to R97 alleles 
might provide some insight into this observation. It is well known that self-peptides can 
act as antagonists in T cell function (185), and that they can yield TCR signaling which 
results in peripheral T cell tolerance ((158) and reviewed in (186)). Thus, the self-
peptides associated with binding to R97 alleles could act to tolerize a peripheral 
population of potential HIV-reactive T cells. Whether there are dominant self-peptides, 
for example with HIV peptide structural homologies, that operate in this capacity remains 
to be seen (187-191). The majority of this work has been published in the Journal of 
Biological Chemistry (71). 
 
Figure 3.1 
A 
B 
gcggccgcMGAMAPRTLLLLLAAALAPTQTRAGPHSMRYFETAV
SRPGLGEPRYISVGYVDNKEFVRFDSDAENPRYEPQAPWME
QEGPEYWERITQIAKGQEQWFRVNLRTLLGYYNQSAGGTHTL
QWMYGCDVGSDGRLLRGYEQFAYDGCDYIALNEDLKTWTAA 
DMAAQITRRKWEQAGAAEYYRAYLEGECVEWLHRYLKNGNA
TLLRTDSPKAHVTHHPRSKGEVTLRCWALGFYPADITLTWQLN
GEELTQDMELVETRPAGDGTFQKWASVVVPLGKEQNYTCRV
YHEGLPEPLTLRWEPPPSTDSYMVIVAVLGVLGAMAIIGAVVAF
VMKRRRNTGGKGGDYALAPGSQSSEMSLRDCKA-(stop)-
agacagaattc  
             Ld leader sequence            
NotI 
restriction 
site 
EcoRI 
restriction 
site 
Ld heavy chain  
Primer design for use in QuikChange Lightning protocol to change 
Trp97 codon TGG to Arg97 codon AGG.  
 
Forward primer: 
agcgcgggcggcactcacacactccagaggatgtacggctgtgacgtggggtcggac 
 
Reverse primer: 
gtccgaccccacgtcacagccgtacatcctctggagtgtgtgagtgccgcccgcgct  
Figure 3.1. A, Full length sequence of MHC Ld that was cloned into pMp71 retroviral 
vector using a 5’ NotI restriction site (indicated by lower case underlined sequence) and 3’ 
EcoRI restriction site (indicated by lower case underlined sequence following the indicated 
stop codon). The Ld leader sequence is indicated, as is the start of the cell surface-
expressed Ld protein. The tryptophan (W) at position 97 of the expressed protein is 
indicated in bold green text. B, Forward and reverse PCR primer sequences used to 
induce point mutation (tggagg) W97R in the Ld sequence  with the QuikChange 
Lightning protocol. The codon change is indicated in red text. 
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Figure 3.2. 58-/- cells that were retrovirally transduced to express LdW97 or LdR97, and then sorted 
by FACS to enrich the population based on positive Ld surface expression as detected by the 30-5-
7 and a PE-conjugated secondary antibody. The parental, untransduced 58-/- cell line (black 
traces), the cells transduced to express LdW97 (A) or LdR97 (B) prior to sorting (red traces), and 
post-FACS-sorting (blue traces) were stained with 30-5-7 IgG and goat-anti-mouse IgG conjugated 
to phycoerythrin (PE). Data in A and B show that in the case of LdW97, the population was 
enriched from 21% Ld+ to 97% Ld+ after FACS, and the LdR97 population was enriched from 11% 
Ld+ to 97% Ld+ after FACS. C, The relative Ld surface levels were detected on FACS-sorted 58-/- 
cell lines expressing LdW97 and LdR97 by staining with 30-5-7 and goat-anti-mouse IgG/PE, and 
showed that in the absence of exogenous peptide, LdR97 levels were 2-3 times higher than LdW97 
surface levels. 
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Figure 3.3. A, 58-/- cells expressing either LdW97 (filled circles) or LdR97 (open 
squares)  were incubated with various concentrations of peptide MCMV and the 
percent Ld upregulation was detected by staining with 30-5-7 (anti-Ld) and goat-
anti-mouse PE. Percent upregulation was calculated with reference to Ld surface 
levels detected in the absence of exogenously added peptide. B, Various 
concentrations of peptides QL9 (QLSPFPFDL), MCMV, FLS (FLSPFWFDI), and 
tum- (TQNHRALDL) were sampled in similar Ld upregulation assays and SD50 
values were determined by calculating the concentration of peptide at which 50% 
of maximal upregulation was observed. 
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Figure 3.4. Competitive peptide binding assay using 2.5μM biotinylated 
QLSDKPVDL peptide and various concentrations of the indicated competitor 
peptides using LM1.8-LdW97R cells, and biotinylated QLSDKPVDL/LdR97 
complexes were detected with Streptavidin-PE. If the competitor peptides 
efficiently competed with biot-QLSDKPVDL for LdR97 binding, the raw MFU 
values reflecting the PE-fluorescent signal would be decreased (A). The difference 
in MFU values from cells that were incubated with biot-QLSDKPVDL only, and 
cells that were incubated without peptide, was low. An alternate calculation was 
performed in which the “no peptide” MFU value was subtracted from all the other 
samples, and this no-peptide-corrected value was used to re-calculate a corrected 
MFU1/MFU0 (B). The corrected MFU1/MFU0 value more clearly demonstrated the 
ability of each sample peptide to compete for binding to LdR97. 
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Figure 3.5. A, 58-/- cells expressing either LdW97 or LdR97 were loaded with various 
concentrations of QL9 peptide and stained with biotinylated scTCR m6 and Streptavidin PE. The 
SD50 values indicating sensitivity of m6 binding were: L
dW97, 85nM; LdR97, 17nM. 58-/- cells 
expressing either LdW97 or LdR97 were loaded with either 100nM QL9 and 100μM candidate 
peptides identified through an Ld yeast display platform (B) or 50nM QL9 and 100μM candidate 
peptides identified through an anti-Ld affinity purification (C), and stained with 10μg/mL biotinylated 
m6 scTCR followed by Streptavidin-PE.  
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Figure 3.6. Competitive peptide binding assays with known Ld-binding peptides MCMV 
(YPHFMPTNL) and tum- (TQNHRALDL), as well as naturally derived peptides MPKPLSL, 
QPQHTVRSL, and QFTTLPAGL showed preferences of each peptide to bind either LdW97 or 
LdR97. 58-/- cells expressing either Ld variant were incubated with a mixture of the indicated 
competitor peptide and 50nM QL9. QL9/Ld complexes were detected using biotinylated scTCR m6 
and Streptavidin-PE. The reported MFU1/MFU0 value contains two values for m6 binding. MFU1 
indicates the fluorescent signal from cells that were incubated with the mixture of competitor 
peptide and QL9 prior to m6 staining. MFU0 indicates the fluorescent signal from cells that were 
incubated with 50nM QL9 only prior to m6 staining.  
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Figure 3.7. Competitive peptide binding assays with novel Ld-binding peptides identified from 
several yeast-display LdR97 libraries showed preferential binding to LdR97. 58-/- cells expressing 
either Ld variant were incubated with a mixture of the indicated competitor peptide and 50nM QL9. 
QL9/Ld complexes were detected using biotinylated scTCR m6 and Streptavidin-PE. The reported 
MFU1/MFU0 value contains two values for m6 binding. MFU1 indicates the fluorescent signal from 
cells that were incubated with the mixture of competitor peptide and QL9 prior to m6 staining. MFU0 
indicates the fluorescent signal from cells that were incubated with 50nM QL9 only prior to m6 
staining. Assays performed with APWNPAMMI, ANPSFYFDI, AND ALGPFPFDL began by pre-
loading the cells with 100nM QL9 for 10 minutes, then mixing in an equal volume of 2X competitor 
peptide. 
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Figure 3.8. Competitive peptide binding assays 
with novel Ld-binding peptides identified from 
several yeast-display LdW97 libraries did not show 
significant preferences for either Ld variant. 58-/- 
cells expressing either Ld variant were pre-loaded 
with 100nM QL9 for 10 minutes prior to mixing in 
an equal volume of 2X peptide and incubated. 
QL9/Ld complexes were detected using 
biotinylated scTCR m6 and Streptavidin-PE. The 
reported MFU1/MFU0 value contains two values for 
m6 binding. MFU1 indicates the fluorescent signal 
from cells that were incubated with the mixture of 
competitor peptide and QL9 prior to m6 staining. 
MFU0 indicates the fluorescent signal from cells 
that were incubated with 50nM QL9 only prior to 
m6 staining. competitor peptide. 
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Table 3.1 
Table 3.1. BD50 values were calculated using a non-linear regression from the data obtained in 
competitive peptide binding assays (shown in figures 6, 7, and 8) performed in duplicate or 
triplicate. BD50 values correlate to the concentration of peptide at which 50% of maximal 
competition (indicated by MFU1/MFU0 values) was observed. Differences in BD50 values for each 
peptide binding to LdW97 versus LdR97 indicate preferential binding to one Ld variant.  
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Peptide BD50 W97 (M)* BD50 R97 (M)* Origin Reference
QLSPFPFDL (QL9) Reference peptide Reference peptide
Murine 2-oxoglutarate 
dehydrogenase928-936
(114)
YPHFMPTNL (MCMV) 3.4 x 10-7 ± 4.5 x 10-8 1.1 x 10-7 ± 7.5 x 10-8
Murine cytomegalovirus 
pp89168-176
(38)
TQNHRALDL (tum-) 1.7 x 10-5 ± 7.1 x 10-6 1.5 x 10-4 ± 7.6 x 10-5
Mutated P815 protein 
P91A14-22 containing 
R17H mutation 
(108)
MPKPLSL 4.3 x 10-5 ± 1.1 x 10-5 9.2x 10-5 ± 4.9 x 10-5
Murine myb-related 
protein B606-612
Unpublished
QPQHTVRSL 1.6 x 10-4 ± 5.5 x 10-5 3.7 x 10-5 ± 1.6 x 10-5
Murine leucine-rich 
repeat and calponin
homology domain-
containing protein 280-88
Unpublished
QFTTLPAGL >2 x 10-4 5.8 x 10-5 ± 2.3 x 10-5
Murine peripheral-type 
benzodiazepine 
receptor-associated 
protein 1966-974
Unpublished
FLSPFWFDI (FLS) >2 x 10-4 5.2 x 10-6 ± 2.1 x 10-7
QL9 derivative from 
LdR97 in vitro selection
(102)
QLSDVPMDL 4.4 x 10-5 ± 3.5 x 10-5 3.1 x 10-6 ± 2.5 x 10-6
QL9 derivative from 
LdR97 in vitro selection
(102)
SPLDSLWWI >2 x 10-4 1.3 X 10-5± 1.5 x 10-6 LdR97 in vitro selection (102)
APWNPAMMI** >1 x 10-4 7.8 x 10-5 ± 5.4 x 10-5 LdR97 in vitro selection Unpublished
ALGPFPFDL** 2.5 x 10-5 ± 2.0 x 10-6 1.0 x 10-5 ± 5.6 x 10-7
QL9 derivative from 
LdR97 in vitro selection
Unpublished
ANPSFYFDI** 3.8 X 10-4 ± 3.9 x 10-4 5.2 x 10-5 ± 1.4 x 10-5
QL9 derivative from 
LdR97 in vitro selection
Unpublished
MPDSAGWSL** 2.7 x 10-5 ± 3.2 x 10-5 8.8 x 10-6 ± 6.7 x 10-6 LdW97 in vitro selection Unpublished
VPYMAEFGM** 8.9 x 10-6 ± 1.6 x 10-6 2.2 x 10-6 ± 8.1 x 10-7 LdW97 in vitro selection Unpublished
SPAEAGFFL** 7.2 x 10-6 ± 2.3 x 10-7 1.6 x 10-5 ± 1.3 x 10-6 LdW97 in vitro selection Unpublished
SPAPRPLDL** 3.5 x 10-7 ± 7.7 x 10-8 6.6 x 10-7 ± 1.7 x 10-7 LdW97 in vitro selection Unpublished
WPAEGGFQL** 4.3 x 10-6 ± 5.8 x 10-7 8.9 x 10-6 ± 7.2 x 10-6 LdW97 in vitro selection Unpublished
MPAGRPWDL** 1.7 x 10-6 ± 1.0 x 10-6 3.0 x 10-6 ± 2.7 x 10-6 LdW97 in vitro selection Unpublished
MPGEASFML** 5.0 x 10-6 ± 3.1 x 10-6 4.7 x 10-6 ± 2.2 x 10-6 LdW97 in vitro selection Unpublished
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Figure 3.9. 9/18 peptides tested showed clear preferential binding to the LdR97 
variant; 3/18 peptides showed preferential binding to the LdW97 variant; and 6/18 
peptides did not preferentially bind either Ld variant over the other. The ratio of 
BD50W97/BD50R97 were calculated using the BD50 values obtained in the 
competitive binding assays listed in Table 3.1. If the log of the ratio was a positive 
value for a particular peptide, that peptide bound more strongly to LdR97 
compared to LdW97. If the log of the ratio for a particular peptide was a negative 
value, that peptide bound more strongly to LdW97 compared to LdR97. If the 
calculated standard error for the log BD50 ratio (indicated by error bars) was 
substantial compared to the value of the log BD50 ratio itself, that peptide was 
considered to have no clear preference for binding to one Ld variant more than the 
other. 
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Figure 3.10.  The relative stability of soluble peptide-LdR97 complexes is consistent with 
cell based assays of LdR97 upregulation and QL9 competition for LdR97. Inclusion bodies 
of Ldm31 (R97) were refolded at 3μM in the absence of peptide, or with various 
concentrations of peptides MCMV, FLS, and tum- (30μM, 6μM, and 1.2μM).  Protein 
refold preparations were concentrated to equal volumes and analyzed by SDS-PAGE 
(A).  The intensity of each gel band shown in (A) was determined using ImageJ software.  
The reported protein yields were directly proportionate to the intensity of each gel band, 
and were calculated relative to the intensity of the band corresponding to Ldm31 refolded 
in the absence of peptide, which was set to 1 (B). C, BD50 values for each peptide 
binding to each Ld variant on the surface of transduced 58-/- cells, obtained using the 
competitive binding assay described in Figures 6, 7, 8, 9, and Table 3.1. D, SD50 values 
for each peptide binding to each Ld variant on the surface of transduced 58-/- cells, 
obtained using the Ld upregulation assay described in Figure 3.3. 
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Figure 3.11 
Figure 3.11. Aromatic stacking interactions among W97, F116, and Y156 
create a more rigid binding pocket in LdW97, compared to LdR97. 
Structures of a solved peptide-LdW97 complex (YPNVNIHNF-LdW97), 
resolved LdW97 molecule with peptide QL9 modeled (QL9-LdW97) (A) and 
peptide-LdR97 (B) complexes aligned with highlighted residues at positions 
97, 114, 116, and 156. Peptide sequences are indicated beneath each 
structure.  
105 
RRRWRRLTV- 
HLA-B*14:02 
W97 
L156 
N114 F116 
A 
B 
Figure 3.12 
VPLRPMTY- 
HLA-B*35:01 
R97 
L156 
D114 S116 
Figure 3.12.  Structural similarities between the Ld system and the HLA-
B system. Aromatic stacking interactions between W97 and F116 seen in 
LdW97 structures and charge-charge interactions like those between R97 
and E114 in LdR97 structures are seen in HLA-B structures and known 
sequences. (A) Aligned structures of RRRWRRLTV-HLA-B*14:02 and 
VPLRPMTY-HLA-B*35:01 with highlighted residues at positions 97, 114, 
116, and 156. (B) Side view of the following aligned structures: 
RRRWRRLTV-HLA-B*14:02, VPLRPMTY-HLA-B*3501, YPNVNIHNF-
LdW97, QLSPFPFDL-LdW97, QLSDVPMDL-LdR97, FLSPFWFDI-LdR97, 
and SPLDSLWWI-LdR97. 
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Figure 3.13.  Interactions of residues at positions 97, 114, and 116 may affect the 
peptide binding groove of HLA-B alleles. The aligned structures of peptide-HLA-B 
complexes, and the frequency of position 114/116 residue pairs in known HLA-B 
sequences containing W97, R97, V97, N97, T97, and S97 separated by the 
association of each particular position 97 residue with HIV control (A) or 
progression (B).  The circled values indicate the ratio of allele frequency in HIV 
controllers to progressors for each residue at position 97 of HLA-B, as reported in 
(67). The following aligned structures are shown: RRRWRRLTV-HLA-B*14:02 
(W97), VPLRPMTY-HLA-B*35:01 (R97), KGFNPEVIPMF-HLA-B*57:03 (V97), 
GRFAAAIAK-HLA-B*27:05 (N97), TAFTIPSI-HLA-B*51:01 (T97), 
RPHERNGFTVL-HLA-B*07:02 (S97). 
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CHAPTER FOUR 
 
THE 2C T CELL CLONE RECOGNIZES MANY ENDOGENOUS PEPTIDE-Ld 
ALLOANTIGENS 
 
Introduction 
 The study of cell-mediated immunity has its basis in early studies of T cell 
recognition and reactivity. Many contributions to the understanding of the fundamentals 
of T cells have come from the 2C T cell system. The 2C T cell clone is a CD8+ cytotoxic 
T cell clone that has been studied extensively over the past three decades in a variety of 
capacities, including studies of biological reactivity, insights into the molecular basis of 
transplant rejection, T cell receptor engineering for cancer treatment, structural studies 
examining the T cell receptor interaction with its antigenic ligand, among many others. 
 Cytotoxic T cells are T cells that express on their surface an αβ T cell receptor 
(TCR) and the CD8 co-receptor, both of which engage with an antigenic peptide/MHC 
class I complex on the surface of the target cell. The TCR complementarity determining 
regions form very specific interactions with the peptide (usually 8-10 amino acids long), 
and other residues within the variable regions of the TCR contact the alpha helices of 
the class I MHC protein (166). The CD8 co-receptor contacts the invariant regions of the 
class I complex (22). The typical function of these cytotoxic T cells is to recognize and 
react against virally infected cells or transformed cells- these cells are “syngeneic”, 
meaning that they express the same class I MHC molecules on the surface as the T 
cells themselves, because they are cells from the same individual. The peptides 
displayed on the class I MHC molecules are processed endogenously; proteins (either 
normal self-proteins or virally encoded proteins) are synthesized and degraded in the 
proteasome, resulting in peptide fragments that can be displayed in the context of the 
MHC protein (27). The MHC protein is not stable in the absence of a peptide, and under 
normal healthy conditions the MHC proteins are displaying peptides derived from self 
proteins. T cells in a healthy individual will not react against these complexes due to the 
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tolerance processes in which self-reactive T cells are deleted (reviewed in 
(58,59,62,192).  
 T cell-mediated transplant rejection can be explained by the concept of allo-
reactivity, in which T cells recognize peptides (derived from self proteins) that are 
displayed on foreign MHC molecules. The 2C T cell system was integral in providing 
insights into the mechanics of T cell-mediated transplant rejection. The 2C T cell clone 
was raised in a mouse that expressed class I MHC molecules Kb and Db (H-2b 
haplotype), which was injected with P815 mastocytoma cells that expressed class I 
molecules Dd, Kd, and Ld (H-2d haplotype). An immune response was generated in the 
mouse against the MHC-mismatched P815 cells, and T cells were isolated and tested in 
in vitro assays for reactivity against P815 cells (137).  
In vitro cytotoxicity assays using 2C killer T cells and P815 target cells, as well as 
blocking antibodies specific for each class I MHC on P815, showed that cytotoxicity was 
only reduced in the presence of the anti-Ld blocking antibody 30-5-7 (37). This finding 
indicated that 2C T cell reactivity was directed against a peptide ligand presented on 
MHC Ld on the surface of P815 cells, not other allogeneic peptide/MHC complexes that 
involved Dd or Kd.  
 One of the key questions at the time was whether allo-reactive T cells recognized 
only the MHC molecule, regardless of peptide, or whether a specific peptide, bound to 
the MHC molecule, represented the ligand. Eisen and colleagues were the first to 
determine that an allo-reactive T cell clone (2C) recognized a specific peptide (37,117) 
In their studies, peptide p2Ca (LSPFPFDL) was identified from a collection of acid-
extracted peptides as one that mediated reactivity between the 2C TCR and Ld-
expressing target cells. Longer variants of the p2Ca peptide were identified that also 
mediated some level of reactivity between 2C T cells and Ld+ target cells: QL9 
(QLSPFPFDL) and p2Cb (VAITRIEQLSPFPFDL). Many further characterizations of the 
2C TCR utilized peptide QL9, due to its superior binding to cell surface Ld molecules. 
Since that time, 20 years ago, it has been assumed that the bona fide alloantigen for 2C 
were these p2Ca, or p2Ca-related, peptides identified in their study. As described in this 
chapter, this assumption now appears not to be the case. 
 In subsequent studies, the 2C TCR was the template for engineering TCRs that 
bind with high affinity to the QL9/Ld complex. Two high affinity variants of the 2C TCR, 
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called m6 and m13, contained mutations in the alpha chain that conferred binding to 
QL9/Ld and p2Ca/Ld with KD values in the nanomolar range, approximately one 
thousand-fold tighter binding than the wild type 2C TCR binding to QL9/Ld (KD 2μM) 
(118,119,193). T cells expressing m6 and m13 TCRs were highly reactive when 
incubated with Ld-expressing target cells loaded with exogenous QL9 and p2Ca. 
However, quite unexpectedly, m6 and m13 T cells were not reactive against P815 target 
cells in T cell activation assays. This suggested that neither peptide p2Ca nor QL9 was 
endogenously processed and presented on MHC Ld on the surface of P815. This finding 
meant that neither peptide (p2Ca or QL9) could have been the peptide ligand in complex 
with MHC Ld against which the 2C T cell clone was raised, and that the bona fide peptide 
remained to be discovered.  
As indicated, Udaka et al performed the initial identification of the p2Ca peptide 
as the naturally selecting ligand for the 2C T cell clone (37). In that study, there were 
three distinct peaks of activity from HPLC fractions containing peptides that eluted from 
the column between 30% and 40% ACN. From the least hydrophobic peak, peak a, 
peptide p2Ca was identified. Peptide p2Cb was identified from fractions corresponding 
to the second most hydrophobic peak, labeled as peak b. Significant 2C reactivity was 
mediated against T2-Ld cells in the presence of HPLC fractions corresponding to the 
most hydrophobic peak of activity, labeled peak c, but no peptide was ever identified 
from these HPLC fractions due to low abundance. In this chapter, I hypothesize that the 
HPLC fractions corresponding to activity peak c, which was also present in the sampling 
of HPLC fractions containing anti-Ld-affinity purified peptides, contained the peptide 
ligand that was endogenously processed, presented on Ld, and served as at least one of 
the endogenous allo-ligands for the 2C T cell clone. 
 This chapter details the search for the endogenously processed and presented 
peptide ligand(s) that are presented by Ld on P815 cells, and that originally induced the 
activation and expansion of 2C T cell clone. The project involved the optimization of 
methods used during this process- including the optimization of activating primary 2C 
transgenic T cells and maximizing their sensitivity in 51Cr release cytotoxicity assays. 
Because the Udaka et al 1992 and 1993 publications showed that peptide p2Cc was 
present in HPLC fractions containing peptide species that were isolated by both acid 
extraction from BALB/c liver tissue as well as affinity purification from P815 cells, both 
methods were used in an attempt to verify the results of Udaka et al, to identify the p2Cc 
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species, and to determine if any other peptides might also act as ligands for clone 2C. 
The acid extraction method isolates intracellular and extracellular peptide fragments 
derived from various proteins, not just the ones that are endogenously processed and 
presented on the cell surface MHC, and this was the first method utilized. Additionally, I 
utilized an affinity purification method in which peptide/Ld complexes were isolated from 
the surface of Ld+ mouse liver tissue, and the resulting Ld-presented peptides were 
fractionated based on hydrophobicity and assayed in in vitro cytotoxicity assays using 
2C T cells and Ld-expressing target cells. Liver tissue was selected as a good peptide 
source based on a previous study (117), that examined the relative abundance of 2C-
reactive peptides in various tissues of H-2d haplotype mice. Candidate peptides were 
identified using both mass spectrometry and bioinformatics, and the details of these 
candidate peptides are discussed in this chapter. While a single bona fide peptide 
sequence that is recognized by clone 2C was not identified, the results show clearly that 
there were many peptides recognized by 2C in the context of Ld. Thus, the 2C TCR is 
capable of recognizing an even larger repertoire of ligands than previously described 
(194). 
 
 
Materials and Methods 
 
Cell lines and antibodies 
T2-Ld cells (195) were grown in complete RPMI 1640 with 10% fetal bovine 
serum (FBS).  The anti-Ld mAb 30-5-7 was DEAE purified after being secreted by 
hybridomas into serum-free media. T cell hybridoma cell lines (2C, m6, and m13, all with 
or without CD8αβ) were grown in complete RPMI 1640 with 10% FBS.  
 
IL-2 release activation assays 
 T cell hybridomas transfected to express either the 2C TCR, or high affinity 
mutants m6α and m13α were incubated for approximately 20 hours at 37°C with either 
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P815 target cells or T2-Ld TAP-deficient target cells in the presence of peptides diluted in 
RPMI. The presence of interleukin-2 (IL-2) in the culture supernatants was detected by 
ELISA as described in (102). IL-2 standards were also sampled in these ELISAs to 
provide a means to objectively compare assays from different dates. These assays were 
performed by Dr. Phil Holler. 
 
Acid extraction of naturally derived peptides 
Frozen BALB/c liver (2.2g) were mechanically homogenized in 0.7% 
trifluoroacetic acid (TFA) in water (5mL per gram liver) on ice.  Homogenized liver tissue 
was sonicated for 2 minutes on ice, then left to recover on ice for 30 minutes and 
transferred to Nalgene centrifuge tubes. Sonicated liver tissue was centrifuged at 
20,000rpm in a SS-34 rotor in a Sorvall floor model centrifuge at 4°C. Supernatants were 
transferred to fresh Nalgene tubes and centrifuged again using the same parameters. 
Supernatants were collected and filtered through 10k MW cut off filters in centrifuge 
units. Filtrate was dried by SpeedVac, and when fully “dry” was in the form of a deep 
amber colored oil with a mass of 117.3 mg, which was then emulsified in 1mL buffer 
containing 5% acetonitrile (ACN) and 0.1% TFA (this will be referred to as the “liver oil 
preparation”.  Sold phase extraction (SPE) C4 columns were used to do bulk 
separations of peptides of varying hydrophobicity. The SPE column resin was activated 
by flushing through 2 mL 100% methanol. To prime the SPE column, 7mL of 5% ACN 
with 0.1% TFA was flushed through. Then very slowly, the 1mL liver oil preparation 
(described above) was applied to the prepared SPE column. Then a series of three 
elutions was performed in succession, each with a different concentration of acetonitrile 
in the elution buffer. The first elution used 5mL of 25% ACN with 0.1% TFA, and this 
eluate was collected in one tube. Similarly, elutions were performed with 5mL each of 
either 50% ACN or 100% ACN in the presence of 0.1% TFA, and these eluates were 
collected in one shared tube. The eluates collected from elutions with the 50% or 100% 
ACN buffers were dried by SpeedVac and resulted in oily pellets once again with a mass 
of approximately 7mg. The oil pellet was resuspended in 2mL 25% ACN with 0.085% 
TFA and submitted to the Protein Sciences Facility for reverse phase HPLC fractionation 
on a C18 column. The HPLC protocol utilized a hydrophobicity gradient in which solvent 
B (100% ACN + 0.085%TFA) was increased at a rate of 1%/minute/fraction and the 
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gradient ran from 25% to 50% ACN, followed by 15 fractions eluted from the column with 
100% ACN. The HPLC fractions were dried by SpeedVac and reconstituted in 1mL 
sterile phosphate buffered saline (PBS), and then sampled in a 51Cr release cytotoxicity 
assay using activated 2C transgenic T cells and T2-Ld target cells. 
 
Coupling of 30-5-7 mAb to Affigel-10 resin 
 4mL of Affigel-10 slurry (1mL of packed Affigel-10 resin) was removed from a 
well-shaken vial and washed three times with 15mL of pure water. Anti-Ld monoclonal 
antibody (mAb) 30-5-7 (4mL of 1mg/mL, 4mg 30-5-7 total) was mixed with the packed 
Affigel-10 resin and rotated on a rotisserie agitator at 4°C for 24 hours. Supernatant was 
then removed from the 30-5-7 Affigel resin and 1mL 0.1M ethanolamine was added and 
mixed, and agitated at 4°C for 1 hour, then supernatant was removed. At this point 30-5-
7 Affigel was washed three times with 15mL of 0.1M NaHCO3. Washed 30-5-7 Affigel-
10 was then reconstituted in 2mL of 0.1M NaHCO3 and stored at 4°C. Control (No 
Antibody) Affigel-10 was prepared the same way, but on two fold smaller scale (i.e., 
started with 2mL Affigel-10 slurry) and no antibody was incubated with the resin. 
 
Pilot affinity purification experiments with purified MCMV-Ldm31 
Affigel resin (20μL, either control or 30-5-7 immobilized) was aliquoted into 0.6mL 
Eppendorf tubes. The following steps were performed using a tabletop centrifuge at a 
speed of 15k RPM for 90 seconds per use. The tubes containing Affigel resin were 
centrifuged and supernatant was removed. Purified MCMV-Ldm31 (5μg) was applied to 
the resin and incubated for 10 minutes on ice. Samples were centrifuged and 
supernatant was removed and stored at 4°C.  Half the volume of the pellet was also 
removed and stored at 4°C for analysis by SDS-PAGE. Resin was washed by applying 
HEPES buffered saline (HBS), the same buffer in which the purified MCMV-Ldm31 
protein was applied to the resin. Washed resin was centrifuged, and wash supernatant 
was removed and stored at 4°C. Resin was then eluted three times sequentially by 
applying glycine-HCl pH 2.5 and incubating for 10 minutes on ice, followed by a 
centrifugation step in which the supernatant (in this case, eluate) contained the eluted 
MCMV/Ldm31 complexes. All eluates were stored at 4°C until analysis by SDS-PAGE. 
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The remaining resin after elution was reconstituted in SDS running buffer for use as a 
gel sample.  
 SDS-PAGE molecular weight standards, and SDS-PAGE gel samples taken at 
various steps of the affinity purification process from both the supernatants and resin 
pellets, were prepared using 3X loading dye containing bromophenol blue and 1M DTT 
as a reducing agent. Samples were boiled for 10 minutes, centrifuged, and loaded into 
the wells of purchased BioRad prepared 4-20% acrylamide gels. SDS running buffer 
was freshly prepared and used to run the gels for 45 minutes at 120V. Gels were rinsed, 
stained with Coomassie Blue, and destained with a solution containing glacial acetic acid 
and methanol.  
 
Affinity purification of peptide/Ld complexes 
Four grams of BALB/c liver tissue were dissociated using 2.5 units/mL dispase 
enzyme (Gibco) in serum-free RPMI 1640 media. Dispase enzyme was inactivated using 
RPMI 1640 containing 10% fetal bovine serum (FBS).  Liver tissue was further 
dissociated mechanically using a 3mL syringe plunger and 100uM nylon mesh filter.  
Red blood cells were lysed, and peptide-Ld complexes were isolated from the remaining 
BALB/c liver cell membranes similarly to the method described in (37).  Briefly, BALB/c 
liver cell membranes were solubilized in 4mL of liver lysis buffer containing 20mM Tris 
pH 8.0, 150mM NaCl, 3ng/mL EDTA, and 1% Nonidet-P40, as well as a 100-fold dilution 
of protease inhibitor cocktail for mammalian cells and tissues (Sigma P8340).  Treated 
BALB/c liver tissue was ultracentrifuged for 1hr at 4°C at 100,000 x g, resulting in 
separation of the treated tissue into a dense pellet, a clear aqueous solution layer 
presumed to contain solubilized BALB/c liver cell membrane fragments, and a cloudy 
hydrophobic layer presumed to contain residual fat from the liver preparation.  The 
solubilized membrane fragment solution from the ultracentrifugation step was then 
applied to a Buchner fritted funnel column containing 1mL of packed Affigel-10 resin that 
had been previously coupled to the anti-Ld mAb 30-5-7 and washed four times, each with 
5mL of liver lysis buffer.  The solubilized membrane fragment solution interacted with the 
resin for 1 minute before allowing the column to drip. Flow through was collected and re-
applied to the column three times in succession after the initial application of the soluble 
membrane fragment solution.  The column was washed with 20mL liver lysis buffer 
 
 
115 
before doing twelve serial column elutions, each using 500uL of 100mM glycine-HCl pH 
2.5.  Eluates from the first three column elutions were pooled and filtered through a 
10KDa cut off filter.  The filtrate was dried via speedvac and resuspended in 1mL of an 
aqueous solution containing 25% acetonitrile (ACN) and 1% trifluoroacetic acid (TFA), 
and then submitted for reverse-phase HPLC fractionation on a C18 column at the 
University of Illinois Protein Sciences Facility.  The first round of HPLC utilized a two 
solvent gradient: solvent A was water containing 1% TFA and solvent B was acetonitrile 
containing 1% TFA.  The protocol for the first round of HPLC consisted of an increase of 
1% solvent B (ACN/TFA) per 1mL fraction (at a rate of 1mL/minute) from 0% solvent B 
to 60% solvent B before running 100% solvent B over the column for 5 minutes.  
Fractions were dried by speedvac and resuspended in 600µL phosphate-buffered saline 
(PBS) and 50uL of each fraction was sampled in a 51Cr release cytotoxicity assay using 
activated 2C T cells and 51Cr labeled T2-Ld target cells.  For the second round of HPLC, 
round 1 HPLC fractions corresponding to 36% and 37% ACN were pooled and 
submitted for HPLC fractionation using a 0.25% solvent B increase per 1mL fraction 
(1mL/min); the identity of the solvents for the second round of HPLC was identical to 
those from the first round of HPLC.  These fractions were again dried by speedvac and 
resuspended in 150µL PBS, and once again 50µL of each PBS-resuspended fraction 
was sampled in a 51Cr release cytotoxicity assay using activated 2C T cells and 51Cr-
loaded T2-Ld cells as targets. 
 
Identification of candidate peptides from HPLC fractions 
 HPLC fractions that mediated reactivity between 2C T cells and the Ld-
expressing target cell line T2-Ld were subjected to analysis by mass spectrometry at the 
UIUC Protein Sciences Facility. The mass and charge of each species was used as 
criteria for BLAST searching the entirety of the mouse genome to identify possible 
naturally occurring peptides that could fit the mass spectrometry data. Peptide 
sequences were derived from the sequences of naturally occurring murine proteins, 
such that the peptide sequences that could fit the profile of mass and charge of the 
different species contained within the HPLC fractions. A large collection of all naturally 
derived peptide sequences was identified to correspond to each mass/charge species. 
Peptide sequences eight to ten amino acids in length were identified, and filtered based 
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on MHC Ld anchor residues proline, serine, or phenylalanine at position 2, and 
phenylalanine, isoleucine, leucine, or valine at position 9. Alternatively, peptides that 
contained P-X-X-L motifs at the C-terminal end were also considered because this motif 
had been thought to contribute to 2C T cell reactivity. Ten candidate peptides were 
identified that were seven to nine amino acids long, that contained the appropriate 
anchor residues for Ld binding or motifs for 2C recognition. These peptides were 
synthesized by the Protein Sciences Facility, and dissolved in DMSO and stored at 
50mM at -20°C. The synthetic peptides we received from the Protein Sciences Facility 
were: TSATLQTHF, QFTTLPAGL, PIKLVPRSL, SSAGGPGAL, QPQHTVRSL, 
MPKPLSL, STMPKPLSL, DSKFHKEHF, PSNGGHSYM, and GPASRDASL. 
 
Cytotoxicity assays using 51Cr 
T2-Ld cells were loaded with 2 mCi/mL 51Cr for 2hrs at 37°C, then washed, 
counted, and resuspended at a density of 4 x 104 cells/100µL in complete RPMI 1640.  
Activated 2C T cells were counted and resuspended at a density of 2 x 105 cells/50µL in 
complete RPMI 1640.  Wells of a 96-well roundbottom plate were set up with 50µL of 
PBS-resuspended HPLC fractions or diluted synthetic peptides, 50µL (2 x 105) activated 
2C T cells, and 100µL (4 x 104) 51Cr-loaded T2-Ld cells, and incubated for 4 hours at 
37°C to assay the reactivity of 2C T cells with T2-Ld presenting affinity purified peptides 
from the HPLC fractions.  Additionally, wells were set up containing only 4 x 104 51Cr-
loaded T2-Ld cells and 100µL RPMI 1640 to quantify spontaneous release of 51Cr and 
maximum release of 51Cr from T2-Ld cells, or 2C T cells (2 x 105) and 51Cr-loaded T2-Ld 
(4 x 104) cells in the absence of peptide to quantify non-specific killing of T2-Ld over the 
4 hour incubation period.  The final volume of each well was 200µL and the 2C T cell 
(effector cell) to T2-Ld (target cell) ratio was 5:1.  After the 4 hour incubation period, 
100µL 2% Triton-X-100 was added to wells containing only T2-Ld designated for 
assessing the maximum possible release of 51Cr into the supernatant.  Ninety-six well 
plates were centrifuged at 200 x g for 5 minutes and 100µL supernatant from each well 
was analyzed for the presence of 51Cr by gamma counter, which reported counts per 
minute (CPM) for each sample.  Calculations were performed to quantify the percent 
lysis of T2-Ld by activated 2C T cells for each condition tested. The calculation is 
detailed below: 
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% lysis of T2-Ld = 100 x (sampleCPM – spontaneousCPM) 
                           (maximumCPM – spontaneousCPM) 
 
The value reported in figures as “% Specific lysis of T2-Ld” indicates that the 
percent lysis of T2-Ld by 2C T cells in the absence of peptide or HPLC fraction has been 
subtracted, indicating that the lysis of T2-Ld was peptide-specific, thus “specific lysis”. 
 
MHC upregulation assays using T2-Ld cells 
 T2-Ld cells (2 x 105) were incubated with various concentrations of synthetic 
peptides diluted in RPMI for 3 hours at 37°C. Cells were washed with 2 x 1mL PBS/BSA 
and stained with 20μg/mL anti-Ld monoclonal antibody 30-5-7 diluted in PBS/BSA. Cells 
were washed again and stained with a 1/200 dilution of phycoerythrin-conjugated goat-
anti-mouse Fab’(2) (Southern Biotech). After another thorough wash, fluorescence was 
detected by flow cytometry on the Accuri C6 cytometer and data was analyzed using 
FCS Express software. 
 
 
Activation of primary 2C T cells from transgenic mice 
Spleen tissue was isolated from 2C transgenic mice and dissociated into a single 
cell suspension using a 100µM nylon mesh and excess complete RPMI 1640 with 10% 
FBS.  Red blood cells were lysed and cells were cultured at a density of 2 x 106 cells in 
500µL complete RPMI 1640 with 10% FBS, 5% rat concanavalin-A supernatant, and 
1μM peptide SIYRYYGL in the wells of a flat-bottom 24-well plate (Corning).  After 48 
hours of incubation at 37°C, 500µL fresh RPMI 1640 with 10% FBS was added to each 
well for another 24 hour incubation at 37°C.  Twenty-four hours after the addition of fresh 
media, 2C T cells were removed from the plate and washed re-plated in with RPMI 1640 
with 10% FBS and 5 units/mL recombinant interleukin-2 (IL-2).  Cells were cultured in 
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the IL-2 containing media for another 24 hours before use in the 51Cr release cytotoxicity 
assay. 
 
 
 
Results 
 
2C variants m6 and m13 recognize p2Ca and QL9 but they do not recognize P815 or 
BALB/c cells  
 The results described in this section, to date unpublished, were obtained from 
experiments performed by Dr. Phillip Holler, a former graduate student in the lab. They 
are provided here to summarize the compelling argument that the naturally Ld-presented 
peptide ligand, expressed by P815 and BALB/c cells, is neither p2Ca nor QL9, and that 
it in fact has not yet been identified. The goal of my project was to identify this 2C-
selecting peptide species by obtaining a collection of peptides from a natural source, 
fractionating them by a liquid chromatography such as HPLC, and testing them for 
reactivity using 2C T cells and T2-Ld target cells. A mass spectrometry approach could 
be used to identify candidate peptide sequences contained within HPLC fractions that 
mediated reactivity in these assays. 
Many previous studies of the 2C T cell clone and 2C T cells have included 
biological and structural studies examining the interactions between the 2C TCR and 
peptide QL9 presented on the allogeneic MHC allele Ld (52,113-115,143). As described 
above, variants of the 2C TCR known as m6 and m13 were engineered using yeast 
display technology for higher affinity for peptides p2Ca or QL9 in complex with MHC Ld 
(118,119). High affinity TCRs m6 and m13 were then transfected into both E. coli 
expression vectors and mammalian cell transfection vectors to further study interactions 
with p2Ca, QL9, and related peptide variants presented on MHC Ld in both soluble and 
cell-based assays.   
 T cell hybridomas (both CD8+ and CD8-) of BW5147 lineage bearing 2C, m6, or 
m13 TCRs were incubated with T2-Ld cells and various concentrations of p2Ca (Figure 
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4.1A) and the levels of secreted interleukin-2 (IL-2) were detected using ELISA.  The 
release of IL-2 into the culture supernatant was indicative of T cell activation. T cells 
expressing all three TCRs were activated by T2-Ld cells presenting p2Ca peptide in both 
the presence and absence of CD8 co-receptor, indicating that the activation by p2Ca 
was CD8-independent. Without CD8, 2C T cells were activated with an SD50 of 0.1μM, 
and T cells expressing high affinity 2C mutants m13 and m6 were activated by p2Ca on 
T2-Ld with SD50 values of approximately 50nM (Figure 4.1A). When the TCRs are 
expressed on the T cell surface along with the CD8 co-receptor, 2C T cells were 
activated by p2Ca peptide and T2-Ld with an SD50 of approximately 1μM, m13-
expressing T cells were activated with an SD50 of 50nM, and m6-expressing T cells were 
most sensitively activated with an SD50 of approximately 10nM (Figure 4.1A). T cells 
bearing all three TCRs, but no co-receptor, were activated by QL9-loaded T2-Ld cells 
with very similar sensitivities (SD50 values of approximately 10pM).  In the presence of 
CD8, 2C T cells were activated by QL9/T2-Ld with an SD50 of 10pM (data not shown). 
CD8-positive T cells bearing m6 TCR were activated approximately 20-fold more 
sensitively than 2C by QL9 peptide displayed on T2-Ld cells; m13 T cells were activated 
approximately 10-fold more sensitively than 2C by QL9 presented on T2-Ld. The higher 
affinity of m6 and m13 TCRs (compared to the 2C TCR) for the p2Ca-Ld complex was 
reflected in in vitro biological assays, in the increased sensitivity of both m6 and m13 
transfected T cells being stimulated by p2Ca loaded on T2-Ld.  
 All three transfected T cell lines (2C, m6, and m13) were tested in an IL-2 release 
activation assay for stimulation by P815 cells, the Ld-expressing cell line against which 
the 2C T cell clone was raised (Figure 4.1B).  While 2C was effectively activated by 
P815 cells even at a P815:T cell ratio as low as 0.2:1, m6 and m13 transfected T cells 
exhibited activation near background (without P815), even at a P815:T cell ratio as high 
as 12:1.  Thus, T cells expressing m6 and m13 TCRs have high affinity for the p2Ca 
complex and were activated by p2Ca-Ld complexes in a CD8-independent manner (as 
seen in Figure 4.1A), but were not effectively activated by P815 cells. Additionally, m6, 
m13, and 2C T cells were tested for activation by BALB/c splenocytes (H-2d haplotype) 
(Figure 4.1C). 2C T cells were approximately 4-fold more sensitive to activation by the 
BALB/c splenocytes than m6 or m13.  
 T cells expressing m6 were not activated by P815 cells or BALB/c 
splenocytes alone (Figures 4.1B and 4.1C), but were effectively stimulated by both 
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target cell types in the presence of exogenous peptide QL9 (data not shown). 
Additionally, several variants of the p2Ca peptide were tested in IL-2 release activation 
assays with T2-Ld target cells and CD8+ T cells expressing 2C, m6, or m13 TCRs. T 
cells expressing the high affinity TCRs were reactive against this collection of p2Ca 
variants, suggesting that the 2C-selecting peptide was likely not a peptide structurally 
related to p2Ca (data not shown). The activation of CD8αβ++ 2C T cells by P815 cells, 
was reduced with increasing concentrations of the anti-Ld blocking monoclonal IgG 
antibody (mAb) known as 30-5-7 (data not shown), which verified that the interaction 
between 2C and P815 was mediated though MHC Ld, and not any of the other 
allogeneic MHC alleles on P815. Finally, the activation of 2C by p2Ca (and QL9) Ld 
complexes was CD8-independent, yet the activation of 2C by P815 cells was CD8-
dependent (data not shown).  
All of the evidence summarized above suggests strongly that p2Ca was not a 
peptide presented endogenously on the surface of P815 or BALB/c cells (or these cells 
would have stimulated m6 and m13). Thus, it can be concluded that p2Ca or QL9 are 
NOT the peptides against which the 2C T cell clone was raised.    
  
Optimizing protocols for the activation of 2C transgenic T cells and the 51Cr release 
assay 
 To begin to search for the actual peptide or peptides that 2C does recognize, in 
the context of Ld, I took a biochemical approach to purify candidate peptides. In order to 
probe HPLC fractions containing peptides that were obtained through either acid 
extraction or affinity purification methods, this approach required a sensitive assay to 
detect T cell reactivity toward T2-Ld cells presenting these peptides. The 51Cr release 
cytotoxicity assay is widely considered to be the most sensitive assay to measure direct 
T cell effector function in response to specific peptide/MHC complexes. This assay can 
be one hundred to one thousand times more sensitive than the IL-2 release assay using 
TCR-transfected T cell hybridomas. In the 51Cr release cytotoxicity assay, target cells 
expressing the MHC protein of interest are loaded with 51Cr in normal saline by 
incubation at 37°C, and then washed to remove excess 51Cr that has not been taken up. 
In our case, the target cells used were from the T2-Ld cell line, a TAP-deficient cell line 
that cannot endogenously process and present peptides. As we required a bioassay for 
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2C recognition, I used activated T cells from 2C TCR transgenic mice, in which 
approximately 20-30% of the T cell population expresses the 2C TCR. The 51Cr-loaded 
T2-Ld were incubated with activated primary 2C T cells and the peptide samples in a four 
hour assay. The peptides of interest bind to and stabilize the Ld molecules on the target 
cell surface, and thus the complexes can be recognized by the 2C TCR. If the TCR on 
the activated 2C T cells recognizes the exogenous peptide loaded onto T2-Ld, the 2C T 
cells lyse the target cells and release 51Cr into the supernatant.  
 This assay requires that the T cells isolated from the 2C transgenic mice are fully 
activated for optimal effector function, and that the activation process is specifically 
tailored to activating T cells bearing the 2C TCR, not T cells bearing any other 
endogenous TCRs. The timing of the activation of primary T cells, and the conditions 
used in the activation process, must calibrated to result in activation only of the 2C T 
cells. Initial efforts used several strategies to optimize the protocol for activating primary 
2C TCR transgenic T cells. The 2C TCR is restricted by syngeneic MHC allele Kb, and in 
addition to the alloantgen Ld, and it specifically recognizes a peptide called SIYRYYGL 
(SIY) in complex with MHC Kb. Thus, synthetic peptide SIY was used to activate 2C T 
cells. T cells were isolated from the spleens of 2C TCR transgenic mice (which express 
Kb), and SIY peptide was used in the activation strategy. In addition, appropriate 
cytokines (e.g. interleukin-2 (IL-2), interferon-γ (IFN-γ)) were added by addition of 
conditioned media. The conditioned media, called “ConA supernatant”, was prepared by 
activating rat splenic T cell populations with concanavalin A and collecting the 
supernatant. 
 Several attempts were made at optimizing the conditions for 2C T cell activation. 
ConA supernatant was used at 5% as a greater proportion of T cells were viable and 
exhibited the activation morphology. In addition, 1μM SIY peptide was used, as this 
concentration resulted in a significant proportion of activated T cells (presumably all 2C 
TCR+) that were viable. Subsequent studies revealed that recombinant IL-2 could be 
used in addition to Con A supernatants during the activation of the primary T cells.  
 In summary, in the standard procedure, primary splenocytes were prepared as 
described above and cultured at 37°C in a Corning 24-well plate at a density of 2 x 106 
cells/500μL activation mixture/well.   The activation mixture contained complete RPMI 
1640, 10% fetal bovine serum (FBS), 5% rat conA supernatant, and 1μM SIY peptide. 
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After 48 hours of incubation with this mixture, cells began clustering (an indication of 
early activation of T cells) and there was debris visible at the bottom of each well. 
Another 500μL complete RPMI with 10% FBS was added to each well and cells were 
cultured for another 24 hrs. At this point, cells began taking on the morphology of 
activated T cells; the size of the cells had increased and cells began to take on the 
tennis racquet shape as visible under the microscope. Then, on day 3 of the activation, 
cells were removed from the plate wells, washed, resuspended in complete RPMI 1640 
containing 10% FBS and 5 units/mL recombinant IL-2, and re-cultured at 37°C for 
another 24 hours. The 24 hours of culture with recombinant IL-2 resulted in large scale 
proliferation of the activated T cells, and the T cells harvested on day 4 were retained 
the morphology expected of activated T cells. 
 To examine their cytolytic capabilities, T cells that had been activated for either 
three days or four days according to the protocol described above were sampled for 
reactivity against p2Ca peptide presented on 51Cr T2-Ld target cells in a cytotoxicity 
assay (Figure 4.2A). T cells activated for three days (no treatment with recombinant IL-
2) were able to effectively lyse T2-Ld displaying the p2Ca peptide with an SD50 of 10nM. 
When the T cells were activated for four days (after treatment with recombinant IL-2), 
they were more sensitive in their recognition and lysis of T2-Ld target cells presenting the 
p2Ca peptide, as indicated by the calculated SD50 value of approximately 3nM. 
Additionally, the 2C transgenic T cells appeared to perform more effective cytolysis 
(higher 51Cr release) on the fourth day of activation compared to the third day. For this 
reason, the four-day activation protocol was adopted for further 51Cr release cytotoxicity 
experiments requiring activated 2C transgenic T cells. In both of these assays, 2C T 
cells were present in 5-fold excess compared to the 51Cr-loaded T2-Ld target cells. 
 For further validation of this 2C T cell activation strategy, and to verify that P815 
contained the alloantigen for 2C, I performed a 51Cr release assay using 51Cr-loaded 
P815 cells as targets (Figure 4.2B). The assay was set up with various effector (2C T 
cells) to target (P815 cells) ratios to examine the sensitivity of the assay. 2C T cells 
efficiently lysed P815 target cells at all effector to target ratios (E:T), with the lowest lysis 
taking place at the 2.5:1 E:T, and the greatest lysis of P815 targets occurring when 2C T 
cells were at a 10-fold excess (10:1 E:T). The lysis of P815 by 2C T cells at in a 5:1 E:T 
ratio fell in between, as we expected. 
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A diverse collection of peptides derived from naturally occurring proteins in BALB/c liver 
tissue results in peptide-specific 2C T cell reactivity toward T2-Ld target cells 
Once I had developed the optimized activation protocol for 2C transgenic T cells 
for use in the 51Cr release assay, I began to examine collections of peptides derived 
from natural sources. The first approach followed closely the studies of Udaka et al 
(1992) in order to determine if a peptide candidate with the HPLC properties of p2Cc, as 
discussed in the introduction, could be observed in both acid extracted and affinity 
purified HPLC fractions. I began with the acid extraction method, because of the 
availability of reagents and equipment and the ability to easily perform this technique on 
a large quantity of primary tissue, and because Udaka showed that peptide species 
p2Cc could be obtained with this method.  
The basic method for the acid extraction of peptides using primary tissues is 
shown in a schematic diagram in Figure 4.3. Primary BALB/c liver tissues were isolated, 
mechanically homogenized, and then sonicated in buffer containing trifluoroacetic acid 
(TFA). During sonication, the cells were ruptured, resulting in a collection of solubilized 
peptides derived from naturally expressed proteins. The collection of peptides obtained 
was then separated crudely based on hydrophobicity using solid phase extraction (SPE) 
C4 columns. The columns were prepared and the peptide mixture was applied, and then 
three serial elutions were performed with elution buffer containing different 
concentrations of acetonitrile (25%, 50%, and 100%), a hydrophobic solvent. A great 
abundance of peptides with low hydrophobicity eluted with 25% acetonitrile, and this 
eluate was collected and stored. The range of peptides we were most interested in 
would elute with acetonitrile concentrations greater than 25%, and for this reason the 
eluates collected during elution steps with 50% acetonitrile and 100% acetonitrile were 
collected, pooled, and submitted for higher resolution HPLC fractionation on a reverse 
phase C18 column at the UIUC Protein Sciences Facility.  
Because the earlier studies identifying the p2Ca, p2Cb, and p2Cc peptide 
species showed that these eluted from the HPLC column between 25% and 50% 
acetonitrile on the reverse phase gradient (where peptide species are fractionated based 
on their level of hydrophobicity), we ran the same HPLC protocol for our fractionation 
(Figure 4.4). The HPLC column was run with two solvents- solvent A, water containing a 
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low concentration of TFA; and solvent B, 100% acetonitrile containing a low 
concentration of TFA. The solvents were mixed in a gradient fashion, increased at a rate 
of 1% solvent B per 1mL fraction, which were collected at a rate of 1mL per minute. 
Once the gradient portion of the HPLC protocol was complete, 100% solvent B was run 
through the column to elute any remaining peptide species of very high hydrophobicity. 
HPLC fractions were dried to remove the acetonitrile and TFA, both of which are toxic to 
cultured cells, and reconstituted in phosphate-buffered saline (PBS).  
The prepared HPLC fractions were then sampled in a 51Cr release assay using 
activated 2C transgenic T cells and 51Cr-loaded T2-Ld target cells (Figure 4.5A). Many 
HPLC fractions, throughout the entirety of the acetonitrile gradient, contained peptides 
that mediated lysis of T2-Ld by activated 2C T cells. Synthetic peptide p2Ca was also 
sampled in this same assay as a positive control, and effectively mediated killing of T2-
Ld by 2C T cells (Figure 4.5B). There was a broad peak of 2C reactivity toward peptides 
that eluted between 30% and 40% acetonitrile, which is the range within which peptides 
p2Ca, p2Cb, and p2Cc eluted from the HPLC column in the Udaka et al 1992 study. 
However, there was an abundance of reactivity outside of that range as well, suggesting 
that there were more than three possible naturally-derived peptide species that could 
mediate reactivity between 2C T cells and Ld-expressing target cells.  
This was a surprising result, given that previous data identified only three distinct 
peaks of activity. We believe this discrepancy may have to do with the differences in the 
target cells that were used, and this is addressed in the next section as well as in the 
discussion. Briefly, the target cells used in the 1992 study were a cell line called B2, 
which is a cell line competent in performing low levels of antigen processing and thus 
these cells display self peptides on the surface in the context of the Ld MHC. The target 
cells I used to probe the HPLC fractions were of the T2-Ld cell line, a TAP-deficient 
human cell line which does not endogenously process peptides and for this reason, the 
Ld proteins on the surface must be stabilized by exogenous peptides in order to be 
recognized by a TCR. I believe that the lack of self peptides presented on the T2-Ld 
surface provided increased sensitivity to the presentation of exogenous peptides, 
resulting in greater sensitivity in our 51Cr release assay compared to the assay used by 
Udaka et al.  
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While the acid extraction technique was useful in that it revealed the greater 
breadth of naturally derived peptides that could be recognized by the 2C TCR in the 
context of cell surface Ld, this strategy also clearly yields peptides (such as p2Ca and 
p2Cb) that are present in a cell but may not be naturally displayed on Ld on the surface 
of the cells. Thus, I shifted my effort toward an alternative strategy of identifying peptides 
from an affinity purification method that utilized the anti-Ld monoclonal antibody 30-5-7 to 
purify peptide/Ld complexes from the surface of Ld+ cells.  
 
Pilot affinity purification using purified peptide/Ld complex confirms efficient coupling of 
30-5-7 to Affigel resin  
 In order to purify peptide/Ld complexes from the cell surface using an affinity 
purification technique, purified antibody 30-5-7 was coupled to Affigel-10 resin. After 
coupling 30-5-7 to the resin and similarly preparing a control resin that was not coupled 
with any antibody, a pilot experiment was performed to verify that active anti-Ld antibody 
had been immobilized on the resin. To examine this, I used a purified Ld molecule 
expressed in E. coli, comprising an Ld mutant called Ldm31 (which binds to the 30-5-7 
antibody), refolded with peptide YPHFMPTNL (MCMV), and purified by gel filtration. 
Purified MCMV/Ldm31 (5μg) (molecular weight 22 kDa) was applied to either control 
resin or 30-5-7 immobilized Affigel-10 resin. The resin was centrifuged and supernatant 
(S1) collected. A sample of the resin was also analyzed after at this step (P1). The resin 
was then washed and supernatant removed (S2). Finally, the MCMV/Ldm31 complexes 
were eluted (E1) from the washed resin with a low pH buffer. Two additional elutions 
were performed (E2, E3), and the resin was analyzed for any non-eluted proteins (P2). 
This pilot experiment was performed using a small amount of resin in microfuge tubes, 
rather than resin in a column, so the resin supernatant in this pilot experiment is 
analogous to the flow-through from resin in a column setup. Samples were taken from 
both the supernatant and the Affigel-10 resin for either the control resin (Figure 4.6A) or 
30-5-7 immobilized resin (Figure 4.6B) at each step and analyzed by SDS-PAGE for the 
presence of MCMV/Ldm31 (22 kDa). Note that antibody 30-5-7 heavy chains migrate at 
about 50 kDa and light chains migrate at about 25 kDa. Also included in each gel was 
one lane containing 5μg of MCMV/Ldm31, the same amount of the protein that was 
applied to the resin. 
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 The S1 sample from the control Affigel contained about the same amount of 
MCMV/Ldm31 (22 kDa) as was added to the resin (Figure 4.6A). In contrast, the amount 
of this protein in the supernatant S1 after incubation with the 30-5-7 immobilized resin 
was significantly lower, suggesting that MCMV/Ldm31 had bound specifically to the 30-5-
7 immobilized resin. 
Conversely, the eluted samples (E1) showed that there was no detectable 22 
kDa band in the control resin, whereas there was significant protein from the 30-5-7 
immobilized resin. The resin pellet (P1) after the application of MCMV/Ldm31 contained 
a low amount of MCMV/Ldm31 complexes in both resins, probably due to the presence 
of the protein within the aqueous sample.  The 30-5-7 immobilized resin also contained 
bands at about 50 kDa and 25 kDa, which no doubt correspond to heavy and light 
chains that have been released from the resin. The elutions E1-3 from the 30-5-7 
immobilized resin showed that about 50% of the protein was found in E1, and there were 
successively lower amounts in each elution. Furthermore, the P2 sample showed 
minimal 22 kDa protein, indicating that the bound Ld complexes could be successfully 
eluted from the antibody immobilized resin with good yield. 
 This pilot affinity purification experiment using purified MCMV/Ldm31 verified that 
the 30-5-7 monoclonal antibody was efficiently coupled to the Affigel-10 resin. 
Additionally, this experiment showed that the affinity purification protocol I used would be 
suitable to both allow endogenous peptide/Ld complexes from the cell surface to 
specifically associate with the resin, and allow the elution of these peptide/Ld complexes 
from the resin. The 30-5-7 resin was thus used for affinity purification of endogenous 
peptide/Ld complexes from the surface of BALB/c liver tissue (Ld+).  
   
A diverse collection of endogenous peptides bound to Ld on BALB/c liver tissue mediate 
killing by activated 2C T cells 
 In order to examine the diversity of peptides that are actually bound to Ld and 
recognized by 2C, and to attempt to determine the identity of the endogenously Ld-
presented peptide(s) that selected the 2C T cell clone, BALB/c liver tissue was used as 
the source of natural peptide-Ld complexes in an affinity purification method (Figure 4.7).  
Cell membranes from the dissociated BALB/c liver tissue were solubilized in a buffer 
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containing 1% NP40 and the membrane proteins were applied to a resin with 
immobilized anti-Ld mAb 30-5-7.  Endogenously presented peptides bound to the Ld 
were eluted from the resin using a low pH buffer.  Eluates were filtered (10 kDa cutoff) to 
separate the presented peptides (about 1 kDa) from the Ld molecules (about 45 kDa), 
and the pass through was subjected to reverse phase HPLC fractionation using a 
gradient of acetonitrile (ACN), using the same reverse phase hydrophobicity gradient 
used for the acid extracted peptides.  
The HPLC trace for the first round of HPLC is shown in Figure 4.8A.  Each 
fraction from the HPLC was dried and reconstituted in phosphate-buffered saline (PBS) 
before sampling for 2C T cell reactivity in a cytotoxicity assay using 51Cr-loaded T2-Ld 
cells as the target.  Peptides contained in each HPLC fraction could be loaded onto Ld 
on the surface of T2-Ld and potentially recognized by the activated CD8+ 2C T cells, 
resulting in lysis of the 51Cr-T2-Ld.  Activated 2C T cells lysed T2-Ld in the presence of 
many of the HPLC fractions, spanning the entirety of the acetonitrile gradient, again 
suggesting the presence of many possible endogenously presented peptides that are 
recognized by the 2C T cell clone (Figure 4.9A).   
After the first round of HPLC, each fraction likely contained a collection of 
peptides of a similar hydrophobicity. To separate some of these peptides further, a 
second round of HPLC was performed. HPLC fractions corresponding to 36% and 37% 
ACN, which resulted in high 2C reactivity, were pooled and subjected to HPLC on a four-
times shallower gradient of acetonitrile to more sensitively separate these peptides 
based on hydrophobicity (Figure 4.8B).  The resulting fractions were again sampled in a 
51Cr-release cytotoxicity assay using activated 2C T cells and 51Cr-loaded T2-Ld cells. 
Once again, many fractions resulted in 2C-mediated killing of T2-Ld cells suggesting the 
presence of more than one naturally presented (by Ld) peptide species that can mediate 
reactivity between the 2C TCR and MHC Ld (Figure 4.9B). 
 
Efforts to identify candidate peptides using mass spectrometry 
 Approximately five peaks from the second round of HPLC contained activity in 
cytotoxicity assays using activated 2C transgenic T cells and T2-Ld target cells (Figure 
4.9B). Because the solvent gradient used in this round of HPLC was quite shallow, and 
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the concentration of acetonitrile in each successive fraction increased by only 0.25% 
acetonitrile and spanned only from 32% to 42% acetonitrile, I reasoned that peptides 
could be more sensitively separated on the basis of hydrophobicity than in the first round 
of HPLC. In addition, there were clear peaks of activity within this collection of HPLC 
fractions, the main ones occurring between 34 and 35% ACN, as well as 39% and 40% 
ACN. As discussed in the introduction, the unidentified peptide known as p2Cc eluted 
from the HPLC column towards the more hydrophobic end of the 30%-40% acetonitrile 
spectrum, and for this reason, the fractions corresponding to about 39% and 40% ACN 
were pooled and submitted for mass spectrometry at the UIUC Protein Sciences Facility.  
The mass spectrometry data revealed the molecular weights of possible peptide 
species that were present in the HPLC fractions. Because the goal of this project was to 
identify the naturally occurring peptide ligand against which the 2C T cell clone was 
raised, the mass spectrometry data was coupled to a BLAST search, in which the 
mass/charge data was matched to sequences of peptides derived from murine proteins. 
Candidate peptides for the endogenously presented 2C peptide ligand were identified 
based on two different criteria: 1) the size of the peptide must be between seven and ten 
amino acids in length in order to efficiently bind to MHC Ld; and 2) the presence of 
anchor residues or particular peptide sequence motifs. The peptide motifs known to elicit 
binding to MHC Ld often contain a proline at position 2 and a phenylalanine, isoleucine, 
leucine, or valine at position 9. Previous experiments performed in the lab of Dr. Herman 
Eisen indicated that peptides with a C-terminal P-X-X-L motif have the potential to 
mediate reactivity between the 2C TCR and MHC Ld. Because the known Ld-binding 
peptide p2Ca (LSPFPFDL) itself contains a serine at position 2 instead of proline, this 
residue, as well as phenylalanine, was also considered an acceptable position 2 anchor. 
Peptide fragments containing putative Ld-binding motifs (anchor residues) or 2C-
reactivity motifs (C-terminal P-X-X-L) that were shorter than 7 amino acids long were 
synthesized in extended forms (7-9 amino acids in length) according to the amino acid 
sequences that flanked the peptide sequence in its parental protein (Table 4.1). The 
peptides I chose to explore were synthesized by the UIUC Protein Sciences Facility: 
TSATLQTHF, QFTTLPAGL, PIKLVPRSL, SSAGGPGAL, QPQHTVRSL, MPKPLSL, 
STMPKPLSL, DSKFHKEHF, PSNGGHSYM, and GPASRDASL. 
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MHC Ld stabilization by synthetic candidate peptides 
 The candidate peptides listed in the previous section were tested in a flow-
cytometry based assay to examine the binding of each peptide to Ld on the surface of 
T2-Ld cells. T2-Ld cells were incubated with various concentrations of each peptide 
diluted in RPMI, and the stabilization of peptide/Ld complexes on the cell surface was 
evaluated by staining with the anti-Ld monoclonal antibody 30-5-7. In the absence of 
peptide, Ld levels on the surface of T2-Ld are low because the class I MHC protein is 
unstable. Peptides can be added exogenously to stabilize class Ld molecules on the cell 
surface. If Ld surface levels increase in the presence of an exogenous peptide compared 
to Ld surface levels in the absence of added peptide, we can conclude that the peptide 
successfully binds to cell surface Ld. Out of all the ten synthetic peptides (listed in Table 
4.1) sampled in this manner, only peptides MPKPLSL, its longer variant STMPKPLSL, 
and QPQHTVRSL showed detectable binding to MHC Ld (Figure 4.10A). Surprisingly, 
out of those three peptides, the heptamer peptide MPKPLSL showed the highest level of 
stabilization (strongest binding) of cell surface Ld. Peptides STMPKPLSL and 
QPQHTVRSL were able to detectably stabilize Ld only at the highest concentration 
tested, 100μM, whereas the heptamer MPKPLSL stabilized Ld on the surface of T2-Ld at 
concentrations as low as 10μM. This is still considerably weaker binding than the 
nonamer peptide QL9 (QLSPFPFDL) but similar to the octamer peptide p2Ca 
(LSPFPFDL) (Figure 4.10B). 
 
None of the candidate peptides mediated reactivity between 2C T cells and T2-Ld targets 
 Each of these candidate peptides was sampled in a cytotoxicity assay to assess 
the 2C reactivity against them when presented on 51Cr-loaded T2-Ld target cells (data 
not shown). None of the peptides resulted in 2C-mediated killing of T2-Ld, suggesting 
that these peptides, when bound to Ld (MPKPLSL, STMPKPLSL, and QPQHTVRSL) do 
not represent an endogenously presented allo-peptide ligand that stimulates the 2C T 
cell clone. Due to the exquisite sensitivity of CD8+ T cell clones, it is possible that the 
levels of the bona fide endogenous allo-peptides are extremely low, perhaps just a few 
molecules per cell (see below). 
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Discussion 
 The salient findings of this chapter were that the 2C TCR recognizes a much 
larger repertoire of allo-peptides than previously thought. Surprisingly, these peptides do 
not include the peptides p2Ca and QL9, which have long been thought to be the 
predominant antigens for clone 2C.  Although one of the bona fide peptides was not 
identified despite considerable effort, these results are consistent with those described in 
Chapter 2, that TCR 42F3, related to the 2C TCR, can also bind to many different 
peptides. 
The findings in this chapter were made possible by the observations of Dr. Holler 
that the two engineered TCRs, m6 and m13, contained mutations in the CDR3α loops 
that confer higher affinity than the wild type 2C TCR for peptides p2Ca and QL9 
presented on MHC Ld. The higher affinity of m6 and m13 for the three OGDH peptide 
variants (p2Ca, p2Cb, and QL9) was reflected in the increased binding by m6 and m13 
TCRs to these peptides in complex with Ld on the surface of T2-Ld cells as compared to 
soluble 2C scTCR.  Although all three TCRs, 2C, m6, and m13, recognized both p2Ca 
and QL9 Ld complexes with affinities (KD values of 2μM for 2C-QL9/L
d, 36μM for m6-
QL9/Ld, 120μM for m13-QL9/Ld) high enough to result in CD8-independent activation of 
T cells bearing these receptors, m6 and m13 did not recognize the naturally processed 
peptide-Ld complexes that 2C could recognize. Thus m6 and m13 were not stimulated 
efficiently by either P815 cells or BALB/c splenocytes (Figures 4.2B and 4.2C).   
Based on these findings, efforts were made to identify the actual endogenously 
Ld-presented peptide ligand that selected the 2C T cell clone. I embarked on this part of 
the project by performing an acid extraction from BALB/c liver tissues, which resulted in 
the isolation of peptides derived from naturally expressed proteins. Based on our 
observations about p2Ca, it is quite possible that many of these peptides were likely not 
endogenously processed and presented by Ld. The acid extracted peptides were 
fractionated and sampled for 2C reactivity in a cytotoxicity assay with T2-Ld target cells, 
the results of which suggested that there were many more than three peptide species 
that could mediate 2C effector function. This information highlighted the complexities of 
searching for naturally occurring peptide ligands for a TCR/MHC system and indicated 
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that this method was not likely the best one to use to identify the naturally Ld-presented 
peptide ligand for the 2C T cell clone.  
Using an affinity purification method, surface peptide-Ld complexes from BALB/c 
liver cells were isolated, and the peptides were separated via HPLC fractionation and 
sampled for reactivity with 2C T cells and T2-Ld cells in a 51Cr release cytotoxicity assay.  
Once again, many HPLC fractions contained peptides that resulted in significant 2C-
mediated killing of target T2-Ld cells after the first round of HPLC, which utilized a wide 
hydrophobicity gradient and thus sampled a broad collection of potential peptide 
alloantigens.  This suggests that the collection of peptides endogenously presented by 
Ld on the surface of BALB/c liver cells and recognized by 2C vary significantly in their 
hydrophobic character and amino acid composition.   
Active fractions corresponding to 36-37% acetonitrile were pooled and subjected 
for a second round of HPLC to further separate the peptide species contained within 
them. When the second round HPLC fractions were sampled in a cytotoxicity assay with 
2C T cells and T2-Ld targets, there were at least five separate peaks of active HPLC 
fractions.  If one assumed that each group of active HPLC fractions from this second 
round of HPLC contained just one peptide species, then it is possible to make an 
estimate of how many distinct peptides endogenously presented on Ld could mediate 
some level of reactivity from 2C T cells.  If each of the approximately six main peaks of 
active fractions from the first round of HPLC contained five distinct active peptides, then 
there may be thirty peptides that could mediate reactivity between 2C T cells and 
BALB/c liver cells.  This is likely an underestimate as most fractions in the second round 
probably contained more than one active peptide species. 
Mass spectrometry was utilized in an attempt to identify peptides contained 
within fractions from the second round of HPLC, however a successful identification was 
not made. Candidate peptides were identified from second round HPLC fractions 
corresponding to 39.5%-39.75% acetonitrile using a combined mass spectrometry and 
BLAST search approach, and peptides were selected for synthesis based on the 
presence of anchor residues proline, serine, or phenylalanine at position 2, and 
phenylalanine, isoleucine, leucine, or valine at position 9 of the peptide. The other 
peptide motif that was selected for amongst the large collection of candidate peptides 
was the C-terminal motif of proline-X-X-leucine, which has been thought to contribute to 
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2C T cell recognition and reactivity against peptides presented on MHC Ld. Of all ten 
peptides that were synthesized, there were only three peptides (MPKPLSL, 
STMPKPLSL, and QPQHTVRSL) that were able to bind to MHC Ld, and none mediated 
reactivity with 2C T cells. It is unclear why more of the candidate peptides didn’t bind 
well to Ld, since they were originally eluted from Ld. One possibility is that the 
intracellular antigen delivery system for class I MHC facilitates loading into nascent Ld, 
and once the Ld is on the surface it is more difficult to bind to the mature Ld-2m 
complex. 
This study highlights the potential difficulties in identifying peptide ligands that 
might mediate reactivity between a T cell receptor and the MHC Ld. While anchor 
residues have been identified as crucial for Ld binding, the presence of these amino 
acids within an octamer-nonamer peptide sequence is not very predictive of binding to 
this particular MHC allele. However, the presence of identified anchor residues for other 
murine MHC alleles, such as MHCs Kb and Db, often does lead to loading of the peptide 
on the cell surface MHC protein. Compared to these other well-studied murine MHC 
class I alleles, MHC Ld is less stable and is more difficult to work with in a soluble setting. 
Crystal structures of MHC Ld in complex with various peptides (43,44,50,52,102) have 
shown that many peptides which bind to MHC Ld show some degree of protruding out of 
the peptide binding groove and form less extensive contacts within the peptide binding 
groove of Ld. Part of this may be mediated by the position 156 tyrosine that stems from 
the Ld alpha 2 helix and has a side chain directed toward the interior of the peptide 
binding groove; the tyrosine hydroxyl group is seen in several structures forming pi-pi 
stacking interactions with aromatic amino acid residues at positions 5 of the peptide. The 
aromatic phenylalanine residue at position 5 of the QL9 peptide was previously found to 
be crucial for interaction with the 2C TCR, but the orientation of the phenylalanine side 
chain in the 2C-QL9/Ld complex as seen in (52) may be due to the interactions of this 
aromatic residue with the Tyr156 sidechain. This is important to keep in mind, because 
the environment of the peptide-binding groove is the determining factor in impacting 
peptide binding and the variety of peptides that can be bound within the groove. Proline 
is considered a somewhat unusual position 2 anchor residue, and because of the 
various degrees of turns this residue can inflict upon a peptide backbone that consists of 
only eight to ten amino acids, the presence of this anchor residue may contribute to the 
less predictable nature of searching for naturally occurring peptides that can bind MHC 
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Ld. The nature of the Ld peptide-binding groove and the contributions of anchor residues 
to peptide/MHC binding must be considered in identifying candidate peptides for both 
binding to Ld and recognition by the 2C TCR.  Because previous studies using 2C T cells 
and the 2C TCR showed that the position 5 aromatic residue (phenylalanine in QL9) was 
crucial for 2C reactivity, this criterion could also be included in selecting further 
candidate peptides that may have selected the 2C T cell clone. Chapter 3 further 
discussed the relationship between the peptide-binding groove and the breadth of the Ld-
binding peptide repertoire. 
Another approach that might be useful in identifying a bona fide peptide ligand for 
2C, among the 30 or more peptides estimated above, involves identifying which fractions 
might have the most abundant peptides. In this regard, an additional experiment was 
performed in which the first round HPLC fractions were diluted 10-fold or 100-fold and 
assayed along with undiluted round one HPLC fractions in a 51Cr release cytotoxicity 
assay using 2C T cells and T2-Ld to identify fractions that contained the most potent 
alloantigen for 2C (Figure 4.11).  A fraction corresponding to 46% ACN from the first 
round of HPLC was active even when diluted 100-fold (Figure 4.11C), indicating that 
this fraction contained the strongest or most abundant agonist peptide(s) that was 
endogenously presented by MHC Ld on the surface of BALB/c liver cells, and likely P815 
cells as well. As discussed previously, the p2Cc peptide appeared to have eluted 
between approximately 37% and 40% acetonitrile from a similarly-run HPLC column, but 
it is still possible that this peptide which was eluted in the 46% acetonitrile fraction is the 
true p2Cc peptide. The elution profiles of peptides depend on a variety of factors, 
possibly relating to their actual source. For example, extracted mouse liver tissue has 
varying degrees of fat content; livers from older mice tend to have higher fat content than 
livers from young mice. Because the HPLC column is run with a hydrophobicity gradient, 
the level of fat in the applied peptide mixture might affect the solubility of various 
peptides as well as the concentration of acetonitrile required to elute the peptides from 
the column. The original paper describing the identification of p2Ca and p2Cb (37) used 
an acid extraction method applied to thymus tissue, which likely differs in fat content 
compared to liver tissue, and that may have contributed to having each peptide elute at 
a lower concentration of acetonitrile. 
We were surprised to find so many distinct HPLC fractions that mediated 
reactivity between 2C T cells and T2-Ld target cells, because the experiments described 
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by Udaka et al suggested that there were only three active peptides found from the acid 
extracted thymus tissue. As indicated above, one reason for this discrepancy might be 
that the original antigen presenting cell line used was a line called B2, which is 
competent in low levels of antigen processing and presentation on surface MHC 
proteins. Because B2 cells were able to present some endogenous peptides, only the 
peptides that bound to surface Ld stronger than the endogenous peptides would have 
been able to exchange. T2 cells are fully TAP deficient, so even peptides that weakly 
bound Ld would have been displayed on the cell surface, albeit at low levels.  
It is possible that the abundance of the p2Cc peptide and the protein it is derived 
from are at lower levels in both mouse thymus tissue and liver tissue compared to the 
ubiquitous OGDH protein, because the abundance of this peptide was too low for 
identification whereas OGDH peptides p2Ca and p2Cb were sufficiently abundant to 
identify by N-terminal sequencing. For 2C to react to such low levels of this peptide as 
displayed on the surface of T2-Ld, i.e. reactivity even when this HPLC fraction was 
diluted 100-fold (Figure 4.11), we can hypothesize that the affinity of this peptide for Ld 
must be fairly high, although given the CD8-dependence of the 2C recognition of P815, 
the affinity of the 2C TCR for this complex may be low. For 2C T cells to be able to 
recognize and kill P815 target cells in vivo, 2C must be able to engage very efficiently 
engage P815 peptide/Ld complexes. From the data presented here, we suggest that 
there may be many naturally presented peptides of varying abundance and strength of 
Ld binding that could mediate this strong anti-P815 2C reaction. Such peptides would 
likely not allow for antigen escape variants of P815 to arise, as could occur with only a 
single peptide antigen. 
These findings with the 2C T cell clone, that there are many more peptide ligands 
than thought, is similar to what was observed using the in vitro selection methods and 
the closely related 42F3 T cell system described in Chapter 2. The 42F3 T cell clone 
(102), was also an allo-reactive T cell clone raised against the MHC-mismatched P815 
mastocytoma. Characterization of the 42F3 TCR included findings that this TCR 
recognized the p2Ca/Ld complex, and because this was thought to be an alloantigenic 
complex on the surface of P815, it is frequently suggested that p2Ca was the peptide 
ligand that also selected the 42F3 TCR (49,101). As per our results shown here, this is 
now unlikely to be the case, and the true alloantigenic Ld-presented peptide against 
which this 42F3 T cell clone was raised is also unknown at this time. Identifying the 
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naturally selecting peptide ligand for the 2C T cell clone might provide insights into the 
bona fide selecting peptide ligand(s) for 42F3 as well. 
 
 
Figure 4.1 
A 
Figure 4.1.  A, T cell hybridomas 2C(open squares), m6 (filled circles), or m13 (open 
circles) TCRs either with CD8 (right) or without the CD8 co-receptor (left) were activated 
in response to T2-Ld target cells loaded with peptide p2Ca (LSPFPFDL). m6 T cells were 
most sensitively activated by p2Ca, followed by m13 T cells, and wild type 2C T cells 
were least sensitive to activation by p2Ca/Ld. B, CD8αβ T cells expressing 2C (open 
squares) were activated in response to P815 target cells, and CD8αβ T cells expressing 
p2Ca/Ld high affinity TCRs m6 and m13 were not activated in response to P815 target 
cells. C, CD8αβ T cells expressing 2C T cells were most sensitively activated by BALB/c 
splenocytes, followed by low activation of  CD8+ m6 T cells, and lastly CD8+ m13 T cells 
were least sensitively activated by this target cell.   
CD8-negative CD8-positive 
C 
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Figure 4.2 
Figure 4.2. A, 2C transgenic T cells specifically lysed T2-Ld target cells presenting p2Ca 
in a dose-dependent manner. 2C T cells that were sampled on the third day of activation 
killed T2-Ld in the absence of peptide with a percent lysis of approximately 15%, while on 
the fourth day of activation this non-specific killing was reduced to approximately 6%. 2C 
T cells sampled on the fourth day of activation were activated by p2Ca presented on T2-
Ld with an SD50 of 3nM; 2C T cells sampled on the third day of activation resulted in an 
SD50 of 10nM. Optimized 2C T cell activation strategy: Day 0, Initial activation of 
splenocytes from a 2C transgenic mouse with RPMI containing 5% rat concanavalin A 
supernatant and 1μM SIYRYYGL peptide. Day 2, Fresh RPMI was added to activating 
2C T cells. Day 3, T cells were washed and resuspended in RPMI containing 5 units/mL 
recombinant interleukin-2 and cultured for another 24 hours. B, 2C transgenic T cells 
were activated using the four day protocol described above and sampled in a 51Cr 
release cytotoxicity assay to test reactivity against 51Cr-loaded P815 target cells at 
various effector (2C) to target (P815) cell ratios.  
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Figure 4.3 
BALB/c 
liver cells 
A, BALB/c liver tissue was homogenized and 
sonicated to release intracellular proteins and 
peptides 
B, Acidic environment enhances solubility of 
intracellular peptides 
C, Peptide fragments applied to prepared solid phase 
extraction C4 column and eluted with buffers 
containing varying acetonitrile content 
25% 
ACN 
50% 
ACN 
100% 
ACN 
Abundant 
peptides 
Peptides eluting from 25%-100% ACN 
D, HPLC fractionation on reverse phase C18 column 
with acetonitrile gradient 
Figure 4.3. Schematic 
representation of the acid 
extraction technique used to 
isolate peptides from proteins 
naturally expressed in BALB/c 
liver cells. A, BALB/c liver tissue 
was mechanically homogenized 
and sonicated in the presence 
of 0.7% trifluoroacetic acid 
(TFA). B, The acidic sonication 
environment resulted in 
precipitation of large 
intracellular proteins and 
increased solubility of peptide 
fragments. C, Peptides were 
dried to an oil and reconstituted 
in 5% acetonitrile with 0.1% 
TFA and applied to a prepared 
solid phase extraction (SPE) C4 
column. Sequential elutions 
were performed with 25% , 
50%, or 100% acetonitrile 
(ACN) in the presence of 0.1% 
TFA. D, Eluates from 50% and 
100% ACN were pooled, dried, 
and reconstituted in 25% ACN 
with 0.1% TFA and submitted 
for reverse phase HPLC 
fractionation. 
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Figure 4.4 
Figure 4.4. HPLC trace for peptide mixture isolated by acid extraction from 
BALB/c liver tissues shows a variety of species eluting from the reverse 
phase C18 column through the entirety of the acetonitrile gradient. The 
gradient ran from 25%-50% acetonitrile followed by 100% acetonitrile, and 
increased at a rate of 1%/1mL fraction/minute. The unit of “mAU” on the Y-
axis indicates the change in absorbance units at 280nm. The X-axis of this 
trace indicates the percent acetonitrile present in the elution buffer that has 
been applied to the column. 
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Figure 4.5 
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Figure 4.5. 51Cr release activation assays with activated 2C T cells, T2-Ld target 
cells, and HPLC fractions from acid extracted liver tissue. A, 2C T cells lysed 51Cr-
loaded T2-Ld target cells in the presence of many distinct HPLC fractions 
containing peptides isolated during the acid extraction of liver tissue. B, Specific 
lysis of T2-Ld by activated 2C T cells in the presence of various concentrations of 
p2Ca peptide. The data shown in this figure is representative of samples tested in 
triplicate. 
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Figure 4.6 
A 
B 
Figure 4.6. Pilot affinity purification experiment using 5μg of purified YPHFMPTNL (MCMV)- Ldm31 
(22 kDa) and either Affigel resin alone (A, control Affigel), or Affigel resin that was immobilized with 
anti-Ld mAb 30-5-7 (heavy chain 50 kDa, light chain 25 kDa) (B), showed that the 30-5-7 mAb was 
properly coupled to the Affigel resin, and that the protocol used to prepare the column and elute the 
MCMV-Ldm31 complexes allowed for efficient association and dissociation from the column. Shown 
are Coomassie Blue-stained SDS-PAGE gels containing samples of each step of the affinity 
purification process. Lane labels: Std, SDS-PAGE standards with indicated molecular weights for 
each band; M, 5μg of purified MCMV-Ldm31; S1, Supernatant after incubating MCMV-Ldm31 with 
resin for 10minutes; P1, Affigel resin sample after incubation with MCMV-Ldm31; S2, Supernatant 
wash solution after washing resin (after incubation with MCMV-Ldm31); E1-E3, eluates from serial 
elutions with glycine HCl pH 2.5; P2, Affigel resin sample after three serial elutions with glycine HCl. 
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Figure 4.7 
Figure 4.7. Schematic 
representation of the anti-Ld 
affinity purification technique 
used to identify endogenously Ld-
presented peptide ligands. A, 
BALB/c liver cell membranes 
were solubilized with NP-40 
detergent, isolating membrane 
fragments containing peptides 
(blue, red, orange, cyan circles) 
displayed on MHC Ld (green 
three domain heavy chain with β-
2-microglobulin (blue rectangle). 
B, Peptide/Ld membrane 
fragments were applied to 
Affigel-10 resin with anti-Ld mAb 
30-5-7 covalently coupled. C, 
Low pH glycine buffer eluted 
peptide/Ld complexes from resin-
bound 30-5-7 mAb and 
dissociates peptides from Ld 
proteins. D, Filtration through a 
10k MWCO filter separated 
peptides from Ld. 
A, BALB/c liver cells treated with NP-40 
B, Pep/Ld membrane fragments applied to 30-5-7 resin 
C, Elution with Glycine-HCl pH 2.5 elutes Pep/Ld 
complexes from resin 
D, Filtration through 10k MWCO filter separates 
peptides from Ld 
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Figure 4.8 
Figure 4.8. HPLC traces for peptide mixture isolated by affinity purification of peptide/Ld complexes 
from BALB/c liver tissue shows the variety of species that eluted from the reverse phase C18 
column through the entirety of the Round 1 (A) and Round 2 (B) acetonitrile gradients. The Round 1 
gradient ran from 25%-50% acetonitrile followed by 100% acetonitrile, and increased at a rate of 
1%/1mL fraction/minute. The Round 2 gradient increased at a rate of 0.25%/1mL fraction/minute 
and spanned from 32%-42% acetonitrile. For both panels, the X-axis indicates the percent 
acetonitrile present in the elution buffer used. The left Y-axis (blue) is in units of “mAU”, which is a 
measure of absorbance units at 280nm. The lime green traces are schematic representations of the 
change in percentage of acetonitrile at each point in the reverse phase gradient. 
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Figure 4.9 
Figure 4.9. 2C transgenic T cells were incubated with 51Cr loaded T2-Ld target cells and 
Round 1 or Round 2 HPLC fractions containing peptides that were affinity purified from 
peptide/Ld complexes on the surface of BALB/c liver cells. The affinity purified peptides 
were fractionated by reverse phase HPLC using an acetonitrile (ACN) gradient with 
trifluoroacetic acid present. The gradient used for Round 1 used an increase in 1% 
ACN/fraction/minute from 25%-55% ACN (A). The fractions from Round 1 corresponding 
to 36-37% ACN (circled in panel A in red) were pooled and re-fractionated during Round 
2; the gradient used for Round 2 used an increase of 0.25% ACN/fraction/minute from 
32%-42% ACN (B). The data shown in this figure is representative of samples tested in 
duplicate. The peak of activity mediated by HPLC fractions corresponding to 39.5% and 
39.75% acetonitrile (circled in panel B in blue) resulted in these fractions being pooled and 
submitted for mass spectrometry analysis to identify candidate peptides as indicated in 
Table 4.1. 
24 34 44 54 64
0
10
20
30
40
% ACN
%
  
S
p
e
c
if
ic
 l
y
s
is
 o
f 
T
2
-L
d
A 
32 34 36 38 40 42
0
20
40
60
% ACN
%
  
L
y
s
is
 o
f 
T
2
-L
d
B 
144 
Table 4.1 
Molecular 
weight of 
peaks from 
mass 
spectrometry 
(Daltons) 
Predicted sequence 
(from mass 
spectrometry and 
BLAST) 
Synthesized 
sequence 
Molecular 
weight of 
synthetic 
peptide 
(Daltons) 
1987.2 QVFKTSATLQTHFNEVH TSATLQTHF 1005.1 
819.0 FTTLPAGL QFTTLPAGL 947.1 
1178.5 PIKLVPRSLR PIKLVPRSL 1022.3 
1178.3 SFLDSSAGGPGAL SSAGGPGAL 715.8 
1178.4 LQPQHTVRSL QPQHTVRSL 1065.2 
785.0 MPKPLSL MPKPLSL 785.0 
785.0 MPKPLSL STMPKPLSL 973.2 
824.9 KFHKEH DSKFHKEHF 1174.3 
767.8 LPSNGGHS PSNGGHSYM 949.0 
615.6 PASRDA GPASRDASL 872.9 
Table 4.1. Left-most column indicates the molecular weight values obtained from mass 
spectrometry data analyzing the peptide species contained in  Round 2 HPLC fractions 
corresponding to 39.5%-39.75% acetonitrile. Left-center column indicates naturally 
occurring murine peptide sequences  (according to BLAST) that fit the mass spectrometry 
data listed in the left column. Right-center column indicates the sequences of peptides 
that were synthesized that contain MHC Ld anchor residues (red position 2 anchor, blue 
position 9 anchor) or 2C recognition motifs of P-X-X-L (indicated in purple). If the peptide 
sequence in the left-center column was shorter than nine amino acids in length, the 
BLAST search data provided the flanking amino acid sequences such that a naturally-
occurring nonamer peptide could be synthesized. If the peptide sequence in the left-
center column was longer than nine amino acids, the nonamer sequence fitting the Ld-
binding or 2C-reactivity criterion was synthesized. Right-most column indicates the 
molecular weight of the synthetic peptide sequences listed in the right-center column. 
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Figure 4.10 
A 
B 
Figure 4.10. MHC stabilization assay using T2-Ld cells showing the binding and 
stabilization of various peptides to cell surface Ld. Various concentrations of the indicated 
peptides were incubated with T2-Ld cells for 3 hours and the surface Ld levels were 
evaluated using 20ug/mL 30-5-7 anti-Ld mAb and a PE-conjugated secondary antibody. 
Peptides tested included various concentrations of QL9, MPKPLSL, STMPKPLSL, 
QPQHTVRSL (A), or comparing two OGDH derived peptides QL9 (QLSPFPFDL) and 
p2Ca (LSPFPFDL) (B).  In both panels the 30-5-7 staining of T2-Ld cells incubated in the 
absence of peptide is shown, indicating the basal surface levels of Ld without stabilization 
from exogenous peptides. 
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Figure 4.11 
Figure 4.11. 51Cr release cytotoxicity assay examining the reactivity of activated 2C T cells against 
T2-Ld cells in the presence of Round 1 HPLC fractions which were undiluted (A), diluted ten-fold 
(B), or diluted one hundred-fold (C). This data shows that one fraction, corresponding to 46%, was 
able to mediate reactivity against T2-Ld by 2C T cells even when diluted one hundred-fold, 
indicating that this HPLC fraction contained a very potent agonist peptide which resulted in very 
sensitive interactions between the 2C TCR and MHC Ld. *Asterisk indicates the 2C-mediated 
cytotoxicity against 51Cr-loaded T2-Ld cells incubated with the Round 1 HPLC fraction 
corresponding to 46% acetonitrile. 
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